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Children 6-59 months with uncomplicated severe and moderate acute malnutrition (SAM and MAM) 
are treated in separate programs with different food products. The aim of this research was to 
generate evidence on a simplified, combined SAM and MAM approach, using a mid-upper arm 
circumference (MUAC)-based dosage protocol. 
Methods 
 
An analysis of routine program data of 5,518 children from five countries estimated the energy 
requirements of children recovering from acute malnutrition to develop a MUAC-based combined 
protocol. A cluster-randomized controlled trial in Kenya and South Sudan tested if the combined 
protocol was as effective at recovering children but more cost-effective than standard treatment. A 
secondary analysis explored outcomes in children with low weight-for-age (WAZ <-3.0) and/or 
MUAC <11.5 cm. 
Results 
 
In the routine program analysis, energy requirements for children with a MUAC <12.5 cm could be 
met or exceeded by 1,000 kcal/day. In the trial, 2,488 children completed treatment; 981 (76.3%) 
on the combined protocol and 884 (73.5%) on the standard protocol recovered. The combined 
protocol was non-inferior to standard treatment at a 10% non-inferiority margin, with a risk 
difference of 0.03 (95% CI -0.05 to 0.10, p=0.52) in per-protocol analysis, adjusted for country, age 
and sex. The amount of ready-to-use food to fully recover a child admitted with SAM was less in the 
combined protocol (122 versus 193 sachets), and the combined protocol cost $123 less per child 
recovered ($918 vs 1,041). Children with a WAZ <-3.0 or a MUAC <11.5 cm respond similarly to the 
combined protocol or standard treatment. 
Conclusion 
 
A simplified, combined protocol for SAM and MAM achieves similar recovery as standard treatment 
and improves cost-effectiveness. Improving cost-effectiveness may enable health programs to treat 
more children. Adding WAZ <-3 as an admission criterion to simplified programs may help target 
high-risk children who benefit from treatment. 
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London completing my MSc at LSHTM- and the rest primarily in Latin America, Africa and Asia 
working in nutrition programs with Action Against Hunger (AAH), Save the Children and Médecins 
Sans Frontières (MSF). In January 2014 I was sitting in a meeting of nutrition advisors from various 
UN and NGO’s and listening to colleagues share recent research. As I looked at graphs depicting 
weight and MUAC gain in the early weeks of treatment, it struck me how the line between severe 
and moderate acute malnutrition (SAM and MAM) was largely arbitrary. It seemed inefficient to 
organize programming this way- with different protocols, food products and programs to treat SAM 
and MAM. In my own field experience, I had rarely seen programs that had the time or resources to 
set up both SAM and MAM treatment in the early stages of an emergency. I observed frustrated 
parents turned away from feeding programs because their children barely missed the admissions 
cut-offs. They would return to their communities where aggravating factors often caused their 
moderately malnourished children to deteriorate. Many eventually returned with a much sicker 
child who had developed SAM, now eligible for treatment but at a higher risk of death and long- 
term health consequences. Once they developed SAM, these children required much more intensive 
intervention, with systematic medications, greater quantities of therapeutic food and sometimes 
hospitalization. 
I had seen enough to know the system was not working well. I walked to the flip chart at the front 
of the room and drew a few lines across the page. I asked my colleagues to forget about SAM and 
MAM for a moment and just think about a spectrum of severity, correlated with rate of growth and 






Figure 1: Drawing of initial research idea, February 2014 
 
I looked back at my colleagues, waiting for their reaction. We talked at length about this continuum 
and what it means for programming. We were curious to know what would happen if we could 
simplify things, save money, and perhaps reach more children with similar resources- before they 
became severely malnourished. 
This idea eventually became the Combined Protocol for Acute Malnutrition Study (ComPAS), a 
project that defined my work at the IRC from 2014-2021. After finding funding for the research and 
building a coalition of partners to support it, I registered as a PhD candidate in January 2016. 
ComPAS became a global research coalition of NGO’s, academics, UN agencies and Ministries of 
Health. 
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investigators across the IRC, AAH, MSF, No Wasted Lives, the Wasting Stunting Technical Interest 
Group, Office of U.S. Foreign Disaster Assistance (OFDA), Children’s Investment Fund Foundation 
(CIFF), United Nations Children’s Fund (UNICEF), World Food Programme (WFP), Ministries of Health 
and beyond who reviewed drafts, gave advice, helped us find funding, designed tools, worked day- 
to-day treating children in the clinics, supervised data collection, and so much more- I am grateful 
to all of you. Thank you to Dr. Rachel Chase, Dr. Natasha Lelijveld and Dr. Mark Myatt for your close 
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1.1.1 Global landscape of childhood malnutrition 
 
 
Childhood malnutrition is one of the world’s greatest public health challenges. Malnutrition is a 
leading underlying cause of mortality and morbidity worldwide,1 and contributes to nearly half of 
all deaths in children under five years of age.2 Millions of children die every year when their bodies 
fail due to inadequate nutrition and the associated medical complications that develop as a result.2 
At any given time, approximately 50 million children experience acute malnutrition,3 and the total 
numbers each year are likely much higher given this estimate is derived from prevalence surveys.4- 
6 Government investments to address malnutrition do not meet the need. In 48 mainly low-income 
countries reporting health expenditures, nutrition received the lowest funding of any disease 
category.1 Global and national nutrition data hides inequalities that become apparent only at the 
most localized level, with childhood malnutrition up to nine times higher in more vulnerable 
communities within the same country.1 Climate change, conflict and global health crises have 
worsened existing inequities in food and health systems, slowing and even reversing progress to 
reduce global childhood malnutrition in some communities affected by poverty and conflict.1, 7 
 
 
1.1.2 Defining acute malnutrition 
 
 
Malnutrition has many forms, including acute malnutrition (wasting), chronic malnutrition 
(stunting), micronutrient deficiencies, underweight, overweight and obesity. Acute malnutrition in 
children, or wasting, has a high short-term fatality rate and long-term health consequences for those 
who survive.8-10 Acute malnutrition in children 6-59 months is currently defined as: 
• Severe acute malnutrition (SAM): weight-for-height <-3.0 standard deviations (z-scores) 
below the WHO reference median and/or a mid-upper arm circumference (MUAC) <11.5 
cm and/or edema 
• Moderate acute malnutrition (MAM): weight-for-height between -3.0 to <-2.0 z-scores 
below the WHO reference median and/or a MUAC from 11.5 cm to <12.5 cm. 
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The focus on children 6-59 months reflects the research showing the first years of life beginning at 
conception are the most critical for growth and development, and malnutrition treatment programs 
may have the greatest impact in children in these early years.11, 12 
 
 
1.1.3 Overview of the Community-based management of acute malnutrition (CMAM) 
 
 
In the past 20 years, great progress was made to refine the diagnostic tools, therapeutic food 
products and delivery model to reach more acutely malnourished children with treatment. The 
Community-based Management of Acute Malnutrition (CMAM) approach was adopted by the 
global nutrition sector after it was piloted in the early 2000’s.13-15 CMAM is comprised of four key 
components: 
• community outreach and mobilization, 
• inpatient treatment of SAM with medical complications, 
• outpatient treatment of SAM without medical complications, and 
• services or supplementary feeding for MAM.16 
 
Prior to CMAM, treatment was delivered only on an inpatient basis using therapeutic milks (F75 and 
F100). Inpatient care presented many challenges including over-crowding, cross-infection, long 
duration of hospital stay, and the high opportunity costs to families of completing a full course of 
treatment.16 CMAM enabled health systems to deliver malnutrition treatment on a primarily 
outpatient basis, using ready-to-use therapeutic foods (RUTF) provided to the caregiver to feed 
children at home. Only children with medical complications required treatment on an inpatient 
basis.17 The system shifted from a primarily inpatient to a primarily outpatient care model, with 
greater potential to increase coverage of treatment. Media covered the development of ready-to- 
use food as a ‘magic bullet’ that with more investment could save millions more lives.18 
 
 
1.1.4 Challenges scaling CMAM 
 
 
Nearly twenty years after the first CMAM pilots,19 coverage of treatment remains at 25% or lower.20 
National health services grapple with scaling up a CMAM model that is costly and complex, with 
different supply chains for therapeutic and supplementary foods and challenges integrating the 
model into health systems.20 In many contexts where resources are limited, governments and 
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humanitarian actors may not be able to support the scale-up of a CMAM model for SAM and 
separate supplementary feeding programs for MAM.21 New solutions are needed to reach children 
more efficiently and effectively and increase the global coverage of treatment. 
Low coverage of treatment may be due to many factors, related primarily to access and availability. 
Accessing care may be difficult or impossible for families due to the high opportunity costs of seeking 
treatment, long distances to health facilities, and lack of knowledge of services, among other 
reasons.22 Availability of care may be affected by factors external to the humanitarian aid system 
including lack of funding, low or non-functioning local health systems, disruptions to the supply 
chains of ready-to-use foods and staffing. But within the humanitarian aid system, several 
inefficiencies in the way care is set-up and delivered also affect the availability of treatment. 
 
 
1.1.5 Global oversight of SAM and MAM programs 
 
 
In the current system, SAM and MAM are managed separately, using different food products, and 
following different protocols, and often in different programs that may or may not be offered in the 
same physical location. In contrast to the systematized nature of SAM treatment, with clear global 
guidelines from the World Health Organization (WHO) and national adoption in most countries 
where acute malnutrition is high, the treatment of MAM changes according to context and varies in 
the type of supplementary food product given,23, 24 or whether a supplement is given at all.25 Three 
different UN agencies have oversight on the protocols, supply chain and management of SAM and 
MAM treatment: 
• United Nations Children’s Fund (UNICEF), based in New York, manages treatment of SAM 
and the supply chain of RUTF; 
• World Food Programme (WFP), based in Rome, manages treatment of MAM and the supply 
chain of ready-to-use supplementary food (RUSF) or fortified blended flours; 
• WHO, based in Geneva, issues the guidelines and protocols followed by international actors 
and national governments. 
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1.1.6 An inefficient system to manage acute malnutrition 
 
 
The system set up to deliver care is fragmented and the components may not always connect. Often 
in emergencies or when resources are scarce, the treatment of SAM is prioritized and children with 
MAM may not be eligible for treatment until their condition deteriorates into SAM. Supplementary 
feeding programs may be established outside the health system as part of either blanket or targeted 
feeding initiatives. Children with MAM are often left out of the health systems approach to 
nutritional treatment, leading to frustrated families and health care practitioners who see children 
with nutritional needs who do not yet qualify for therapeutic feeding. Coverage surveys may not 
always account for MAM so there is little data on the coverage of MAM treatment services.26 There 
is no globally-accepted protocol for the management of MAM, only guidance on the management 
of MAM in specific circumstances.23-25 Without global consensus on managing MAM, the burden of 
SAM remains high despite treatment advances. 
 
 
1.1.7 A new vision to unite and simplify SAM and MAM management 
 
 
The humanitarian community is thus faced with a paradox when it comes to managing SAM and 
MAM: with a continuously high burden of SAM, there may not be enough RUTF or financial 
resources to treat all children with MAM. But if MAM is not adequately addressed, the burden of 
SAM may remain high. If we can simplify and optimize the care of SAM to maximize resources and 
get further upstream of the problem to adequately address MAM, this in turn may help prevent 
SAM. To do so requires a re-thinking of the way we see malnutrition, to reconnect SAM and MAM 
as a continuum condition rather than as two separate conditions to be addressed separately. The 
dividing line for the weight-for-height definition of acute malnutrition is statistical, with no 
physiological reason to classify a child differently on either side of the -3 z-score cut-off. 
This more holistic but simplified view of acute malnutrition should not lose sight of the most 
vulnerable children. As part of this movement towards optimizing treatment, we must also address 
the way we identify and treat children most at risk of mortality and adverse outcomes. The goal is 
to achieve the right balance between meeting the needs of the highest risk subgroups of children, 
such as the youngest, those with concurrent wasting and stunting, and others at high risk of 
mortality,27-29 with a programming approach that simplifies treatment, saves money, and extends 





1.2 Rationale for the ComPAS project 
 
 
The Combined Protocol for Acute Malnutrition Study (ComPAS) was conceived to test hypotheses 
about how treatment could be combined and simplified to reach more children when resources are 
limited. The ‘combined’ aspect refers to treating SAM and MAM together in a single protocol. The 
‘simplified’ aspect refers to the MUAC-based dosage protocol. ComPAS tested a protocol using only 
RUTF at doses designed to optimize growth and minimize cost at each stage of treatment, with 
admission, dosage and discharge determined by MUAC and oedema only. The vision for a simplified, 
combined protocol is to unite the treatment of uncomplicated SAM and MAM into a single protocol 
to improve coverage, quality, continuity of care and cost-effectiveness. A simplified, combined 
protocol for SAM and MAM that is non-inferior to standard treatment is primarily useful if it 
demonstrates improved cost-effectiveness and overall program efficiencies, conferring value for 
both the health system and patients and their families. 
Hypothetically, a simplified and combined approach to treatment could eliminate the need for 
separate products, infrastructure and procedures for SAM and MAM, and enable treatment of MAM 
before children deteriorate into more costly and life-threatening SAM. By uniting the treatment of 
SAM and MAM and making MAM treatment more widely available, programs may eventually be 
able to reduce the caseload of SAM and reduce the costs associated with SAM treatment including 
the higher dosage of RUTF, systematic medications, treatment of complications and 
hospitalizations. Reducing the caseload of SAM may allow for a re-distribution of resources further 


























1.3 Thesis aim and objectives 
 
 
The overall aim of this thesis was to generate evidence on a simplified, combined SAM and MAM 
approach to treat uncomplicated acute malnutrition in children 6-59 months, using a MUAC-based 
RUTF dosage protocol. 
The thesis objectives were to: 
 
1. Assess MUAC and weight gain trends in children recovering from acute malnutrition and 
estimate energy requirements correlated with MUAC category, to inform the development 
of a simplified, MUAC-based dosage protocol for SAM and MAM. 
 
2. Evaluate if the simplified, combined protocol was non-inferior to the standard protocol in 
terms of recovery and assess whether it improved cost-effectiveness. 
 
3. Explore the outcomes of subgroups of children with severely low weight-for-age and/or 
severely low MUAC, to contribute evidence on the optimal dosage required by children who 
may be at a high risk of near-term mortality.27-30 
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1.4 Description of PhD research 
 
 
In the first stage of the research to address objective 1, routine program data from five countries 
was retrospectively analyzed to assess the rate of MUAC and weight gain as children recovered. The 
rate of MUAC and weight gain was correlated with estimated energy requirements according to 
MUAC category. We developed a MUAC-based RUTF dosage protocol that simplified and combined 
treatment for SAM and MAM children. Paper II of this thesis describes this first stage of the research 
and shares the science underpinning the development of the MUAC-based RUTF dosage protocol. 
In the second stage of the research to address objective 2, the simplified, combined protocol was 
tested in a multi-country cluster-randomized controlled non-inferiority trial in Kenya and South 
Sudan. Our first hypothesis was that the combined protocol would be non-inferior to standard 
treatment because the protocol met the full energy needs of children with a MUAC <11.5 cm and 
provided a supplement to the diet of children with a MUAC between 11.5 cm and <12.5 cm. Aside 
from the dosage protocol, all other aspects of nutritional and medical management of children 
remained the same. Our second hypothesis was that the combined protocol would be more cost-
effective, due to the streamlined approach and the optimization of dosage for children with SAM. 
Paper I describes the methods for the cluster-randomized controlled trial (RCT) and Paper III 
shares the results on the overall effectiveness and cost-effectiveness of a simplified, combined 
protocol. 
In the final step of the research to address objective 3, the impact of the new dosage protocol on 
specific subgroups of children was explored, particularly those believed to be at a higher risk of 
adverse outcomes. Children that may fall into this category include those with concurrent wasting 
and stunting and/or low weight-for-age.27, 28 Low weight-for-age has been shown to correlate well 
with concurrent wasting and stunting, as most children with a WHZ <-3.0 and a HAZ <-3.0 also have 
a WAZ <-3.0.28, 29 The combination of low WAZ and low MUAC also identifies most children at risk of 
mortality.28, 29 Paper IV explores the impact of the simplified dosage protocol on high-risk subgroups 
of children with a MUAC <11.5 cm and/or a WAZ <-3.0. 
A follow-up study in the RCT assessed relapse and body composition four months post-discharge in 
Kenya. The aim of the follow-up study was to evaluate if children with MAM treated with RUTF as 
opposed to RUSF are at increased risk of adiposity, and if children with SAM treated with a reduced 
dosage of RUTF have an increased risk of relapse. The follow-up study goes beyond the scope of this 
thesis and the publication of results are shared in Annex J. 
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Specific objectives Method for 
achieving objectives 
1 II Compare MUAC and weight gain trends in 
children treated for acute malnutrition to 
assess if MUAC is a valid proxy of proportional 
weight gain during treatment. 
 
Calculate energy requirements needed to 
support observed weight and MUAC gain in 
children recovering from acute malnutrition 
and explore any differences by age and by 
MUAC category. 
 
Assess the ability of a simplified MUAC-based 
dosage protocol to meet the estimated energy 
needs of children recovering from acute 
malnutrition. 
Secondary analysis of 
routine program data 
from Kenya, South 
Sudan, Chad, 
Pakistan and Yemen 
2 I, III Assess whether recovery in a simplified, 
combined protocol is non-inferior to standard 
treatment. 
 
Assess whether a simplified, combined protocol 
is more cost-effective than standard treatment. 
Cluster-randomized 
controlled   non- 
inferiority trial in 
Kenya and South 
Sudan 
3 IV Assess outcomes and response to treatment in 
children admitted with a MUAC <11.5 cm as 
two separate groups - those with a WAZ <-3.0 
and those with a WAZ ≥-3.0 - both of which 
would be included in current therapeutic 
feeding programs, as well as children with a 
moderately low MUAC (i.e. MUAC between 
Secondary analysis of 
ComPAS RCT data 





  11.5 cm and 12.5 cm) and a WAZ <- 3.0, who 
would be eligible for admission into 
supplementary feeding programs in many 
settings. 
 
Explore outcomes and response to treatment in 
each group by dosage protocol: a simplified, 
MUAC-based dosage in a combined treatment 
program compared to the weight-based dosage 
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Chapter 2: Review of the literature 
 
2.1 Description of methods for the narrative review 
 
 
At the time when I began my PhD work, most published research studies had looked only at SAM or 
MAM treated with separate protocols.14 There was only one published study on the integrated 
treatment of SAM and MAM in a single protocol which used a weight-based dosage protocol.31 
This section presents a narrative review of the literature conducted on PubMed/Medline in 
November 2016 at the start of my PhD, and then updated in April 2019 and March 2021. This is a 
summary of key evidence related to ComPAS through March 2021, excluding the evidence produced 
from the ComPAS research itself. A full systematic review was not conducted because I am aware 
of only two other published studies that have tested a combined SAM and MAM protocol,31, 32 even 
as new studies are on-going.33-35 This narrative review searched for evidence on the novel aspects 
of the protocol tested in ComPAS, with a brief overview of the key research for each topic: 
 
(1) the combined treatment of SAM and MAM in a single protocol, 
(2) mid-upper arm circumference as the primary anthropometric criteria guiding admission, 
monitoring and discharge in nutritional treatment, 
(3) energy requirements related to rate of growth during recovery from acute malnutrition, and 
(4) the use of RUTF for MAM. 
 
 
Only papers related to acute malnutrition in children 6-59 months were included. Terms related to 
“acute malnutrition,” “wasting,” “integrated treatment,” “mid-upper arm circumference,” “ready- 
to-use food,” and “energy needs,” were used to identify key papers without a time limit. The search 
strategy is available in Annex A. A review of references from key papers and grey literature sources 
including the Emergency Nutrition Network and State of Acute Malnutrition websites were also 
searched. The evidence is organized by topic area below. 
 
2.2 Combined treatment of SAM and MAM in a single protocol 
 
 
There were two studies that met the criteria for combined SAM and MAM treatment in a single 
protocol: one prior to ComPAS in Sierra Leone in 2013-201431 and one that originated after ComPAS 
began in Burkina Faso in 2017-2018.32 The cluster-randomized controlled trial in Sierra Leone 
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included 1,100 children in the integrated protocol arm and 857 children in the standard treatment 
arm. It found improved recovery, increased program coverage and lower therapeutic food costs in 
the integrated protocol compared to standard care.31 In the intervention arm, children received 
different doses of RUTF according to MUAC category: <11.5 cm received 175 kcal/kg/day, and 11.5 
to <12.5 cm received 75 kcal/kg/day. Children in the intervention were also discharged with a 
package of preventive health care and infant and young child feeding (IYCF) support. In the standard 
care arm, children received 200 kcal/kg/day of RUTF for SAM and super cereal plus for MAM (1,250 
kcal/day). The study found similar recovery (83% (95% CI 81 to 85) vs. 79% (95% CI 77 to 82)) and 
higher coverage (71% vs. 55%, p=0.0005) in the intervention arm, as well as a reduced caseload of 
SAM due to earlier treatment of children presenting with MAM. Children receiving the integrated 
protocol also recovered more rapidly, with greater MUAC gain and a higher WHZ at discharge. The 
cost of RUTF to treat a SAM case was less in the integrated program: $36 vs. $68 in the standard 
program. 
A single-arm proof of concept trial in Yako district, Burkina Faso evaluated an integrated treatment 
protocol for SAM and MAM using a combination of weight and MUAC-based criteria to determine 
dosage (the OPTIMA study).32 The OPTIMA protocol used a graduated dosing protocol with three 
key categorizations used to determine treatment protocol: MUAC <11.5 and/or oedema received 
175 kcal/kg/day, MUAC 11.5 to <12.0 cm received 125 kcal/kg/day, and MUAC 12.0- <12.5 cm 
received 75 kcal/kg/day. Mothers in the OPTIMA trial were trained to screen and refer their own 
children using MUAC and oedema. The study aimed to demonstrate that this approach adhered to 
SPHERE standards of recovery rates of ≥75%. It included 4,958 children treated with the integrated 
protocol. Overall recovery of trial participants was 86.3% (95% CI 85.4, 87.2) and for the 16% of 
children admitted with MUAC <11.5 cm and/or oedema, recovery was 70.5% (95% CI 67.5, 73.5). 
The average RUTF consumption for children who met the standard SAM admission criteria was 72.2 
sachets/child, nearly half the sachets planned by UNICEF in Burkina Faso to treat a child with SAM 
(140 sachets on average). Children who met the criteria for MAM also consumed less ready-to-use 
food, averaging 54.3 sachets/child in the study compared to 60-90 sachets of RUSF planned for 
children in a supplementary feeding program. 
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2.3 MUAC-only based nutrition programming 
 
2.3.1 MUAC to identify children at high-risk of mortality 
 
 
MUAC is currently one of two primary anthropometric criteria used for admission and discharge in 
CMAM programs, along with WHZ.36, 37 MUAC and WHZ identify similar but not completely 
overlapping subsets of children, particularly in certain contexts.38 WHZ may overestimate the 
prevalence of wasting in pastoralist populations with longer, leaner body types.39 
Multiple studies show that mid-upper arm circumference is effective for identifying children at 
highest risk of mortality,40-50 but debate continues over whether MUAC alone detects all children at 
risk of mortality.48, 51-54 MUAC tends to identify children who are younger and shorter48, 55 but these 
children also have a higher mortality risk.40, 50, 56 Higher sensitivity for the same level of specificity 
may be achieved by raising the MUAC cut-off.45 In a study of children receiving therapeutic feeding 
in South Sudan, all deaths were identified when the MUAC cut-off was increased to 13.0 cm.46 In 
Bangladesh, age-stratified MUAC cut-offs have been proposed ranging from <12.0 cm for WHZ <- 
3.0 and <12.5 cm for WHZ <-2 for ages 6-24 months, up to <13.5 cm for WHZ <-3.0 and <14.0 cm for 
WHZ <-2 for ages 37-60 months.57 
 
 
2.3.2 Adding WAZ to MUAC to detect children at high-risk of mortality 
 
 
A combination of MUAC and weight-for-age z-score (WAZ) has been studied for its ability to detect 
near-term deaths in children with concurrent wasting and stunting and/or low WHZ.28, 29 Children 
with concurrent wasting and stunting (defined as WHZ <-2 and HAZ <-2) are among the most 
vulnerable to mortality of all malnourished children,28-30 but there is no set of admission criteria 
specifically targeted to identify them for therapeutic feeding.17 Adding WAZ to MUAC as a criterion 
for therapeutic feeding admissions may address concerns that MUAC-only programming excludes 
children who meet WHZ criteria but not MUAC criteria.58 Low WAZ captures children at high risk of 
mortality who would have been identified by WHZ but not MUAC, while focusing the targeting of 
programs on the most vulnerable children with multiple anthropometric deficits.28, 29 A WAZ <-3.0 




2.3.3 MUAC as a discharge criterion for treatment 
 
 
Discharging children who meet a MUAC of 12.5 cm with no oedema for two consecutive visits is 
associated with low mortality,60, 61 low relapse,61-63 high recovery and good weight gain,55, 64, 65 good 
MUAC gain66 and longer lengths of stay for the most severely malnourished.61, 64 Discharging a child 
before their MUAC reaches 12.5 cm is associated with a higher risk of relapse.62 
 
 
2.3.4 MUAC to monitor progress during treatment 
 
 
In addition to admission and discharge, some studies have assessed the ability of MUAC to monitor 
progress during treatment.67 MUAC gain tends to mirror weight gain during treatment53, 67-69 and 
MUAC and weight gain are affected similarly by acute illness.67 
 
 
2.3.5 MUAC as a simplified tool for detection and treatment 
 
 
MUAC-only programming is simpler and may be easier to implement than programs that also use 
WHZ.45, 70, 71 Recent studies have shown that mothers are able to use MUAC to screen their own 
children for wasting.72, 73 
 
 
2.4 Rate of growth and energy requirements during recovery from SAM or MAM 
 
 
2.4.1 Energy requirements during recovery from acute malnutrition 
 
 
Maintenance energy requirements for a child recuperating from acute malnutrition has been 
estimated at approximately 82 kcal/kg/day.74, 75 The energy cost of growth is uncertain but 




2.4.2 Energy provision in nutritional treatment programs 
 
 
In an inpatient setting, severely wasted children have been shown to gain from 10-15g/kg/day,78, 79 
to 20 g/kg/day.80 Energy provision of 150-220 kcal/kg/day is recommended for the inpatient 
treatment of SAM.78, 81 In an outpatient setting, typical weight gain is closer to 4.5-6.8g/kg/day82 or 
5.5g/kg/day,83 but national protocols typically provide 175-200 kcal/day for the outpatient 
treatment of SAM, an amount determined from studies of weight gain in the inpatient setting.84, 85 
 
 
2.4.3 Reducing the dosage of therapeutic food 
 
 
Recent work has hypothesized that the therapeutic food dosage could thus be reduced in outpatient 
programs without a negative impact on growth or recovery.31, 32, 86, 87 Several studies have assessed 
the impact of reduced or alternate dosage protocols on recovery from SAM or MAM.31, 32, 83, 86, 87 An 
observational study in Myanmar reduced the dosage of RUTF to one sachet (500 kcal) per day after 
children reached a WHZ ≥-3 or MUAC ≥11.0 cm, and achieved 90.2% recovery, 2.0% defaulted, 0.9% 
were classified as non-responders with no deaths reported.86 A randomized controlled trial in 
Burkina Faso reduced the dosage of ready-to-use therapeutic food as children with severe 
malnutrition gained weight and found that overall recovery rates remained above global Sphere 
standards. For children with uncomplicated SAM (WHZ <-3.0 and/or MUAC <11.5 cm) reducing the 
RUTF dose by 30-53% after two weeks’ of standard treatment did not reduce overall weight or 
MUAC gain velocity or affect recovery or lengthen treatment time. There was a small but 
significant negative effect on linear growth, especially among children under 12 months.87 As 
described above in the section on integrated treatment of SAM and MAM, an operational study in 
Burkina Faso provided 175 kcal/kg/day for children with a MUAC <11.5 cm, 125 kcal/kg/day for 
children with a MUAC 11.5 to <12.0 cm, and 75 kcal/kg/day for children with a MUAC 12.0 to <12.5 
cm. Overall recovery across all three groups was 86.3% (95% CI 85.4, to 87.2), with 70.5% (95% CI 
67.5 to 73.5) recovering among those admitted with a MUAC <11.5 cm and/or oedema.32 An 
integrated SAM/MAM trial in Sierra Leone provided 175 kcal/kg/day for children with a MUAC 
<11.5 cm and 75 kcal/kg/day for children with a MUAC between 11.5 to <12.5 cm, and reported 
recovery of 83% (95% CI 81 to 85) in the intervention arm compared to 79% (95% CI 77 to 82) in 
the standard dosage arm.31 
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2.4.4 Rate of weight and MUAC gain during treatment 
 
 
Rate of weight and MUAC gain is most rapid during the earliest stages of treatment, and as children 
begin to recover from acute malnutrition, their rate of weight and MUAC gain slows.68, 69, 84, 88 
Average weight gain also tends to mirror average MUAC gain.53, 67-69, 88 Thus, response to treatment 
and supplemental energy needs decrease as children approximate normal growth80and gain in 
weight and MUAC,83, 88 giving rise to the practice to reduce the dosage as children transition from 
SAM into MAM treatment. Supplementary feeding programs for treatment of MAM in children 6- 
59 months typically provide a supplement to the family diet, rather than meeting total energy 
needs.23, 24 A study analyzing the theoretical performance of different dosage protocols applied 
against a population of children under treatment in Niger found that energy provision may be 
reduced in the latter weeks of treatment.83 
 
 
2.5 Use of RUTF for treatment of MAM 
 
2.5.1 Strategies to manage MAM 
 
 
There is currently no formal WHO protocol for the treatment of MAM, only programmatic 
guidance,23-25 and expert guidance on how to meet the nutrient needs of moderately malnourished 
children.89, 90 Multiple strategies have been recommended for the management of MAM, including 
food supplementation, micronutrient supplementation and/or counseling.24, 25, 91 Children with 
MAM have an elevated risk of mortality, morbidity and deterioration into SAM.14, 92-94 Systematic 
reviews published in 2019 and 2021 found that children with MAM are more likely to recover with 
food supplementation as opposed to counseling, with or without micronutrient supplementation 
alone.91, 95 Counseling alone may not be sufficient particularly in areas of food insecurity.59, 96, 97 
 
 
2.5.2 Lipid-based nutrients supplements vs. fortified blended flours 
 
 
Many of the studies evaluating MAM treatment with food supplements have assessed the 
effectiveness of lipid-based nutrient supplements compared to fortified blended flours. Studies 
have shown the provision of a lipid-based nutrient supplement (LNS), like ready-to-use food, results 
in improved recovery compared to fortified blended flours.14, 95, 97-107 The composition of fortified 
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blended flours used for young children was improved to include dairy proteins and reduce anti- 
nutrients,108-110 and improved products such as corn-soya blend (CSB) ++ have been shown to be 
comparable to LNS in some studies.99, 111-113 The Treat Food study in Burkina Faso evaluated the 
effectiveness of matrix (CSB vs. LNS), soy quality and milk content and found better recovery and 
higher proportional accretion of fat-free mass among children who received LNS.76 Fat-free mass is 
a component of lean mass, which is associated with improved immunity, survival and 
development.76 LNS was also found to improve hemoglobin and iron status better than CSB.100, 114 
 
 
2.5.3 Protein composition in lipid-based nutrient supplements 
 
 
Among the different types of lipid-based nutrient supplements used for treatment of MAM, those 
with the highest quality of protein, such as dairy protein, may be the most effective.23, 76, 101, 115-118 
RUTF was designed for the treatment of SAM and was originally based on the composition of F100 
therapeutic milk, which is dairy-based.78 RUSF was designed for the treatment of MAM23 and 
originally did not contain dairy protein,108 though in recent years milk-based proteins have been 
added.116, 119 In Malawi, moderately malnourished children given soy + whey RUSF were more 
likely to remain well-nourished (67%) than those treated with corn soy blend (CSB)++ (62%) 
or soy RUSF (59%) (p = 0.01).101 Higher recovery has also been shown in children given a 
whey RUSF (83.9%) compared to soy RUSF (80.5%) (risk difference 3.4, 95% CI 0.3 to 6.6, p 
<0.04), with a higher mean MUAC at discharge (p <0.009), greater MUAC gain during 
treatment (p <0.003), higher mean WHZ at discharge (p <0.008), and greater weight gain (p 
<0.05).116 Lower recovery and lower weight gains were seen in children with SAM treated 
with a 10% milk RUTF compared to 25% milk RUTF.120 A random effects meta-analysis of 
three trials comparing whey/milk LNS vs. no animal product/soy LNS found no evidence of 
a difference in recovery, risk of progression to SAM or risk of death.95 In recent years, new 
versions of RUF have been tested with alternate compositions.76, 115, 121-128 In one study, a 
milk-free amino acid-enriched soya-maize-sorghum (SMS) RUTF was shown to be non- 
inferior to milk-based RUTF in terms of recovery and length of stay in children with SAM, 
with a superior ability to restore body iron stores.115, 122 
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2.5.4 RUTF for the treatment of MAM 
 
 
RUTF has occasionally been used in the treatment of MAM in programmatic settings129 and tested 
in research settings with good recovery and response to treatment.13, 31, 32, 97, 102, 130 The physiology 
of children with SAM and MAM is similar and therefore the treatment of MAM using RUTF is 
expected to be similar to the treatment of SAM using RUTF.131 A systematic review of LNS used for 
MAM treatment indicated increased recovery with RUTF compared to RUSF in sub-analyses.97 
 
 
2.6 Implications of available evidence 
 
 
In summary, the evidence available before ComPAS – and the evidence which has accrued from 
other studies over its duration – suggested that a MUAC-based protocol may be simpler to use and 
could better identify children at high risk of mortality, especially when combined with WAZ as 
admission criteria to therapeutic feeding programs.28, 29, 48 Furthermore, a tapered dose of RUTF as 
children reach the end of treatment appears to theoretically meet children’s energy requirements83 
and leads to similar recovery and program outcomes,31, 32, 86, 87 and LNS could improve recovery and 
fat free mass accretion in children recovering from MAM.76 Finally, integrated treatment of SAM 
and MAM improves cost-effectiveness while maintaining program effectiveness.31, 32 
These findings are consistent with the foundational hypotheses of this PhD research, that a 
simplified, combined protocol for acute malnutrition using a MUAC-based RUTF dosage protocol 
would be as effective as standard treatment but more cost-effective. 
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2.7 Building the evidence on a simplified and combined protocol 
 
 
This PhD research aimed to build on the only other combined protocol study published as of 2016,31 
as well as test several innovative components of a simplified, combined treatment protocol. 
ComPAS was the first randomized controlled trial I am aware of to test a MUAC-based dosage 
protocol for the treatment of acute malnutrition. It added to the Maust et al. 201531 study and the 
existing body of evidence by: 
(1) basing dosage on MUAC instead of weight, 
(2) comparing a combined protocol with a control group using ready-to-use supplementary 
food for MAM, instead of fortified blended flours, 
(3) comparing against a control group with an equivalent definition of recovery (MUAC ≥12.5 
cm and no oedema, instead of WHZ ≥-2), 
(4) using a larger sample size across two countries, with both urban and rural contexts, 
(5) analyzing overall program cost-effectiveness from the household, health facility and 
program perspectives, and 
(6) exploring outcomes and response to treatment in children with a severely low weight-for- 
age, who may be at a higher risk of mortality or adverse outcomes. 
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Chapter 3: Methods 
 
3.1 Overview of the PhD research process 
 
 
3.1.1 Pre-PhD: finding funding and building the research coalition 
 
 
After sharing the initial idea for a simplified, combined protocol at a meeting of nutrition advisors 
in January 2014 (described in the Preface), I wrote a concept note for the research. I reached out to 
academics I considered mentors- including Dr. André Briend and Dr. Mark Manary- and asked them 
to review the concept paper. I learned that Dr. Manary had led an integrated SAM/MAM study in 
Sierra Leone that we could build on.31 Dr. Manary’s team had used two different products and 
continued to base dosage on weight, so there were some differences from the ideas we sought to 
test in a simplified, combined protocol. 
In April 2014 I presented the idea to a group of nutrition colleagues again, in more detail. As a result 
of this presentation, the Office of U.S. Foreign Disaster Assistance (OFDA) invited me to submit a 
funding proposal on behalf of the International Rescue Committee (IRC). I reached out to my 
colleagues at Action Against Hunger (AAH) to develop a research partnership, and I spent the next 
few months developing the funding proposal, engaging partners, and laying the groundwork for 
what would soon become the ComPAS research coalition. Through a sub-grant via the No Wasted 
Lives Coalition, we received additional funding from the Children’s Investment Fund Foundation 
(CIFF) to complement our funding from OFDA. 
I met with my future PhD supervisor, Dr. Marko Kerac, in May 2014 at the International Symposium 
on Understanding Moderate Malnutrition in Children for Effective Interventions in Vienna, Austria. 
I hoped to develop the research into a PhD and asked Dr. Kerac if he might be interested in 
supervising. I was aware there was much I did not know-- as a public health professional with a 
background in humanitarian response- and I sought to develop the necessary research skills through 
a PhD. Dr. Kerac introduced me to my second supervisor, Dr. Charles Opondo, a medical statistician 
and clinical trialist. 
I reached out to a scientific committee of experts in pediatrics, nutrition, epidemiology, and 
statistics to guide the study and review progress at key milestones. In addition to my supervisors Dr. 
Kerac and Dr. Opondo, the initial scientific committee also included Dr. André Briend, Dr. Mark 
Manary and Dr. Rachel Chase. 
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I was also aware that a study that challenges the status quo would potentially come up against 
political and economic resistance, and so I invited a group of representatives from UNICEF, WFP, 
WHO, United Nations High Commissioner for Refugees (UNHCR), European Civil Protection and 
Humanitarian Aid Operations (ECHO), and OFDA to participate in a policy stakeholder committee. I 
sought to develop a research plan that could directly inform future policy and practice. I met with 
senior nutrition advisors from UNICEF, WFP and WHO to discuss the ideas behind a simplified and 
combined protocol and the UN’s perspectives on the continuum of care between SAM and MAM. 
We continued to expand the research over the subsequent years and built a coalition of nutrition 
experts, humanitarian programmers, epidemiologists, scientists and statisticians across the IRC, 
AAH, LSHTM, Médecins Sans Frontières (MSF), No Wasted Lives, the Wasting Stunting Technical 
Interest Group, UNICEF, WFP, and the Ministries of Health in Kenya and South Sudan. 
 
 
3.1.2 Research process during the PhD 
 
 
After I registered as a PhD candidate in January 2016, I convened a meeting of the scientific 
committee and the IRC, AAH and LSHTM research partners to: 
(1) Review the research on energy requirements and rate of growth in children recuperating 
from acute malnutrition to propose a simplified, MUAC-based dosage protocol, and 
(2) Discuss potential study designs for the clinical trial. 
 
In the first year of my PhD in 2016, I worked closely with the scientific committee to finalize the 
analyses of rate of MUAC and weight gain and energy requirements to inform the MUAC-based 
dosage protocol. I developed the trial study protocol and analysis plan and sought feedback from 
the scientific committee to refine the study design. I hired the project coordinators and key staff to 
lead the research in each country. I submitted the study protocol for LSHTM ethical approval and 
supervised the submission of the protocol to the relevant national ethical committees in Kenya and 
South Sudan. At the end of 2016, I completed the narrative review of evidence and submitted my 
upgrading report to LSHTM. 
In the second and third years of my PhD in 2017-2018, I hired and trained additional field-based 
staff, coordinated the development and piloting of digital and paper-based data collection tools, 
began recruitment in Kenya and South Sudan, visited the field sites in Kenya, and performed all trial 
management duties as the principal investigator. We completed treatment of the last enrolled child 
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in August 2018. I began cleaning and analyzing the data in September 2018 and prepared 
preliminary results to share with the research coalition partners and key stakeholders by the end of 
2018. 
In the fourth and fifth years of my PhD in 2019-2020, I finalized the analyses, prepared results for 
peer-reviewed publications, and presented the final results to relevant stakeholders including the 
Ministries of Health in South Sudan and Kenya, UNICEF, WFP and WHO. 
The specific methods towards achieving each objective during the PhD research process are 
summarized below, with a full description of methods in the respective papers. 
 
 
3.2 Summary of methods for objective 1 
 
 
The first stage of research was a secondary analysis of routine patient card data from 5,518 children 
6-59 months in SAM and MAM outpatient treatment programs in Kenya, Chad, South Sudan, Yemen 
and Pakistan. Data from the patient cards in Kenya, Chad, Yemen and Pakistan was entered into 
Excel files and cross-checked with double data entry by data entry clerks in the field offices of the 
NGO’s in each country. An excel dataset was provided for the data from MSF-France in South Sudan, 
following the signing of a data sharing agreement. Ethical approval for this work was given from the 
LSHTM (reference 11820). Anonymized data from the five countries was received by the PI and 
stored on a password-protected IRC institutional server. The data were cleaned and merged into a 
single anonymized dataset by a statistician in preparation for analysis. 
Analyses were reviewed by the ComPAS research team and scientific committee. The MUAC-based 
dosage protocol was developed in consultation with the scientific committee and approved for 
development into the simplified, combined protocol to be tested in the RCT. 




3.3 Summary of methods for objective 2 
 
 
The second stage of research was a cluster-randomized controlled non-inferiority trial that enrolled 
4,110 children 6-59 months with SAM or MAM in Kenya and South Sudan. This stage was designed 
as a multi-country trial to increase generalizability across settings. Aweil East in South Sudan was 
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chosen because of AAH’s long-term presence operating nutrition programs and because it 
represented a rural, humanitarian setting with a high burden of acute malnutrition. Nairobi, Kenya 
was selected as the second setting because of IRC’s presence in the country and ability to work 
closely together with the MoH to implement the research to a high standard, as well as the high 
absolute numbers of acutely malnourished children in the urban slums. A cluster-randomized 
controlled design was chosen to improve simplicity of delivery and thus adherence to the protocol 
in each clinic and to improve the collection of cost data by protocol type. We tested for non- 
inferiority in the primary outcome of recovery because we did not anticipate that simplifying and 
combining treatment would improve recovery compared to standard treatment, rather we wanted 
to assess that recovery was at least as good as standard treatment. Ethical approvals were given by 
LSHTM (reference 11826), the Kenya Medical Research Institute (reference non-KEMRI 551) and the 
Ministry of Health in South Sudan (approved 21 November 2016). Enrollment for the trial began in 
May 2017 in both countries. Recruitment was completed in both countries by March 31, 2018, and 
the last children completed their treatment in July 2018 in Kenya and August 2018 in South Sudan. 
A detailed description of the RCT methods can be found Papers I and III. The ethical approvals, 
consent form and data collection tools can be found in Annexes B-D. 
To evaluate cost-effectiveness, an economic analysis was embedded within the RCT to account for 
program and household costs, inclusive of accounting records, key informant interviews with 
health care workers, and discharge exit interviews and focus group discussions with caretakers. 
The methods paper for the cost-effectiveness analysis can be found in Annex H. 
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3.4 Paper I: Methods for the cluster-randomized controlled trial 
 
Paper I: Bailey J, Lelijveld N, Marron B, Onyoo P, Ho LS, Manary M, Briend A, Opondo C, 
Kerac M. Combined Protocol for Acute Malnutrition (ComPAS) in rural South 
Sudan and urban Kenya: study protocol for a randomized controlled trial. Trials. 
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Background: Acute malnutrition is a continuum condition, but severe and moderate forms are treated separately, 
with different protocols and therapeutic products, managed by separate United Nations agencies. The Combined 
Protocol for Acute Malnutrition Study (ComPAS) aims to simplify and unify the treatment of uncomplicated severe 
and moderate acute malnutrition (SAM and MAM) for children 6–59 months into one protocol in order to improve 
the global coverage, quality, continuity of care and cost-effectiveness of acute malnutrition treatment in resource- 
constrained settings. 
Methods/design: This study is a multi-site, cluster randomized non-inferiority trial with 12 clusters in Kenya and 12 
clusters in South Sudan. Participants are 3600 children aged 6–59 months with uncomplicated acute malnutrition. 
This study will evaluate the impact of a simplified and combined protocol for the treatment of SAM and 
MAM compared to the standard protocol, which is the national treatment protocol in each country. We will 
assess recovery rate as a primary outcome and coverage, defaulting, death, length of stay, average weekly 
weight gain and average weekly mid-upper arm circumference (MUAC) gain as secondary outcomes. Recovery 
rate is defined across both treatment arms as MUAC ≥125 mm and no oedema for two consecutive visits. 
Per-protocol and intention-to-treat analyses will be conducted. 
Discussion: If the combined protocol is shown to be non-inferior to the standard protocol, updating guidelines to 
use the combined protocol would eliminate the need for separate products, resources and procedures for MAM 
treatment. This would likely be more cost-effective, increase availability of services, enable earlier case finding and 
treatment before deterioration of MAM into SAM, promote better continuity of care and improve community 
perceptions of the programme. 
Trial registration: ISRCTN, ISRCTN30393230. Registered on 16 March 2017. 
Keywords: Non-inferiority, Acute malnutrition, Cluster randomized trial, Community-based management of acute 







* Correspondence: jeanette.bailey@rescue.org 
1International Rescue Committee, New York, NY, USA 
2Department of Population Health, MARCH Centre, London School of 
Hygiene and Tropical Medicine, London, UK 
Full list of author information is available at the end of the article 
 
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and 
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver 







Acute malnutrition is a major global public health problem 
affecting an estimated 52 million children under 5 years of 
age [1]. Of these, some 35 million have moderate acute mal- 
nutrition (MAM) and 17 million have severe acute malnu- 
trition (SAM). The true burden of disease is however likely 
much higher. This is because most current estimates are 
based on cross-sectional survey data giving prevalence fig- 
ures, whereas SAM and MAM, being short-lasting condi- 
tions, should ideally be assessed in terms of incidence [2, 3]. 
Malnutrition in all its forms is an underlying cause of 3.1 
million (45%) of deaths among children under 5, with wast- 
ing alone responsible for 875,000 child deaths per year [4]. 
Despite the availability of effective, evidence-based 
treatment programmes, especially for SAM, their public 
impact is often limited by low coverage of the affected 
population. According to recent estimates, less than 20% 
of children with SAM receive the treatment they need 
[5]. Figures for MAM programme coverage are un- 
known—but are likely to be lower since it is often per- 
ceived to be less of a priority compared to SAM. This is 
despite wasting, the major manifestation of  both  SAM 
and MAM, being on a continuum, with the cut-off be- 
tween the two defined statistically (based on weight-for- 
height/length standard deviations from the median)  ra- 
ther than by any distinguishable clinical changes. 
In humanitarian settings (as well as many other non- 
emergency but fragile contexts where malnutrition is com- 
mon), current international and national recommendations 
involve treating SAM and MAM in separate programmes, 
using separate protocols and separate products managed by 
two large but separate United Nations agencies. SAM is 
treated with ready-to-use therapeutic food (RUTF) in an 
outpatient therapeutic programme (OTP), with oversight 
and technical guidance from the United Nations Inter- 
national Children’s Fund (UNICEF). MAM is treated with 
ready-to-use supplementary food (RUSF) or fortified corn 
soy blend ++ (CSB++) in a supplementary feeding 
programme (SFP), with oversight and technical guidance 
from the World Food Programme (WFP). The shortcom- 
ings of this system include the following: (1) it is logistically 
complicated to implement, requiring the procurement of 
two different nutritional products and the set-up of two 
separate programs, in coordination with two separate UN 
agencies, (2) it is consequently expensive, and (3) it often 
results in the prioritization of SAM over MAM: many aid 
agencies and governments offer treatment only of SAM 
due to the challenges associated with procuring two prod- 
ucts and coordinating two programmes. This results in a 
situation where treatment may not be available to children 
with MAM until they deteriorate to SAM. 
Responding to these current challenges, the Combined 
Protocol for Acute Malnutrition Study (ComPAS) will 
assess the effectiveness of a simplified, combined 
protocol for the treatment of uncomplicated SAM and 
MAM for children 6–59 months. The study aims to im- 
prove the quality, coverage, continuity and cost- 
effectiveness of care (Fig. 1). The  combined  protocol 
uses one product (RUTF) for both SAM and MAM, at 
doses designed to optimize growth and minimize cost at 
each stage of treatment. Admission and discharge is 
assessed using only mid-upper arm circumference 
(MUAC) and oedema [6]. Differences between the com- 
bined and standard protocol are presented in Table 1. 
ComPAS was inspired by increasing realization that 
combining the treatment of SAM and MAM makes 
biological sense—since wasting is a continuum condition 
rather than two distinct and different problems; oper- 
ational and financial sense—since staff skill set and infra- 
structure are very similar for the two programmes  and 
may thus usefully be shared; and public health sense— 
since a combined programme should be easier to access 
and should thus improve overall programme coverage. 
Early data supporting the hypothesis of clinical non- 
inferiority comes from a 2013 Washington University trial 
in Sierra Leone [7]. This study explored the efficacy of an 
integrated SAM/MAM treatment protocol using one 
product (RUTF) but at different doses for children 
<115 mm (175 kcal/kg/day) and 115  to  <125  mm 
(75 kcal/kg/day). Controls followed standard care guide- 
lines: RUTF for SAM and SFP with CSB++ for MAM. Re- 
sults showed that the integrated programme had a 
reduced caseload of SAM, due to earlier treatment of chil- 
dren presenting as MAM, with a similar recovery rate 
(83% vs. 79%) and higher coverage (71% vs. 55%, p = 0. 
0005). Children who received integrated management re- 
covered more rapidly, with greater MUAC gain and higher 
weight-for-height Z-score (WHZ) upon discharge. 
Other data supporting the use of a single nutritional 
product but at different doses comes from our own second- 
ary analysis of routine nutrition programme data from five 
countries (Yemen, Pakistan, South Sudan, Chad, Kenya) 
and three different agencies (International Rescue Commit- 
tee (IRC), Action Against Hunger—USA (ACF-USA), and 
Médecins Sans Frontières—France (MSF-France)) [8]. This 
analysis used observational data to assess the rate of growth 
of children recovering from acute malnutrition in OTPs 
and SFPs in order to determine energy requirements and 
propose an optimized dose of RUTF that correlates with 
the MUAC category. We found that: 
 
• Growth trends in MUAC mirror those of 
proportional weight gain and rates of MUAC and 
weight gain slow with increasing MUAC. 
• As the rates of MUAC and weight gain slow, 
proportional energy needs decrease. 
• Total energy needs of 95% of all children with a 









Based on these observations, the combined and simpli- 
fied MUAC-based dosage protocol was developed, and it 
is this which is being tested in the current study: 
 
• Children with a MUAC <115 mm and/or oedema 
receive two sachets of RUTF per day (1000 kcal). 
• Children with a MUAC 115 to <125 mm receive 
one sachet of RUTF per day (500 kcal). 
 
The objective of our current project is to assess the ef- 
fectiveness of a combined SAM/MAM protocol com- 
pared to standard care (separate SAM/MAM treatment) 
in two countries: Kenya and South Sudan. The outcomes 
of stage 2 are described in Table 2. 
We will add to the available evidence by (1) testing a 
dosing protocol based on the  MUAC  category,  not 
weight [6, 9, 10]; (2) comparing against a control SFP 
using RUSF, instead of CSB++; (3) comparing equivalent 
definitions of recovery in both control and intervention 
groups; (4) using a larger sample size across two coun- 
tries; and (5) conducting a thorough cost-effectiveness 
analysis using proven methodologies. 
The publication of this study protocol aims to improve 
transparency and share information to support the de- 
velopment of similar studies that seek to simplify the 
protocols for acute malnutrition and increase the avail- 




The study is a multi-country cluster randomized con- 
trolled non-inferiority trial. The units of randomization 
are health facilities stratified by country and then ran- 
domly assigned to the control or intervention group. 
Children in the control group receive the standard 
protocol while those in the intervention group receive 
the combined protocol. The study includes a total of 24 
clusters, 12 in each country. 
 
Hypothesis 
We hypothesize that the combined protocol will be as 
effective as the standard protocol in the treatment  of 
severe and moderate acute malnutrition as measured by 
recovery rate, length of stay, average weekly weight and 
MUAC gain, and coverage. The combined protocol will 
be more cost-effective than the standard protocol. Dif- 
ferences between the combined and  standard  protocols 
are presented in Table 2. 
 
Study site and population 
There are two sites in this multi-center cluster random- 
ized trial: Aweil East, South Sudan and Nairobi, Kenya. 
Aweil East is a rural setting in the former state of North- 
ern Bahr el Ghazal with a total population of 309,921 
and an under five population of 59,574 according to the 
most recent national population and housing census in 
2008. ACF-USA supports 16 malnutrition clinics in the 
area; each is approximately 20–30 km apart. At the time 
the study was initiated, only 12 of these clinics were sup- 
ported by ACF-USA, and these 12 were all selected for 
inclusion in the study. 
Nairobi county is an urban area with a total population 
of approximately 3.1 million, of which 13% are children 
under 5 years, according to the 2009 population census. 
Three sub-counties of Nairobi were selected in collabor- 
ation with the Ministry of Health (MoH) based on a high 
burden of malnutrition and a need for nutritional support 
(Embakasi North, Embakasi South and Embakasi West). 
Out of the 32 health facilities in the three sub-counties, 12 
health facilities were selected based on the following key 
factors: the level of care provided (hospitals and dispensar- 
ies excluded), the type of care provided (routine  child 







Table 1 Nutritional protocol for the control and intervention trial arms 
Standard protocol (control) Combined protocol (intervention) 
 
Admission criteria OTP • MUAC <125 mm 
• WHZ <−3 
and/or 
• MUAC <115 mm 
and/or 
• Bilateral pitting oedema (+/++) 
and 
• Clinically uncomplicateda 
SFP 
• Discharged from OTP 
and/or 
• WHZ <−2 to >−3 
and/or 
• MUAC 115 to <125 mm 
and 
• Clinically uncomplicateda 
and/or 
• Bilateral pitting oedema (+/++) 
and 
• Clinically uncomplicateda 
Treatment frequency OTP MUAC <115 mm and/or oedema (+/++) 
Weekly 
SFP MUAC 115 to <125 mm 
14 days 
Treatment transition criteria ▪ Child meets OTP ‘cured’ definition 
as described below 
• Two consecutive MUAC measurements 
at or above 115 mm 
and 
• No oedema 
Dosage OTP MUAC <115 mm and/or oedema (+/++) 
RUTF 200 kcal/kg/day RUTF 1000 kcal/day (2 sachets/day) 
SFP MUAC 115 to <125 mm 
RUSF 500 kcal/day (1 sachet/day) RUTF 500 kcal/day (1 sachet/day) 
Cured OTP ≥125 mm for 2 consecutive measurements 
▪ Child maintains MUAC ≥115 mm 
for 2 consecutive visitsb 
and/or 
▪ WHZ >−3 for 2 consecutive visitsb 
and 
▪ No oedema for 2 consecutive visits 
SFP 
Child maintains WHZ >−2 and/or MUAC 
≥125 
mm for a period of 2 consecutive visitsb 
and no oedema 
 
 
aClinically uncomplicated: passes the appetite test, no Integrated Management of Childhood Illness (IMCI) danger signs [11]/no serious medical complications 
bDependent on which criteria the child was admitted on 
 
health services available), the population served (slum or 
peri-urban communities), and expected caseload of mal- 
nutrition. Each treatment facility is approximately 3–5 km 
apart. The clinics in Nairobi are run by the MoH, and the 
IRC supports with research staff at each clinic to imple- 
ment the ComPAS trial. 
 
Eligibility 
Children 6–59 months with uncomplicated acute malnutri- 
tion are eligible for inclusion in the study per the following 
criteria: 
 
• MUAC <125 mm 
and/or 
 
• Bilateral pitting oedema (+/++) 
and 
 
• Passes the appetite test (consumption of 30 g of 




• No medical complications (i.e. no features of severe 






Table 2 Outcomes  
 Measurement variable Analysis metric Method of aggregation Time point 
Primary     
Recovery MUAC ≥125 mm and no oedema Final value Proportion End of treatment 
Secondary     
Coverage % of children eligible for treatment 
(MUAC <125 mm) who receive it 
Final value Proportion Mid-point of study 
Defaulter Child discharged as defaulter 
(3 missed visits) 
Final value Proportion End of treatment 
Died Child died during treatment Final value Proportion End of treatment 
Length of stay Days in treatment Duration of time Sum End of treatment 
Average daily weight gain g/kg/day Daily Mean End of treatment 
Average daily MUAC gain mm/day Daily Mean End of treatment 
 
Childhood Illness (IMCI) [11], e.g. no severe nausea/ 
vomiting, no severe dehydration, no severe pneumonia) 
 
A child is excluded from the study if  he  or  she  has 
ever been enrolled in the ComPAS trial or if he or she is 
receiving SAM or MAM treatment elsewhere, unless he 
or she was recently discharged from SAM treatment in 
order to attend MAM treatment. 
 
Informed consent procedure 
Consent is sought at two levels: at the level of the cluster, 
by the health facility officer in charge of each clinic prior 
to cluster randomization, and at the level of the individual, 
by the caretaker of each child prior to enrolment. When a 
caretaker arrives to any health facility included in the 
ComPAS trial seeking treatment for their malnourished 
child, they are seen by a community health or nutrition 
worker to confirm that they are eligible to receive treat- 
ment (i.e. they have a MUAC <125 mm, and/or a WHZ < 
−2, and/or oedema). Once their eligibility for treatment is 
confirmed, they are seen by the ComPAS research officer 
and clinical officer responsible for their care. First, the re- 
search officer will confirm that the present caretaker is a 
primary guardian for the child. If yes, the research officer 
describes the aims of the study as detailed in the ‘partici- 
pant information sheet’, ensuring that the caretaker feels 
comfortable and understands the information. The partici- 
pant information sheet provides details of the treatments 
provided in the study. The research officer will ensure the 
caretaker understands that treatment is available for all 
malnourished children regardless of whether they choose 
to participate in the study. Caretakers who agree to par- 
ticipate in the study will indicate their consent by signing 
a written consent form. If caretakers are not able to read 
or write, an impartial witness will oversee the consent 
process and attest to the caretaker’s verbal consent. If the 
caretaker is not a primary guardian or chooses not to par- 
ticipate in the study, their child is enrolled for treatment 
only, and their information is not collected. 
Randomization and blinding 
Sequence generation 
Randomization sequence is generated using an online 
sequence generator [12]. 
 
Type 
There is stratification by country to ensure equal, 1:1 
distribution of control and intervention clinics (clusters) 
in each country. 
 
Allocation concealment mechanism and implementation 
Clinics agree to participate understanding that group allo- 
cation is unknown in advance and is allocated randomly. 
The study statistician applies the random number se- 
quence to a pre-written list of participating clinics, and the 
study team conveys the resultant allocation to the clinic 
staff. Individual carers attending clinics for the first time 
are very unlikely to know in advance whether their local 
clinic is in the intervention or control arm of the study. 
 
Blinding 
Due to the nature of intervention, this is not a fully blinded 
study. Front-line clinical and study staff must know 
whether they are treating children according to interven- 
tion or control (standard care) protocols, and the same staff 
enrol, manage and follow up patients. Staff in the standard 
protocol clinics were given refreshing trainings to reinforce 
standard protocol implementation, and staff in the com- 
bined protocol clinics were given trainings to roll out the 
new protocol. Staff in the clinics do not have access to 
overall treatment outcomes for each clinic or each arm of 
the trial; they are only aware of individual outcomes for the 
children they are responsible for treating. Similarly, individ- 
ual carers cannot be blinded to the intervention being given 
to their child. Important to note however is that inter- 
group differences are unlikely to be striking to anyone but 
expert observers: both study arms use nutrient-dense food 
pastes, with RUTF and RUSF being peanut-based with 






clinically managed in exactly the same way in both study 
arms. The principal investigator is blinded to the treatment 
outcomes, in order to maintain objective trial management 
and analysis of results. 
 
Treatment 
The combined protocol will be compared against the 
standard protocol (the national protocol in each country). 
The combined protocol admits all children with a MUAC 
<125 mm and/or oedema (+/++) and treats them accord- 
ing to a standardized dose of RUTF (children with a 
MUAC <115 mm or oedema receive 1000 kcal/day of 
RUTF; children with a MUAC 115 to <125 mm receive 
500 kcal/day of RUTF). The combined protocol  remains 
in line with globally accepted practice, with children recov- 
ering from SAM receiving enough therapeutic food to 
cover their total energy needs and children with MAM re- 
ceiving a supplement to their family diet (most SFP proto- 
cols provide approximately 500–550 kcal/day of RUSF). 
The standard protocol includes treatment of SAM in an 
OTP using RUTF (200 kcal/kg/day) and MAM in a SFP 
using RUSF (500 kcal/day), as approved by the WHO, 
UNICEF, WFP and Ministries of Health in each country. 
The medical components of each protocol are the same, 
with children in the combined protocol with a MUAC 
<115 mm and/or oedema receiving the same systematic 
medications as those in the standard protocol enrolled in 
the OTP  (per national guidelines). Children are managed 
at level 1 (community) health facilities by nurses or clinical 
officers for the medical aspects of care and by nutritionists 
for the nutritional components. If a child requires any add- 
itional medical care, they are seen by a nurse or clinical of- 
ficer in the same facility. The few requiring higher level 
treatment are referred to the nearest inpatient facility. The 
qualifications of the staff and level of care are the same 
across both arms. The combined and standard nutritional 
treatment protocols are summarized in Table 1. 
At each weekly follow-up visit, SAM cases are seen by a 
clinician (nurse or clinical officer) for the medical review 
and a nutritionist for the nutritional review. MAM cases 
differ in that they return for follow-up bi-weekly and re- 
ceive a medical assessment only if they exhibit signs of ill- 
ness or non-response to treatment. If a child has developed 
any medical complications or needs more specialist assess- 
ment, they are referred to the nearest inpatient facility 
(hospital in Nairobi, Kenya; Stabilization Centre in Aweil 
East, South Sudan). If a child is not gaining weight or mid- 
upper arm circumference appropriately, the nutritionist 
will discuss with a clinician based at the health facility, ex- 
ploring possible underlying medical conditions, as well as 
counselling the caregiver to address possible contributory 
factors (e.g. sharing of RUTF/RUSF with other children, 
household food insecurity, breastfeeding for younger chil- 
dren). This is the same process across both arms. 
 
Children who miss visits are followed up by a commu- 
nity health worker (Kenya) or community  volunteer 
(South Sudan) to encourage caretakers to  return. Chil- 
dren who default are followed up by a community health 
worker to ascertain the child’s true status (cured, died or 
remains malnourished). 
Participants will be followed up 4 months post- 
discharge to assess nutritional status (weight, height, 
MUAC and oedema), health status (any hospitalizations 
since discharge and morbidities in the prior 2 weeks), and 
breastfeeding status. The objective of the follow-up study 
is to assess long-term impacts of the combined protocol. 
The timeline for enrolment, interventions and assess- 
ments is in Fig. 2. 
 
Outcomes 
The primary outcome, ‘recovery’, in both the control and 
intervention groups is defined as two consecutive mea- 
surements with a MUAC ≥125 mm and no oedema. The 
secondary outcomes include coverage, rates of defaulting 
and death, length of stay, and average daily weight and 
MUAC gain. Cost-effectiveness will be assessed through 
an economic analysis of financial data following  the 
study. The outcome metrics are described in Table 2. 
 
Quality control and supervision 
A research officer is based in each of the 24 clinics in- 
cluded in this study. Each research officer oversees the 
consent process, enrolment and treatment of children 
according to the study protocol and data management. 
They participate in initial and refresher trainings with 
health facility staff as well as provide continuous on-the- 
job trainings to clinicians and community health volun- 
teers involved in administering  treatment  according  to 
the study protocol. They assess the accuracy of an- 
thropometric measurements taken by health facility staff 
and review the patient cards and registers  on  a  daily 
basis to ensure data quality. 
Research officers are supervised by a team of roving 
senior supervisors, including senior research officers, 
deputy manager, research field coordinator and the nu- 
trition coordinator. 
 
Data collection and management 
In Kenya, patient anthropometry data is immediately tran- 
scribed from paper patient cards by the research officer 
based at the clinic using a digital data collection applica- 
tion (CommCare HQ; https://www.commcarehq.org) on 
Wi-Fi- and SIM card-enabled 7-in. Samsung Galaxy Tab 
A tablets. Due to Internet connectivity challenges in South 
Sudan, patient information is collected on paper first and 
later transferred to a 9.6-in. Samsung Galaxy Tab E tablet 
by a central data entry clerk. Data is reviewed weekly by 
the field coordinators and any discrepancies corrected and 
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recorded using a digital ‘data error correction form’. In 
addition to the primary and secondary outcomes listed in 
Table 2, additional information is collected from the care- 
giver on morbidity, breastfeeding, protocol adherence, 
food security, hygiene and sanitation, caretaker education 
and demographic characteristics. 
The procedures for assessing child anthropometry 
(weight, height, MUAC and oedema) are detailed in 
Additional file 1. 
 
Analysis 
Sample size calculation was determined using an ex- 
pected recovery rate of 85% based on the average 
programme statistics provided by the MoH in Nairobi, 
Kenya, and Action Against Hunger in Aweil East, South 
Sudan. If the combined protocol is non-inferior to the 
current protocol, allowing for a 10% non-inferiority mar- 
gin, then we require 12 clusters in each arm with 100 
children in  each  cluster  to  demonstrate  non-inferiority 
of the combined protocol, with 80% power at the 5% 
level of significance. An intra-cluster correlation coeffi- 
cient (ICC) of 0.05 was assumed, a conservative estimate 
based on the results of a  similar  cluster  randomized 
study testing an integrated SAM/MAM protocol in Si- 
erra Leone [7]. In order to account for losses to follow- 
up (estimated as 15%) and cross-overs (estimated as 5% 
in each arm), 150 children per cluster will be recruited 
for inclusion in the study. The cluster size calculation is 
 
as follows: 100 × 1/(1 − 0.15) × (1/(1 − 0.05 − 0.05)2)=  
146. Therefore, with a cluster size of  150,  and  24 
clusters, 3600 children in total will be recruited in this 
study (1800 in each country). 
Statistical analysis will be conducted at the individual 
level with appropriate adjustment for clustering within 24 
clusters. Descriptive summaries of participant characteris- 
tics by arm will be tabulated. Descriptive statistics for con- 
tinuous variables will include the mean, standard 
deviation, median, range and the number of observations. 
Categorical variables will be presented as numbers and 
percentages. The main analysis of the primary and sec- 
ondary outcomes will be per-protocol given that this is a 
non-inferiority trial. Additionally, intention-to-treat ana- 




If a caretaker consents for their child to be enrolled, they 
are issued a ComPAS ID number, which is affixed to their 
paper forms and entered in digital forms. All patient forms 
are maintained securely in a locked file throughout the 
study to ensure patient confidentiality. In Kenya, data col- 
lection tablets are password protected and research officers 
are assigned individual logins and passwords to access the 
digital data collection application (CommCare). Research 
officers are able to enter data for patients at their assigned 








CommCare platform, which occurs daily. Research officers 
cannot update prior entries unless they use an approved 
data error correction form. They are able to view a very 
limited selection of historical data for the purpose of pa- 
tient identification and missed visit tracking. In South 
Sudan, data entry tablets are password protected and data 
entry clerks based in the ACF office have exclusive access 
to CommCare using individual logins. 
 
Safety 
Adverse events, including  hospitalizations  and  deaths, 
are monitored and recorded by the research team for re- 
view by the independent trial safety committee (de- 
scribed in the ‘Trial governance’ section). 
 
Ethical approval 
This study protocol was approved by the following eth- 
ical review committees: 
 
1. Kenya Medical Research Institute (KEMRI), 
Nairobi, Kenya. Reference: Non-KEMRI 551 
2. Ministry of Health, Juba, South Sudan. Approved 
21 November 2016 
3. London School of Hygiene and Tropical Medicine, 
London, UK. Reference: 11826 
 
Trial governance 
ComPAS is a research consortium of the International 
Rescue Committee, Action Against Hunger and the 
London School of Hygiene and Tropical Medicine. The 
trial is guided by a scientific committee of experts in 
paediatrics, humanitarian nutrition and epidemiology 
from the London School of Hygiene and Tropical Medi- 
cine, Washington University School of Medicine and the 
University of Copenhagen/University of Tampere. A trial 
safety committee, comprising an independent chair and 
a statistician from the London School of Hygiene and 
Tropical Medicine, will review the study outcomes and 
adverse events at the mid-point of the trial. 
This trial is registered as ISRCTN30393230, 16 March 
2017 (Additional file 2). 
 
Discussion 
This study, a multi-site cluster randomized non-inferiority 
trial, expected to be completed by mid-2018, is evaluating 
the effectiveness of a simplified and combined treatment 
protocol for SAM and MAM against the standard protocol 
Assessed for eligibility (n) 
Met Criteria (n) 
Reasons for exclusion: 
Not SAM/MAM (n) (%) 
Declined consent (n) (%) 
Referred to SC (n) (%) 
Missing data (n) (%) 








Per Protocol (Main Analysis) 
Recovered (n) 
Died (n) (included in-programme defaulter deaths 
but not late deaths who did not follow protocol) 
Remained Malnourished (n) 
ITT (Secondary Analysis) 
Recovered (n) 
Died (n) (includes early and late defaulter deaths) 
Remained Malnourished (n) 
Defaulter (lost to follow-up/ unknown) (n) 
Defaulter (non-cure) (n) 
Defaulter (cure) (n) 






of separate products (RUTF, RUSF) and programmes (OTP, 
SFP) for SAM and MAM. If the results show that the com- 
bined protocol has non-inferior recovery rates compared to 
the standard protocol, this study will contribute to the evi- 
dence that current CMAM protocols can be simplified and 
that treatment of SAM and MAM can be combined (one 
product, one protocol and one anthropometric criterion for 
admission and discharge). This would make it easier for 
health care providers to offer treatment, reaching more 
children at an earlier stage before they deteriorate into se- 
vere malnutrition. The results of this trial should be inter- 
preted together with the cost-effectiveness analysis to 
support policy decisions aimed at improving the coverage 
and quality of treatment. 
 
Trial status 
Recruitment of trial participants began on 15 May 2017 
and is expected to be completed by 1  June  2018,  at 
which point data will be analysed. The SQUEAC cover- 
age assessments will be complete in both countries by 
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52  
3.5 Summary of methods for objective 3 
 
Following completion of the RCT, I conducted a secondary analysis on the intention-to-treat dataset 
from the ComPAS trial. This dataset included 4,078 children aged 6 to 59 months with 
uncomplicated severe and moderate acute malnutrition treated in Kenya and South Sudan. The 
analysis assessed outcomes and response to treatment and the impact of different dosage protocols 
for children with a severely low MUAC (<11.5 cm), severely low WAZ (<-3.0), or both. 
A full description of the methods used in this analysis are available in Paper IV. 
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Chapter 4: Results 
 
4.1 Paper II: Results for Objective 1 
 
Paper II: Chase RP, Kerac M, Grant A, Manary M, Briend A, Opondo C, Bailey J. Acute 
malnutrition recovery energy requirements based on mid-upper arm 
circumference: Secondary analysis of feeding program data from 5 countries, 
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Severe and moderate acute malnutrition (SAM and MAM) are currently treated with different 
food products in separate treatment programs. The development of a unified and simplified 
treatment protocol using a single food product aims to increase treatment program efficiency 
and effectiveness. This study, the first stage of the ComPAS trial, sought to assess rate of 
growth and energy requirements among children recovering from acute malnutrition in order 




We obtained secondary data from patient cards of children aged 6–59 months recovering 
from SAM in outpatient therapeutic feeding programs (TFPs) and from MAM in supplemen- 
tary feeding programs (SFPs) in five countries in Africa and Asia. We used local polynomial 
smoothing to assess changes in MUAC and proportional weight gain between clinic visits 
and assessed their normalized differences for a non-zero linear trend. We estimated energy 
needs to meet or exceed the growth observed in 95% of visits. 
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Results 
This analysis used data from 5518 patients representing 33942 visits. Growth trends in 
MUAC and proportional weight gain were not significantly different, each lower at higher 
MUAC values: MUAC growth averaged 2mm/week at lower MUACs (100 to <110mm) and 
1mm/week at higher MUACs (120mm to <125mm); and proportional weight gain declined 
from 3.9g/kg/day to 2.4g/kg/day across the same MUAC values. In 95% of visits by children 
with a MUAC 100mm to <125mm who were successfully treated, energy needs could be 
met or exceeded with 1,000 kilocalories a day. 
 
Conclusion 
Two 92g sachets of Ready-to-Use Therapeutic Food (RUTF) (1,000kcal total) is proposed 
to meet the estimated total energy requirements of children with a MUAC 100mm to 
<115mm, and one 92g sachet of RUTF (500kcal) is proposed to meet half the energy 
requirements of children with a MUAC of 115 to <125mm. A simplified, combined protocol 
may enable a more holistic continuum of care, potentially contributing to increased coverage 





Acute malnutrition (AM) is divided into Severe Acute Malnutrition (SAM) and Moderate 
Acute Malnutrition (MAM), with SAM defined as a MUAC <115mm, weight-for-height z- 
scores below -3 of the median WHO growth standards or by the presence of nutritional 
oedema, and MAM defined as MUAC 115 to <125mm or weight-for-height z-scores of 
between <-2 and ≥-3. Globally, at any one time, it is estimated that more than 50 million chil- 
dren under the age of five suffer from acute malnutrition (AM) [1], likely translating to over 
100 million incident cases of SAM each year [2–5]. SAM accounts for approximately 516,000 
deaths annually, MAM for 359,000 [6,7]. 
Currently, SAM and MAM are treated in separate feeding programs, with separate proto- 
cols, products, and supply chains [8]. Resource constraints and logistical challenges often 
result in SAM being prioritized due to its particularly high case-fatality and long-term adverse 
outcomes [9,10]. MAM services are often unavailable or time-bound (e.g. only present during 
the ‘hungry’ season or in times of food crisis). Increasing evidence suggests that this is an 
important gap: children with MAM-associated anthropometric deficits (a weight-for-height z- 
score between -3 and <-2) are 3 times more likely to die than healthy children [11], and preva- 
lence of MAM can affect the incidence and severity of SAM [12,13]. 
To better tackle both MAM and SAM, there is growing momentum within the nutrition 
community to view the two as a continuum condition rather than as two distinct states [14– 
17]. Thus simplifying and unifying the treatment protocols might ease integration into existing 
health services, increase treatment coverage, and potentially enhance cost-effectiveness by 
treating MAM earlier and more easily, preventing costly and dangerous SAM [15,16,18]. Early 
data on such programming is promising [18]. However, to inform future policy decisions, 
stronger evidence is needed [19]. 
Two questions are key. First, can mid-upper arm circumference (MUAC) be used as the 
primary anthropometric indicator for screening, treatment, and discharge of uncomplicated 
cases of acute malnutrition? MUAC-only programming offers many practical and logistical 
advantages over weight-for-height [20]. MUAC for admission has been found to detect the 




highest-risk children [21,22]. However, further evidence is needed on MUAC as a patient 
monitoring and discharge criterion. In particular, does MUAC reflect similar trends as weight 
gain in response to nutritional treatment [23–25]? 
Second, how much energy is needed to most efficiently treat acute malnutrition? A wide 
variety of products and approaches are available for addressing MAM, not only limited to 
treatment [14,26,27]. Studies show that nutrient-dense pastes (Ready-to-Use Therapeutic 
Food, or RUTF) that are typically recommended for treatment of SAM result in higher recov- 
ery rates for MAM patients than do fortified blended flours [28–34]. For SAM, RUTF is stan- 
dard and is prescribed to provide 175–200 kcal/kg/day [35,36]. This energy dosage is high 
because it is based on inpatient-focused models of care where expected patient weight gain 
was high: 10–15 g/kg/day [37]. In contrast, expected weight gain in today’s outpatient-focused 
programmes is about 4.5 to 6.8 g/kg/day [38]. Children may not thus require all the energy 
they are prescribed, especially as growth slows towards the end of treatment [39–42]. 
We aimed to address these evidence gaps by assessing MUAC and proportional weight 
gain, and estimating energy needs of children as they recover from SAM and MAM. The overall 
aim of this ComPAS Stage 1 study was to design a simplified, MUAC-based dosage protocol and 
statistically assess its theoretical performance providing adequate energy. Driven initially by an 
immediate need to inform a cluster-randomised control trial on a “Combined Protocol for Acute 
Malnutrition Study” (ComPAS study) [43], our goal has been to inform and ultimately improve 
wider SAM/MAM programming. Specific objectives are threefold. First, we aim to describe and 
compare MUAC and weight gain trends in children being treated for acute malnutrition to assess 
if MUAC is a valid proxy of proportional weight gain during treatment. Second, we will calculate 
energy requirements needed to support observed weight and MUAC gain in children recovering 
from acute malnutrition and to explore any differences by age and by MUAC category (SAM vs 
MAM). Third, we will assess the ability of a simplified MUAC-based dosage protocol to provide 




This study was a secondary analysis of routine clinical data obtained from therapeutic and sup- 
plementary feeding programs (TFP and SFP, respectively). 
 
Setting and study sample 
We analyzed data from programmes run by Médecins Sans Frontières (MSF-France) in South 
Sudan in 2010; Action Against Hunger (AAH-USA) in Pakistan in 2012; and International 
Rescue Committee (IRC) in Chad (2013 & 2014), Kenya (2012, 2013, & 2014), and Yemen 
(2014) as these programs had treatment data (rather than survey or cross-sectional data) and a 
partnership to do this research. Admission of children to these outpatient TFPs for SAM or 
SFPs for MAM were based on screenings in the community or directly at the health centre. 
Admission criteria for both TFPs and SFPs followed standard international criteria, as laid out 
in national acute malnutrition treatment protocols in use at the time in that particular country 
[44–47]. Enrolled patients had to be clinically well, alert and demonstrate appetite. Acute mal- 
nutrition cases eligible for treatment were enrolled in the TFP or SFP programme and moni- 
tored on a weekly basis (SAM) or a two-week basis (MAM). Therapeutic rations for SAM 
patients were provided based on weight (200 kcal/kg/day) and supplementary rations for 
MAM patients were provided as a standard ration which varied by country. Patients were dis- 
charged when they reached a combination of discharge criteria, which differed between TFP 
and SFP and also varied by country. 




Patient data were originally available on paper-based patient monitoring cards held securely 
on-site at each programme. Data from the cards were entered into an Excel database between 
October 2014 and May 2015 using double data entry for quality control. The main study team 
at IRC received anonymized data and merged it into a single database stored on a password- 
protected institutional server. We tagged data by type of facility (TFP or SFP) and country 
from which the cards were obtained. 
Participating children were those aged 6 to 59 months and enrolled in either outpatient 
TFPs for SAM or SFPs for MAM. Children were eligible for analysis if they were discharged 
from a feeding programme as recovered, experienced a non-negative MUAC gain, and experi- 
enced either a weight gain of at least 10% from admission to discharge if admitted as a SAM 
patient or at least 3% from admission to discharge if admitted as a MAM patient. By using data 
from patients who achieved these outcomes, trends reflect the most successful cases coming 
out of current TFP and SFP programs. We chose to focus on children who had achieved recov- 
ery in order to establish energy requirements for successful growth. 
Exclusion criteria were those children with unusable data, defined as having no follow-up 
visits, or missing age, sex or date information. Data analysis was limited to MUACs 100mm to 
140mm due to limited information outside these values for reliable estimates of weight change, 
MUAC change, and energy needs within each MUAC category. 
Visits recording extreme high or low anthropometric measures which are thus likely to be 
measurement or recording errors were also excluded according to the following criteria [48]: 
weight-for-height z-score below -5 or above 5, weight-for-age z-score below -6 or above 5, 
height-for-age z-score below -6 or above 6, MUAC below 65mm or above 200mm, weight 
change of more than 25 grams per kilogram weight per day, or MUAC change in either direc- 
tion of greater than 15mm per week. 
 
 
Variables, measurements, and statistical methods 
Variables available on the patient cards included: date of visit to clinic, age in months at admis- 
sion, presence of oedema at admission, mid-upper arm circumference (MUAC) measured in 
millimeters (mm) at each visit, weight measured to the tenth of a kilogram (kg) at each visit, 
and height measured to the tenth of a centimeter (cm) at admission and discharge. Each card 
followed an individual child through one course of treatment. Not all children completed 
treatment, and registration cards could not necessarily be linked if the same child had multiple 
courses of treatment or obtained treatment for both SAM and MAM in separate programmes. 
The total number of study participants was determined by available programme data. 
Because this was a secondary analysis, a priori sample size calculations were not done. Five dif- 
ferent countries were included so as to represent a variety of different settings where acute 
malnutrition is highly prevalent. 
From the total eligible sample, we used different subsamples for analyses. For polynomial 
smoothing used to visually compare trends in weight and MUAC change since prior visit by 
MUAC at prior visit, we randomly selected 1000 visits from each of the five countries from 
which patient cards were obtained, resulting in a single 5000-visit subsample with an equal 
number of observations from each country (to which Yemen could contribute the least with 
1279 eligible observations). One-hundred such subsamples were used to test whether the linear 
trend of the difference in the normalized trends was non-zero. For theoretical assessment of 
the proposed therapeutic protocol, we used 100 different subsamples of 2500 visits (500 visits 
from each country) to simulate average performance of the protocol given varying distribu- 
tions of patient visits from the sample. To estimate indicators to two significant figures, 100 
resamples were sufficient. 




We conducted the analysis using Stata 13.1 [49]. Weight-for-height (WHZ), weight-for-age 
(WAZ) and height-for-age (HAZ) z-scores were calculated at admission and discharge using 
the 2006 WHO child growth standards via the user-written Stata command zscore06 [50]. 
One-week change in MUAC was calculated as the difference between MUAC between two vis- 
its (usually one week apart). If visits were not one week apart, change was assumed constant 
over the period of time between visits, and so change over the course of two weeks was divided 
in half to reflect one-week change in measurements. Proportional weight gain was similarly 
assumed constant between visits, and was calculated as grams of weight gained per kilogram of 
weight at prior visit per day. Change in MUAC (mm/week) and proportional weight change 
(g/kg/day) were primary outcomes with MUAC the predictor. 
Using local polynomial smoothing (via the lpoly command) with the 5000-visit subsample, 
we visually assessed one-week MUAC growth (mm/week) versus MUAC and proportional 
weight gain (g/kg/day) versus MUAC. This was done among all patients with eligible outcomes 
to understand whether MUAC and weight change responded similarly to treatment. A second- 
ary analysis was performed assessing these by age group to determine if the relationships were 
similar for 6–11 month olds, 12–23 month olds, and 24–59 month olds. A set of 100 simula- 
tions (each with a different 5000-visit subsample as used for local polynomial smoothing) 
assessed via linear regression whether the difference in normalized means of MUAC growth 
and proportional weight gain had a non-zero trend. 
Daily energy needs (kcal) were calculated as [51,52]: 
Resting energy needs were estimated at 82 kcal/kg/day, which is slightly more than required for 
normal growth of children aged 6 to 12 months (see Table 3.2 and 3.3 in the Food and 
Agricultural Organization 2001 human energy requirements report) and consistent with prior 
estimates of energy requirements for maintenance among young children [52]. The energy 
cost to add 1 g of tissue was estimated at 5kcal based on several studies cited in the Food and 
Agricultural Organization 2001 report (pg 31) [51]. 
Energy needs to support observed growth were calculated for each patient visit as kcal/day 
per the above formula. 
For children admitted to the clinic with SAM-associated MUACs (MUAC 100mm to 
<115mm) and with MAM-associated MUACs (MUAC 115mm to <125mm), the smallest 
amount of energy that would be sufficient to achieve observed growth in 95% of visits, i.e. the 
95th percentile of their energy requirements, was calculated. 
In secondary analyses, we compared the 95th percentile of energy needs by age group (6–23 
months and 24–59 months), continent (Asia and Africa), and MUAC category at admission 
(<115mm and 115 to <125mm). We selected the above age ranges because most children who 
are admitted to community-based management of acute malnutrition (CMAM) programmes 
are between the ages of 6–23 months, and children <24 months are the most vulnerable to epi- 
sodes of acute malnutrition. The comparison by MUAC category at admission could only be 
made over ranges of MUAC that these children had in common (110mm to <125mm) since, 
in general, patients with eligible outcomes who were admitted with MUAC of 115mm or 
above did not generally return to the clinic with a MUAC below 110mm during treatment. 
The 95th percentile was calculated over 5mm MUAC categories (such as MUAC 110 to 
<115mm). The 95th percentile of energy needs was not reported to reflect average energy 
needs, but the provision of energy sufficient for observed growth in 95% of patient visits in the 
category. 




Having developed a simplified protocol based on the above analyses, we assessed its theoret- 
ical performance among 100 different subsamples of 1000 patient visits each (200 patients 
from each country). One-hundred simulations were found to provide similar results as 1000 
simulations in initial testing, so 100 simulations were considered suitable to achieve stable 
results. Two-hundred patient visits were selected from each country so that the patients repre- 
senting each country would vary in every subsample (Yemen had the fewest cases at 294 
patients). In each of the 100 simulated trials of the protocol, we recorded performance mea- 
sures among patient visits with SAM-associated MUACs (100mm to <115mm) and MAM- 
associated MUACS (115mm to <125mm) separately. For patient visits with SAM-associated 
MUACs and (separately) with MAM-associated MUACs, we estimated the median percentage 
of energy needs covered by the protocol. For patient visits with SAM-associated MUACs, we 
have reported the mean percentage of visits among the 100 subsamples in which at least 100% 
of energy needs to support observed growth would be provided. For patient visits with MAM- 
associated MUACs, we have reported the mean percentage of visits in which at least 50% of 
energy needs to support observed growth would be provided. 
We compared how the proposed protocol would compare in terms of energy provision to 
other protocols: namely comparing average energy provision by MUAC from Golden’s mini- 
mum (135 kcal/kg/day), intermediate (150 kcal/kg/day), and standard (170 kcal/kg/day) pro- 
tocols [53]; the Sierra Leone protocol (175 kcal/kg/day if MUAC<115mm, 75 kcal/kg/day if 
MUAC 115mm to <125mm) [18]; and the National Guideline for Integrated Management of 
Acute Malnutrition for Kenya (or “Kenya protocol”, 200 kcal/kg/day if admitted to SAM treat- 
ment program, 500 kcal/day if admitted to MAM treatment program) [47]. The Golden proto- 
cols call for complete energy needs to be provided through therapeutic care and provides 
minimum and intermediate options with lower energy provisions for resource-constrained 
settings. The Kenya protocol provides complete energy needs to patients with SAM until they 
are discharged as recovered. Like the proposed protocol, the Sierra Leone protocol and Kenya 
protocol provide only supplemental energy to children with MAM. The Sierra Leone protocol 
also uses MUAC as the primary anthropometric admission criterion, with oedema also indi- 
cating SAM treatment should be provided. 
 
Ethical approval 
Stage 1 of the ComPAS study was approved by the London School of Hygiene and Tropical 




A total of 10,068 patient record cards from TFP and SFP programs in Kenya, Pakistan, Chad, 
Yemen, and South Sudan representing 57,138 patient visits were collected (Fig 1). Of these, we 
excluded 1,788 records (7,105 patient visits) from analysis due to unusable data or biologically 
implausible data. Of the 8,280 patient cards with usable and biologically plausible data, 5,518 




In all countries but South Sudan, there were more female patients than male patients (Table 1). 
In all countries, age was frequently rounded to years rather than months, resulting in impre- 
cise age data. Most patients were under 2 years old, with 29% of patients age 6–11 months, and 






Fig 1. Study flow chart. 
https://doi.org/10.1371/journal.pone.0230452.g001 
 





Table 1. Sample description. 
 
 Kenya Pakistan Chad Yemen S. Sudan Total 
Total number of patient cards 439 1952 1422 483 1222 5518 
. . . representing X visits 2701 9052 10085 2916 9188 33942 
Age group, n (%)       
6–11 months 146 (33%) 493 (25%) 548 (39%) 113 (23%) 326 (27%) 1626 (29%) 
12–23 months 135 (31%) 813 (42%) 576 (41%) 128 (27%) 544 (45%) 2196 (40%) 
24–35 months 77 (18%) 400 (20%) 211 (15%) 69 (14%) 248 (20%) 1005 (18%) 
36–59 months 81 (18%) 246 (13%) 87 (6%) 173 (36%) 104 (9%) 691 (13%) 
Sex, n (%)       
Female 226 (51%) 1104 (57%) 802 (56%) 270 (56%) 585 (48%) 2987 (54%) 
Male 213 (49%) 848 (43%) 620 (44%) 213 (44%) 637 (52%) 2531 (46%) 
Stunting at admission, n (%)       
HAZ<-2 206 (47%) 876 (45%) 989 (70%) 201 (42%) 484 (40%) 2756 (50%) 
HAZ�-2 226 (51%) 370 (19%) 429 (30%) 281 (58%) 731 (60%) 2037 (37%) 
Missing height 7 (2%) 706 (36%) 4 (<1%) 1 (<1%) 7 (1%) 725 (13%) 
Admitting facility, n (%)       
TFP 121 (28%) 276 (14%) 386 (27%) 116 (24%) 1222 (100%) 2121 (38%) 
SFP 318 (72%) 1676 (86%) 1036 (73%) 367 (76%) N/A 3397 (62%) 
Oedema, n (%)       
Oedema = 0 239 (54%) 1943 (>99%) 1421 (>99%) 483 (100%) 3 (<1%) 4089 (74%) 
Missing 200 (46%) 8 (<1%) 1 (<1%) 0 (0%) 1209 (99%) 1418 (26%) 





40% age 7–23 months. In Pakistan, nearly half of patients had no height data to assess for 
stunting. Data on presence of oedema were almost always missing or indicative of no oedema; 
if all non-zero, non-missing oedema values indicated presence of oedema, 11 patients would 
have been recorded as having oedema, almost all in South Sudan. In South Sudan, all data 
were from TFP facilities treating SAM; in other countries, 67–82% of patient registration cards 
came from SFP facilities treating MAM. 
 
 
MUAC and weight changes 
Weekly MUAC change showed similar trends as proportional weight gain when assessed by 
MUAC (Fig 2) and were not significantly different when their values were normalized between 
0 and 1 and their differences assessed for a non-zero linear trend in 100 simulations. For 
MUAC 100mm to <125mm, slope ranged from -0.003 to 0.002 with mean of -0.0002, with the 
F-test non-significant in 86% of simulations. For MUAC 125mm to 140mm, slope ranged 
from -0.006 to 0.001 with mean of -0.002, with the F-test non-significant in 54% of simulations 
(i.e., MUAC gain was slightly slower than proportional weight gain at higher MUACs in nearly 
half of simulations with MUAC 125mm to 140mm). Both MUAC gain and proportional 
weight gain were highest at lower MUACs, and declined to lower levels of growth at higher 
MUACs. Specifically, mean weekly MUAC change went from approximately 2mm/week at the 
lowest MUACs (100 to <110mm) to 1mm/week among those with MUAC 120mm to 
<125mm. Similarly, mean proportional weight gain declined from approximately 3.9g/kg/day 
to 2.4g/kg/day across the same MUAC values. An increase of 1mm MUAC was associated 
with a decrease in weekly MUAC growth of 0.06mm (F-test p-value<0.001) and a decrease in 
daily proportional weight gain of 0.05g/kg/day (F-test p-value<0.001), indicating that 











recovering children with higher MUACs grew more slowly according to these measures than 
children with lower MUACs. 
 
Energy needs 
Energy need calculations indicated that 1,000 kilocalories per day were sufficient or more than 
sufficient in 95% of patient visits to support the growth observed among children who ulti- 
mately achieved eligible recovery outcomes (Fig 3). However, we estimated that older children 
(over 24 months) with higher MAM-associated MUACs (MUAC 115mm to <125mm) needed 
1200kcal per day to cover 100% of energy needs to support observed growth in 95% of visits. 
Children over the age of 24 months made up one-fifth of the database (Table 1) and, of these, 
nearly all had MUACs above 115mm throughout treatment. While we estimated that most of 
these visits (83%) needed 1,000 kilocalories or fewer to meet their daily energy needs, this fell 
short of the 95% goal set for this protocol. 
We noted differences in the 95th percentile of daily energy needs among children with 
MUAC < 115mm MUACs in Asia versus Africa, with children in African countries needing 
960kcal/day versus 810kcal/day in Asia (Fig 3); however, the difference was smaller among 
children with MUACs 115mm to <125mm in these two regions (approximately 1050kcal/day 
in Africa and 995kcal/day in Asia). These results are consistent with other studies indicating 
that children in Asia with SAM are different from those in Africa, with a comparatively high 
proportion of recovery and low mortality even in the absence of intensive treatment [54]. 
Comparing children admitted with SAM-associated MUACs (100mm to <115mm) to 
those admitted with MAM-associated MUACs (115mm to <125mm), estimated energy needs 







Fig 3. Estimated daily energy (kcal) that would provide 95% of patient visits in the specified MUAC category with energy needs 
for observed growth. Comparisons are made by: (A) MUAC category at admission, (B) continent, (C) and age group of 6–23 




did not differ greatly. The 95th percentile of daily energy needs among children admitted with 
MAM-associated MUACs was estimated to be 1020 kcal/day; among children admitted with 
SAM-associated MUACs, 960 kcal/day. 
 
Performance of a simplified, combined protocol 
From the above, it appears that most children’s energy needs for recovery from acute malnutri- 
tion would be covered by a protocol providing 1000 kcal/day for children with SAM, whose 
MUAC is 100mm to <115mm and 500kcal/day for children with MAM, whose MUAC is 
115mm to <125mm. That would be equivalent to two sachets per day of RUTF for children 
with SAM-associated MUACs, aiming to provide 100% of daily energy needs; and equivalent 
to one sachet per day of RUTF for children with MAM-associated MUACs and aiming to pro- 
vide 50% of daily energy needs, the remainder coming from home foods [27]. 






Fig 4. Comparison of mean energy provided by each of five protocols: The protocol proposed herein, Golden’s minimum, intermediate, and standard protocols, 





Fig 4 shows how the proposed protocol would compare in terms of energy provision to 
other protocols. For lower MUACs (100mm to <115mm), the proposed protocol provides 
more calories than Golden’s minimum and intermediate protocols, similar kilocalories as 
Golden’s standard and the Sierra Leone protocol, and less than the Kenya protocol. At higher 
MUACs (115mm to <125mm), the proposed protocol provides approximately 100–800 fewer 
kilocalories per day than other protocols. 
Table 2 shows the proportions of clinic visits in which the proposed protocol would provide 
at least 100% of estimated energy needs for children with MUAC < 115mm and at least 50% 
of estimated energy needs for children with MUAC 115mm to <125mm in 100 simulated tri- 
als using subsamples of 1000 visits (200 from each country) per trial. Overall, we found the 
protocol to be adequate for both male and female patients presenting with MAM and SAM, 
for children in Africa and Asia, and in each of the five countries. There were however sub- 
groups whose energy needs were met in less than 95% of visits: older children (ages 24 to 59 
months) and larger children (weights ≥ 8.0 kg). Among the older children with the lowest 
MUACs (age 24 to 59 months, MUAC < 115mm), total energy needs were met on an average 





Table 2. Estimated energy provided by proposed protocol as percentage of energy needed in observational data using 100 trials using subsamples of 200 visits from 
each of five countries (1000 visits total per simulated trial). 










Mean percentage of 
visits with all energy 
requirements provided 















Mean percentage of visits 
with half of energy 
requirements provided 









166% 97% 94%-100% 801 
(775– 
827) 
73% 94% 92%-95% 




168% 97% 95%-100% 432 
(400– 
471) 
75% 95% 92%-97% 
Male 74 (59– 
94) 
161% 96% 89%-100% 369 
(331– 
401) 
71% 92% 88%-95% 
Age (in 
months) 
        
6 to 11 115 
(92– 
138) 
175% 98% 95%-100% 291 
(265– 
335) 
83% 98% 97%-100% 
12 to 23 67 (49– 
89) 
159% 96% 87%-100% 315 
(270– 
349) 
72% 96% 93%-98% 
24 to 59 17 (8– 
29) 
133% 90% 72%-100% 191 
(156– 
220) 
60% 83% 77%-88% 
Weight         
3.5 to 5.9 86 (63– 
109) 
183% 99% 95%-100% 103 
(78– 
130) 
91% 99% 97%-100% 
6.0 to 7.9 106 
(85– 
126) 
157% 96% 90%-100% 470 
(435– 
514) 





123% 83% 50%-100% 228 
(189– 
263) 
61% 84% 79%-90% 
Admission 
type 
        
SFP See 
note� 
   453 
(426– 
485) 




166% 97% 94%-100% 347 
(313– 
378) 
72% 91% 88%-94% 
Continent         
Asia 59 (41– 
72) 
171% 99% 95%-100% 341 
(328– 
359) 




163% 96% 92%- 99% 460 
(438– 
484) 
75% 93% 90%-96% 
 
�Among eligible patients, children who were admitted to SFP facilities seldom had MUAC below 115mm during treatment and therefore performance based on TFP vs 








of 90% of visits (range across simulated trials 72%-100%). Among the largest children with the 
lowest MUACs, their total energy needs were met on an average of 83% of visits (range 50%- 
100%). Estimates for these groups were not reliable due to only 1–2% of visits coming from 
children fitting this description and each subsample having 2 to 29 such visits to assess. For 
older children with higher MUACs (115mm ≥ MUAC < 125mm), an average of 83% (range 
77%-88%) of visits would have had at least 50% of energy needs met by this protocol in the 
simulated trials. Similarly, among visits from larger children (weight ≥ 8kgs) with higher 
MUACs, an average of 84% (range 79%-90%) had half or more of their energy needs covered. 
Children with higher MUACs who were age 24 months or older and/or weighed 8kgs or more 
made up about one-fifth of the 5,518 patients in the sample. In both cases, these values might 
be far enough from the goal of 95% to warrant special consideration for these groups in the 




We assessed how children who successfully completed a course of treatment through an TFP 
or SFP facility grew during their treatment, evaluating growth by the child’s MUAC at their 
prior clinic visit. Growth trends in MUAC mirrored those of proportional weight gain. Rate of 
proportional weight and MUAC gain slow at higher MUAC values. Though absolute energy 
requirements continue to increase as children gain weight, children with higher MUAC mea- 
surements need less supplemental energy per kilogram of body weight than those with lower 
MUAC measurements. According to energy estimates in this study, 1000kcal per day is hypo- 
thetically sufficient to achieve the goal of covering total energy needs 95% of the time for chil- 
dren with a MUAC 100mm to <115mm. For children with a MUAC 115mm-<125mm, 
500kcal per day would be sufficient to supplement the family diet. The protocol met energy 
needs in simulated statistical tests among most subgroups (males and females, each country 
and continent, and both admission types), and fell slightly short of these goals among the old- 
est children (age 25–60 months) and the heaviest children (over 8kg). 
 
Interpretive considerations 
This study used observational data from outpatient feeding programs in five countries in 
Africa and Asia, leveraging existing operational data to inform future studies and protocol 
development efforts. We compared MUAC and proportional weight gain as well as estimated 
the energy needs of patients who recovered from these programs. This information allowed us 
to formulate and theoretically test a simplified protocol. 
Our limitations center around having retrospective data from routine clinical records 
rather than intervention data from a tightly controlled research setting. Records for the same 
children treated twice in the same program or treated for both SAM and MAM could not be 
connected. We were not able to account for possible confounders such as breastfeeding and 
socioeconomic status. We also excluded data points because of incomplete and inaccurate data 
collection, and used imprecise age data that were often rounded to the nearest year. As in any 
observational study, observed associations cannot infer causality. We calculated energy 
requirements to achieve observed growth using an evidence-based- but still theoretical—equa- 
tion, not by controlled dosage tests. We cannot say what actual child energy intake was during 
the course of treatment. We also cannot say how children might have grown on different feed- 
ing regimes. Though RUTF dosages for children with SAM are relatively standard in TFPs 
worldwide, SFP rations vary and we did not have information on the exact type and amount of 
supplementary food given to children with MAM in SFP programs (possibilities include 




ready-to-use supplementary food and different varieties of fortified blended flours). Even if 
exact programme details been known, exact food/energy intake of patients was not measured 
and is unknown. 
Another limitation arose from having very few children in some subcategories (e.g. typically 
fewer than 20 patients over 24 months old with SAM-associated MUACs per subsample). 
Therefore, we could not assess the proposed protocol’s theoretical performance for all sub- 
groups that might be of interest to practitioners. This is not a major problem given that our 
programmes are representative of many others which also have most children younger than 24 
months and lighter than 8kg. Care must be taken when extrapolating beyond children <24 
months and <8kg. 
Variations in completeness of data from the different country sources was expected. To 
minimize bias, the analysis was based on data that were most consistently available from all 
five countries. For example, because height data were missing from nearly half the cases in 
Pakistan, height was not used in the primary analysis, nor were height-based values such as 
stunting status and weight for height z-scores (WHZ). 
Limiting our sample to those children with successful treatment outcomes allowed us to 
determine a theoretically sufficient amount of energy that would support observed growth in 
almost all cases represented in this sample. This analysis does not address how those children 
came to achieve that growth nor how children who did not successfully recover fared. 
Finally, growth curves do not average the courses of individual children, but how much 
children tended to grow between visits given their MUAC at their prior clinic visit. 
 
Generalisability 
These data represented growth among children age 6–59 months in standard treatment pro- 
grams in five countries in Africa and Asia. The data represent very different operational con- 
texts. The age and anthropometric characteristics of the children included in this study reflect 
the reality of admissions in CMAM programs globally. However, the results should not be 
extended to groups for which we did not have adequate data to assess, such as older and larger 
children with SAM and children with very low (<100mm) MUAC. 
 
Interpretation 
This study considered the rate of weight and MUAC gain and energy needs of children with 
acute malnutrition as defined by MUAC status. We found that 1000 kcal/day (equivalent to 
two RUTF sachets per day) should meet the total energy requirements of children with a 
MUAC of 100mm to <115mm more than 95% of the time; 500kcal (equivalent to one RUTF 
sachet per day) meets half the energy requirements of children with a MUAC 115 to <125mm 
95% of the time. Even among the subgroups of older and larger children that did not have 
these goals met 95% of the time, the protocol was estimated to meet their needs approximately 
83% of the time. This protocol remains in line with globally accepted practice in which chil- 
dren recovering from SAM receive enough therapeutic food to cover their total energy needs, 
and children with MAM receive a food supplement to complement their family diet [14,27]. 
Most SFP protocols currently provide 500-550kcal/day of ready-to-use supplementary food 
(RUSF). Similarly, recently published studies indicate that admitting children with a MUAC 
<125mm leaves very few high risk children untreated [20,21,55]. 
The combined protocol developed through this study provides a novel MUAC-based proto- 
col to test in operational and clinical trials. The combined protocol was recently tested in a 
cluster-randomized controlled trial in Kenya and South Sudan, with results of the trial 
expected in early 2020 [43]. 





These results are consistent with and bolster other global child malnutrition studies [23,56]. 
There is increasing evidence that MUAC-based admission and discharge criteria are effective 
at improving efficiency and care outcomes [20,57,58]. Several extant protocols that provide 
supplementary foods to families of children with MAM rather than provide all energy needs 
with therapeutic foods have been found to be successful [18,47]. 
Answering the questions of whether a single protocol for the management of MAM and 
SAM will increase cost-effectiveness and access to treatment are among the objectives of the 
ComPAS stage 2 randomized controlled trial (the results of which currently under review). 
Since the conclusion of the ComPAS stage 2 trial, several operational studies and additional 
RCT’s have begun evaluating these questions as well [42,59–62]. The premise is that a single 
protocol will result in increased coverage of MAM cases before these children deteriorate into 
SAM. MAM treatment is less costly for a number of reasons: less frequent visits (bi-weekly 
instead of weekly), less RUTF (one sachet per day), and minimal medical treatments. In this 
way, we hypothesize that the increase in cost by expanding treatment to MAM will be balanced 
by the reduction in the more costly treatment of SAM. Additionally, an important aspect of 
the protocol tested in ComPAS Stage 2 is the optimized dosage for SAM children. The opti- 
mized dosage provides two sachets of RUTF per day for all children less than 115mm. In the 
standard protocol currently used in most countries, the dosage of RUTF is based on weight 
and ranges between two to five sachets per day. Therefore, an additional aspect of cost savings 
is not just the reduction in SAM cases, but the reduced dosage of RUTF used for SAM. We will 
need to see this play out in operational studies in multiple countries to assess the practical 
implications, and that is what the UN and non-governmental organizations (NGOs) are doing 
now [63]. 
Future research can expand on these findings by powering samples to estimate energy 
needs of smaller subgroups of children with acute malnutrition such as those with oedema and 
older and larger children with SAM. Primary data collection can be used to obtain more pre- 
cise data regarding age of children for more granular analysis by age. Additionally, growth dif- 




Using data from several large therapeutic feeding programs, we found MUAC to be a good 
proxy for proportional weight gain, demonstrating similar growth pattern changes. Using 
observed growth, we estimated that 1000 kcal of energy per day is sufficient for recovery of 
children with uncomplicated acute malnutrition. This suggests that a simplified protocol of 
two RUTF packets per day for children with MUAC 100mm to <115mm and one RUTF 
packet per day for children with MUAC 115mm to <125mm is an acceptable therapeutic 
approach to uncomplicated acute malnutrition. Since most children in our sample were 
young, we can be most confident or our results for children aged <2 years. Further research 
should focus on needs of older children. In particular, intervention trials are needed for testing 
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Malnutrition underlies 3 million child deaths worldwide. Current treatments differentiate 
severe acute malnutrition (SAM) from moderate acute malnutrition (MAM) with different 
products and programs. This differentiation is complex and costly. The Combined Protocol 
for Acute Malnutrition Study (ComPAS) assessed the effectiveness of a simplified, unified 
SAM/MAM protocol for children aged 6–59 months. Eliminating the need for separate prod- 
ucts and protocols could improve the impact of programs by treating children more easily 
and cost-effectively, reaching more children globally. 
 
Methods and findings 
A cluster-randomized non-inferiority trial compared a combined protocol against standard 
care in Kenya and South Sudan. Randomization was stratified by country. Combined proto- 
col clinics treated children using 2 sachets of ready-to-use therapeutic food (RUTF) per day 
for those with mid-upper arm circumference (MUAC) < 11.5 cm and/or edema, and 1 sachet 
of RUTF per day for those with MUAC 11.5 to <12.5 cm. Standard care clinics treated SAM 
with weight-based RUTF rations, and MAM with ready-to-use supplementary food (RUSF). 
The primary outcome was nutritional recovery. Secondary outcomes included cost-effec- 
tiveness, coverage, defaulting, death, length of stay, and average daily weight and MUAC 
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gains. Main analyses were per-protocol, with intention-to-treat analyses also conducted. 
The non-inferiority margin was 10%. From 8 May 2017 to 31 March 2018, 2,071 children 
were enrolled in 12 combined protocol clinics (mean age 17.4 months, 41% male), and 
2,039 in 12 standard care clinics (mean age 16.7 months, 41% male). In total, 1,286 
(62.1%) and 1,202 (59.0%), respectively, completed treatment; 981 (76.3%) on the com- 
bined protocol and 884 (73.5%) on the standard protocol recovered, yielding a risk differ- 
ence of 0.03 (95% CI −0.05 to 0.10, p = 0.52; per-protocol analysis, adjusted for country, 
age, and sex). The amount of ready-to-use food (RUTF or RUSF) required for a child with 
SAM to reach full recovery was less in the combined protocol (122 versus 193 sachets), and 
the combined protocol cost US$123 less per child recovered (US$918 versus US$1,041). 
There were 23 (1.8%) deaths in the combined protocol arm and 21 (1.8%) deaths in the 
standard protocol arm (adjusted risk difference 95% CI −0.01 to 0.01, p = 0.87). There was 
no evidence of a difference between the protocols for any of the other secondary outcomes. 
Study limitations included contextual factors leading to defaulting, a combined multi-country 





Combined treatment for SAM and MAM is non-inferior to standard care. Further research 
should focus on operational implications, cost-effectiveness, and context (Asia versus 













Why was this study done? 
 
• For decades, children with severe and moderate acute malnutrition have been treated 
separately, using different feeding products, protocols, and programs. 
• Low coverage limits the global impact of acute malnutrition treatment programs. 
• To improve impact and efficiency, we designed a simplified and combined approach to 
treat acute malnutrition, using mid-upper arm circumference to determine therapeutic 
food dosage. 
• We hypothesized that this new approach would be as effective but more cost-effective 
than standard care, thereby raising the potential for improved future treatment 
availability. 





What did the researchers do and find? 
 
• We conducted a cluster-randomized trial in Kenya and South Sudan to assess whether 
recovery in a simplified, combined protocol was non-inferior to standard treatment. 
Our main secondary objective was to assess cost-effectiveness. 
• The needed sample size was calculated for a per-protocol analysis, with a target of 12 
clusters of 100 children in each arm (2,400 children in total). 
• Recovery in the combined protocol arm was non-inferior to that in the standard proto- 
col arm, with 76.3% recovering in the combined protocol arm and 73.5% recovering in 
the standard protocol arm (risk difference of 0.03, 95% CI −0.05 to 0.10, p = 0.52). 
• The average amount of ready-to-use food required for a child with severe malnutrition 
to reach full recovery was less in the combined protocol arm than in the standard proto- 
col arm (122 versus 193 sachets), and the combined protocol was US$123 less per child 
recovered (US$918 versus US$1,041). 
 
 
What do these findings mean? 
 
• A simplified protocol for severe and moderate acute malnutrition is as effective as stan- 
dard treatment, achieving the same numbers of children recovered. 
• The simplified, combined protocol saves money. Resource-constrained health systems 
could treat more children for the same investment, thereby extending coverage and 
improving public health impact. 
• Prolonged and severe emergencies like the COVID-19 pandemic may increase global 
food insecurity and malnutrition and strain health systems further, increasing the need 
for simple, easy-to-use, and cost-effective malnutrition treatment approaches that 






Malnutrition is a major global public health problem, contributing to the deaths of approxi- 
mately 3 million children under age 5 years each year [1]. Acute malnutrition affects more 
than 50 million children under age 5 and is particularly serious: As well as having a high short- 
term case fatality rate, it also has important long-term sequelae [2–5]. Tackling malnutrition is 
unfinished business from the Millennium Development Goals and remains prominent in the 
Sustainable Development Goals (SDGs). SDG 2.2 aims to “end all forms of malnutrition, 
including achieving by 2025 the internationally agreed targets on stunting and wasting in chil- 
dren under 5 years of age” [6]. Despite its importance, there is increasing concern that current 
approaches to acute malnutrition are suboptimal [7–9]. Successful treatments are available, 
but treatment program coverage is low, with at least 75% of acutely malnourished children 6–
59 months old not accessing care [10,11]. This makes achieving impact at national and 
international levels difficult. 
Acute malnutrition can be seen as a continuum condition, but current treatments for acute 
malnutrition are separated into 2 components: those treating severe acute malnutrition (SAM) 




and those treating moderate acute malnutrition (MAM). Children with SAM have the highest 
risks for morbidity and mortality, but children with MAM remain at risk for adverse outcomes 
including illness and death [1,12–16]. SAM is currently defined as weight-for-height < −3 
standard deviations (z-scores) below the WHO reference median and/or a mid-upper arm cir- 
cumference (MUAC) < 11.5 cm and/or edema; MAM is currently defined as weight-for- 
height from −3 to <−2 standard deviations (z-scores) below the WHO reference median and/ 
or a MUAC from 11.5 cm to <12.5 cm. 
SAM and MAM are managed in separate programs, using different food products and pro- 
tocols. There is currently no globally accepted guidance for the treatment of MAM, and MAM 
is not always routinely treated [17,18]. International mandate adds an additional layer of com- 
plexity: UNICEF supports the treatment of SAM and provides ready-to-use therapeutic food 
(RUTF) for use in outpatient therapeutic programs (OTPs); the World Food Programme sup- 
ports the treatment of MAM and provides ready-to-use supplementary food (RUSF) or forti- 
fied blended flours for use in supplementary feeding programs (SFPs) [19,20]. In 
humanitarian settings, providing treatment for both SAM and MAM adds to the logistical and 
financial burden of health systems. When resources are scarce, and in the many settings where 
prevalence is not high enough to reach emergency thresholds, treatment of SAM is often prior- 
itized, and children with MAM may not be eligible to receive care unless they deteriorate. 
The Combined Protocol for Acute Malnutrition Study (ComPAS) unified the treatment of 
uncomplicated SAM and MAM for children 6–59 months into one protocol, with simplified 
diagnostic criteria and a single therapeutic food product. This is the first randomized con- 
trolled trial we are aware of to test a simple, MUAC-based dosage protocol for the treatment of 
SAM and MAM in children 6–59 months. A clinical trial assessing the effectiveness of an inte- 
grated SAM/MAM approach using a weight-based dosage protocol found similar recovery 
and lower therapeutic food costs in the integrated treatment arm [21]. An operational study of 
children admitted with a MUAC < 12.5 cm and/or edema and treated with a gradually 
reduced dosage of RUTF based on a combination of MUAC status and weight also found a 
high overall recovery rate [22]. Multiple studies assessing the use of MUAC in nutrition pro- 
grams have shown that MUAC is effective at identifying children most at risk of mortality and 
is simpler and easier to use than weight-for-height measures [23,24]. MUAC gain can be used 
as a proxy for weight gain [25–28], and rate of weight and MUAC gain in response to treat- 
ment appears to decline as children recover [25,26,28,29]. Current standard of care provides a 
weight-based dosage of up to 200 kcal/kg/day for all children with SAM (S1 Table), but this 
dosage is based on the rate of weight gain in inpatient settings, which is higher than in outpa- 
tient settings [29]. Several recent studies of children with SAM in outpatient settings indicate 
that recovery with a reduced dosage is similar to recovery with standard treatment 
[21,22,30,31]. A study of children treated for SAM in Myanmar reduced the dosage to 500 
kcal/day of RUTF once children reached a MUAC of 11.0 cm and a weight-for-height z-score 
(WHZ) ≥ −3 and achieved recovery above Sphere standards [30]. A study in Burkina Faso 
found that a reduced dosage of RUTF offered to SAM patients beginning in the third week of 
treatment resulted in non-inferior weight gain velocity and similar recovery and length of stay, 
though height gain velocity was reduced [31]. As children recover from SAM to MAM, current 
global practice reduces the dosage of energy received to provide a supplement rather than a 
replacement for the family diet, typically offering 1 sachet of RUSF per day (500–550 kcal/day) 
[18,32]. We previously conducted a secondary analysis of program data from 5 countries and 
found that children recovering from acute malnutrition with a MUAC < 12.5 cm may require 
1,000 kcal per day, a reduced dosage compared to standard care [25]. The rationale for a 
reduced dosage is to facilitate increased coverage—and in turn increased public health impact 
—of treatment in a resource-constrained environment. The optimal dosage achieves the right 




balance between meeting individual energy needs and extending treatment to more children. 
This study contributes to the evidence on the impact of different dosage regimes. 
This study aimed to test the hypothesis that the combined protocol would be non-inferior 




ComPAS was a cluster-randomized non-inferiority trial conducted in 24 health facilities in 
Nairobi, Kenya, and Aweil East, South Sudan. We selected a cluster-randomized design in 
order to ensure fidelity to the assigned protocol at the health facility level, and to improve dis- 
aggregation of cost data by protocol type. We tested for non-inferiority, assuming recovery 
under the simplified protocol would be at least as good as under standard care. The clinical 
trial described in this paper builds on analysis conducted by our team to develop a simplified, 
combined protocol [25]. We previously published a full description of the protocol for this 
trial, as well as the methods for the cost-effectiveness analyses [33,34]. Ethical approval was 
given by the London School of Hygiene & Tropical Medicine (reference 11826), the Kenya 
Medical Research Institute (reference non-KEMRI 551), and the Ministry of Health in South 
Sudan (approved 21 November 2016). 
 
Participants 
Aweil East, South Sudan, is a rural, agro-pastoralist region in Northern Bahr el Ghazal State 
with a total population of 309,921 and an under 5 population of 59,574 [35]. Nairobi, Kenya, is 
an urban area with a total population of 3,078,108 and an under 5 population of 462,849 [36]. 
Three sub-counties of Nairobi were included in the study: Embakasi North, Embakasi East, 
and Embakasi West. 
Health facilities were eligible for selection as clusters. Only 12 health facilities were operat- 
ing nongovernmental organization (NGO)–supported nutrition services in Aweil East at the 
time of randomization, and all were selected for participation. In Nairobi, the Ministry of 
Health aided selection of 12 health facilities in 3 sub-counties with the highest burden of mal- 
nutrition. Of the 32 health facilities in the 3 sub-counties of Nairobi, clinics were selected 
based on the following factors: the level of care provided (hospitals and dispensaries excluded), 
the type of care provided (routine child health services available), the population served (slum 
or peri-urban communities), and expected caseload of malnutrition. Children aged 6–59 
months presenting to any of the 24 clinics involved in the study were eligible to enroll (S2 
Table). Active case finding was also conducted by community health workers using MUAC to 
find and refer children. Active case finding was conducted in the same way for all clinics across 
both treatment arms and countries. Children admitted with a MUAC < 12.5 cm and/or 
edema (+/++, i.e., mild or moderate) were eligible for inclusion. Children exhibiting signs of a 
severe illness or danger sign according to the Integrated Management of Childhood Illness 
(IMCI) algorithm, or not passing the appetite test (consumption of 30 g of RUTF within 20 
minutes), were excluded and referred for further assessment and care at an inpatient stabiliza- 
tion center or hospital [33,37]. 
Clinic-level and individual consent were obtained. Local health authorities and clinic man- 
agers gave written permission for their clinics to be included prior to randomization. For indi- 
vidual caretakers of malnourished children, participation was first explained in their local 
language (Dinka in South Sudan; Kiswahili or English in Nairobi). Caretakers were provided 
with an information sheet describing details of the interventions, and staff emphasized that 
treatment would be available to all regardless of whether they chose to participate. A consent 




document was signed by caretakers, or by a witness who could attest to the caretaker’s verbal 
consent. 
 
Randomization and blinding 
The 24 health clinics were indexed and sent to the senior statistician (CO) based in London, 
who did not have any prior knowledge of their identities or characteristics. The statistician 
generated a randomized sequence list stratified by country using the Sealed Envelope random- 
ized sequence generator and applied it to the list of the health facilities [38]. Participants were 
enrolled in the study arm of the clinic they presented to, by the research officer based at each 
clinic. Given that the intervention was applied at the facility level, clinic staff could not be 
blinded to group allocation, and neither could participants. To ensure objective trial manage- 
ment, the principal investigator (JB) was blinded to clinic allocation and outcomes by treat- 
ment arm until the last participant exited the trial and the database was locked. For data 
monitoring purposes during the trial, a data manager sent de-identified data to the PI, with 
site codes replacing clinic names and all information identifying clinics or treatment arms 




In standard protocol clinics, children with SAM received RUTF according to weight (200 kcal/ 
kg/day) in the OTP (S2 Table). Children with MAM received 500 kcal/day of RUSF (1 sachet/ 
day) in the SFP. The OTPs and SFPs in the control arm in both countries operated from the 
same clinics with the same staff. In combined protocol clinics, children with a MUAC < 11.5 
cm and/or edema (+/++) received 1,000 kcal RUTF/day (2 sachets/day), and children with a 
MUAC of 11.5 to <12.5 cm and no edema received 500 kcal RUTF/day (1 sachet/day). When 
children met the criteria for transition from SAM to MAM (MUAC ≥ 11.5 cm and no edema 
for 2 consecutive visits), they were switched from 2 sachets of RUTF/day to 1 sachet of RUTF/ 
day. This reduction in dosage is based on the slowing rate of growth that we observed at a 
MUAC of approximately 11.5 cm in our stage 1 study [25] and aligns with UN guidance on 
the treatment of MAM [18,32]. Children in the combined protocol arm were registered as 
either an OTP or SFP patient based on their admission MUAC. 
In the standard protocol, children were only included in this analysis if their MUAC on 
admission was <12.5 cm and/or they had edema (+/++). If they also met the WHZ < −2 crite- 
rion on admission and reached WHZ ≥ −2 prior to reaching MUAC≥ 12.5 cm during treat- 
ment, they were not discharged until they had a MUAC measurement of ≥12.5 cm for 2 
consecutive visits, to ensure parity of the definition of recovery between the intervention and 
control arms. 
In both arms, children with SAM came once a week for a medical and nutritional evalua- 
tion and received systematic medications per the national protocol. Children with MAM 
attended every 2 weeks and received only a nutritional consultation, unless they required med- 
ical attention. Children who were found not to be gaining adequate weight or not progressing 
towards recovery (non-responders) were referred for medical assessment and/or inpatient 
care. Defaulters were traced by community health workers and referred to care if they were 
found to still be malnourished (though they were not re-enrolled in the study). All non-nutri- 
tional components of treatment such as systematic medications, frequency of follow-up, and 
home visits to prevent defaulting were identical between the combined and standard protocol 
arms. Full details of the combined and standard protocols were previously published [33] and 
are summarized in S2 Table. 





The primary outcome was recovery in the per-protocol analysis, defined as reaching a MUAC 
measurement of ≥12.5 cm and no edema for 2 consecutive visits (weekly for SAM and 
biweekly for MAM). Secondary outcomes included cost-effectiveness, death (including post- 
defaulting deaths confirmed during defaulter tracing and follow-up phone calls when possi- 
ble), non-response (16 weeks in treatment without achieving recovery), transfer (to either a 
stabilization center or a different facility), and defaulting (3 consecutive missed visits). The 
outcome categories recovery, death, non-response, defaulting, and transfer were mutually 
exclusive. To account for MAM children attending visits biweekly, we extended the non- 
response cutoff for all children to 17 weeks to evaluate the status of MAM children who would 
not have come for a visit at 16 weeks. Clinic staff determined whether children had met speci- 
fied criteria in the protocol and discharged them from further follow-up. The criteria for each 
outcome (e.g., recovery being defined by 2 consecutive visits with a MUAC ≥ 12.5 cm and no 
edema) were prespecified in the study protocol, and outcomes were assigned according to the 
strict definitions described in the study protocol. This process ensured that any discharge 
errors by clinic staff would be identified and accounted for during the analysis. An additional 
outcome category of early discharge was added during the analysis phase to account for chil- 
dren mistakenly discharged by the clinic staff before their outcome could be ascertained. The 
providers in each of the clinics were given on-site practical trainings in anthropometry and 
refresher trainings. Details of the procedures for taking anthropometric measurements are 
available in S1 Text. Research officers (registered nutritionists and supervisors for clinic staff) 
oversaw and repeated measurements to ensure agreement with clinic staff. Analyses of length 
of stay, average daily weight gain (g/kg/day), and average daily MUAC gain (mm/day) were 
conducted on children who achieved recovery. All outcomes were measured at the individual 
level. A formal data and safety monitoring board was not planned due to the expected short 
duration of recruitment. Instead, a trial safety committee comprising an independent chair 
and a statistician conducted a safety review at the midpoint of the trial. Outcomes and adverse 
events, including hospitalizations and deaths, were reported to the safety committee at the 
midpoint of recruitment. The committee, upon reviewing the safety report, recommended 
continuation of recruitment with no amendments to the protocol [33]. 
To assess cost-effectiveness, we calculated costs from a societal perspective, using account- 
ing data, interviews with key informants, and survey questionnaires given to a subset of staff 
and all caregivers. Details have been described in our cost analysis methods paper [34]. We cat- 
egorized costs into treatment, outreach, supply logistics, supervision, management, and house- 
hold costs for each country. 
We used a modified version of the Semi-Quantitative Evaluation of Access and Coverage 
(SQUEAC) assessment to assess coverage [39]. The SQUEAC method uses Bayesian tech- 
niques with a small sample survey to produce single coverage estimates. The coverage surveys 
assessed only MUAC and edema, in keeping with the study definitions of SAM and MAM. 
Coverage estimates are presented for SAM (MUAC < 11.5 and/or edema) and MAM (MUAC 
11.5 to <12.5 cm) in each country and for each arm. 
 
Statistical analysis 
Our sample size was designed to detect non-inferiority of recovery for the combined protocol 
compared to the standard protocol in the per-protocol analysis with a 10% non-inferiority 
margin and 80% power at a 2-sided level of significance of 5%. Based on these parameters, 12 
clusters per arm were required, with 100 children in each cluster. The 10% non-inferiority 
margin was selected based on previous program data reporting a recovery rate of 85%, with a 




minimum acceptable recovery rate of 75% per Sphere standards [40]. An intra-cluster correla- 
tion coefficient of 0.05 was assumed, based on results of a similar trial [21]. An additional 
adjustment to the sample size calculation was made to anticipate losses to follow-up and cross- 
overs (children who are cross-registered across arms and need to be excluded during the analy- 
sis), in order to determine how many children should be recruited per cluster to ensure 100 
children with completed treatment for the per-protocol analysis. Thus, the sample size was cal- 
culated to recruit enough children per cluster so that when defaulters (and other non-adher- 
ents, such as transfers or early discharges) were removed from the denominator, the power of 
the study would be maintained. Losses to follow-up were expected to be 15%, based on Sphere 
standards, and crossovers were expected to be 5%, so we aimed to recruit 150 children per 
cluster to achieve our target of 100 per cluster for the per-protocol analysis [33,41,42]. 
We used CommCare for data management [43]. In Kenya, clinic-based research officers 
entered data on Samsung Galaxy Tab A tablets running Android OS v.5.1.1 and uploaded data 
to the CommCare server. In South Sudan, nutrition supervisors initially collected data on 
paper forms. Data were then entered by 2 data entry clerks into Samsung Galaxy Tab A tablets 
running Android OS v.4.4 and uploaded to the CommCare server. Data entry onto paper 
forms and tablets was supervised and cross-checked by field coordinators. Data entry errors 
were logged and checked by the field coordinators and the principal investigator before incor- 
poration into the database [33]. 
We conducted both per-protocol and intention-to-treat analyses. We designed this trial 
with per-protocol as the main analysis because it is more conservative and is the recommended 
approach for primary analysis of non-inferiority trials [33,44,45]. Non-inferiority was assessed 
only for the primary outcome of recovery. For secondary outcomes we explored evidence of a 
difference, rather than non-inferiority. The intention-to-treat analysis included all children 
enrolled, and the per-protocol analysis excluded children who did not complete treatment: 
those who exited the study as transfers to other facilities, defaulters lost to follow-up, or early 
discharges from treatment. Non-inferiority of the primary outcome of recovery was defined as 
a difference in proportion of children recovering from acute malnutrition with the upper 
bound of the 95% confidence interval being less than 10%. We used binomial regression mod- 
els for binary outcomes and linear regression models for continuous outcomes. In both 
approaches we used clustered robust standard errors to adjust for repeated measures (cluster- 
ing) within health facilities. We adjusted for the baseline characteristics of age, sex, and coun- 
try in all the adjusted analyses. For costs with the greatest uncertainty we conducted a 
univariate sensitivity analysis. We present a mean base-case value across both countries, in US 
dollars, for cost per child treated, cost per child recovered, and the incremental cost of imple- 
menting the combined protocol compared to standard treatment. Analysis was conducted 
using Stata/IC v.13.1 [46]. Stata’s zscore06 package was used to calculate WHZ, height-for-age 
z-score, and weight-for-age z-score (according to WHO Child Growth Standards) and flags 
[47]. 
The trial is registered at ISRCTN: trial number ISRCTN30393230 (http://www.isrctn.com/ 
ISRCTN30393230). This study is reported according to the Consolidated Standards of Report- 




Recruitment began 8 May 2017 and ended 31 March 2018. Trial activities were completed in 
Kenya on 31 July 2018 and in South Sudan on 31 August 2018, when the last enrolled children 
completed treatment. Among the children attending nutrition services at the participating 
health clinics, 157 children had WHZ < −2 but did not meet eligibility criteria because they 




had a MUAC ≥ 12.5 cm and no edema; these children were enrolled in a sub-study and their 
outcomes will be presented in a forthcoming paper. A total of 4,110 children met eligibility cri- 
teria and were enrolled (Fig 1). Of these, 30 were excluded from analysis due to a missing 
admission date. Two more were excluded due to implausible MUAC values. The intention-to- 
treat analysis included 24 clusters and 4,078 children. After removing those who did not com- 
plete treatment, the per-protocol analysis included 24 clusters and 2,488 children (Fig 1). The 
target per-protocol sample size of 100 children per cluster was met: In the combined protocol 
arm the median sample per cluster was 107.5 (IQR 99.5–118); in the standard protocol arm 
the median sample per cluster was 102.4 (IQR 97–107.5). 
Baseline characteristics were similar in the 2 study arms (Table 1). There were more females 
than males in the sample, and children had a mean age of around 17 months. About three- 
quarters of the children were aged between 6 and 24 months. Baseline characteristics by coun- 
try are shown in S3 Table. Inter-country differences include the following: children in South 
Sudan were on average older than in Kenya (mean 22 versus 12 months); the Sudanese popula- 
tion was more rural, with household income mainly from fishing and farming; the Kenyan set- 
ting was more urban, with most household income from shopkeeping, casual labor, and 
salaried work; maternal education level in South Sudan was low, whereas most mothers in 
Kenya reported secondary level education (S3 Table). 
In the per-protocol analysis, children in the combined protocol arm had non-inferior 
recovery (76.3% in the combined arm versus 73.5% in the standard arm; adjusted risk differ- 
ence 0.03, 95% CI −0.05 to 0.10, p = 0.52) (Table 2; Fig 2). There was no evidence of a differ- 
ence in the secondary outcomes death (1.8% versus 1.8%; adjusted risk difference 0.00, 95% CI 
−0.01 to 0.01, p = 0.87) and non-response (21.9% versus 24.7%; adjusted risk difference −0.03, 
95% CI −0.10 to 0.05, p = 0.48). Results in the intention-to-treat analysis were similar, with 
non-inferior recovery in the combined protocol (47.6% in the combined arm versus 43.8% in 
the standard arm; adjusted risk difference 0.03, 95% CI −0.06 to 0.13, p = 0.47) (Table 2; Fig 2). 
There was no evidence of a difference between arms in the risk of the secondary outcomes 
death (1.1% versus 1.0%; adjusted risk difference 0.00, 95% CI −0.01 to 0.01, p = 0.79), non- 
response (13.7% versus 14.7%; adjusted risk difference −0.01, 95% CI −0.05 to 0.04, p = 0.73); 
defaulting (24.7% versus 30.7%; adjusted risk difference −0.06, 95% CI −0.15 to 0.03, p = 0.20), 
and transfer to inpatient care (1.7% versus 1.1%; adjusted risk difference 0.01, 95% CI −0.01 to 
0.02, p = 0.42) (Table 2). The intra-cluster correlation coefficient for recovery was 0.05 (95% 
CI 0.01 to 0.08) for the per-protocol analysis and 0.06 (95% CI 0.02 to 0.09) for the intention- 
to-treat analysis. 
Among children who recovered, there was no evidence of a difference between the combined 
and standard protocols in length of stay (65.4 versus 65.0 days; adjusted mean difference −0.55, 
95% CI −5.75 to 4.65, p = 0.83), average daily weight gain (1.9 versus 1.9 g/kg/day; adjusted 
mean difference 0.08, 95% CI −0.13 to 0.29, p = 0.42), and average daily MUAC gain (0.2 versus 
0.2 mm/day; adjusted mean difference −0.01, 95% CI −0.04 to 0.02, p = 0.45) (Table 3). 
Coverage results were similar for both protocols, with overlapping confidence intervals for 
all results. In Kenya, the coverage for SAM (MUAC < 11.5 cm and/or edema) was estimated 
at 54.9% (95% CI 41.2% to 68.0%) and 52.9% (95% CI 39.1% to 66.2%) for the combined and 
standard protocol arms, respectively. For MAM (MUAC 11.5 to <12.5 cm), coverage was 
48.6% (95% CI 38.0% to 59.4%) and 47.3% (95% CI 37.1% to 58.0%) for the combined and 
standard protocol arms, respectively. In South Sudan, coverage for SAM was estimated at 
45.9% (95% CI 32.5% to 59.9%) and 62.5% (95% CI 47.8% to 75%) for the combined and stan- 
dard protocol arms, respectively. For MAM, coverage was 21.3% (95% CI 14.9% to 29.2%) and 
26.3% (95% CI 19.2% to 35.1%) for the combined and standard protocol arms, respectively (S4 
Table). 






Fig 1. Trial profile. MAM, moderate acute malnutrition; MUAC, mid-upper arm circumference; SAM, severe acute malnutrition. 
https://doi.org/10.1371/journal.pmed.1003192.g001 
 





Table 1. Admission characteristics of children in the combined and standard protocols. 
 
Characteristic Combined protocol (N = 12, 
n = 2,071) 
Standard protocol (N = 12, 
n = 2,039) 
Sex and age 
Male, n (%) 841 (41%) 841 (41%) 
Age in months, mean (SD) 17.4 (11.4) 16.7 (10.7) 
Age category, n (%)   
6 to <24 months 1,502 (73%) 1,542 (76%) 
≥24 months 564 (27%) 495 (24%) 
Anthropometrics 
Weight (kg), mean (SD) 7.2 (1.6) 7.3 (1.6) 
Height (cm)a, mean (SD) 72.9 (8.9) 73.0 (8.7) 
MUAC (cm), mean (SD) 11.7 (.55) 11.7 (.59) 
WHZ, mean (SD) −2.5 (1.0) −2.3 (3.4) 
HAZ, mean (SD) −2.1 (1.6) −1.9 (1.6) 
WAZ, mean (SD) −2.9 (1.0) −2.7 (1.1) 
MUAC < 11.5 cm, n (%) 601 (29%) 634 (31%) 
WHZ < −3 352 (59%) 346 (55%) 
WHZ ≥ −3 to <−2 189 (32%) 208 (33%) 
WHZ ≥ −2 60 (10.0%) 80 (12.6%) 
MUAC 11.5 to <12.5 cm, n (%) 1,461 (71%) 1,397 (69%) 
WHZ < −3 258 (18%) 158 (11%) 
WHZ ≥ −3 to <−2 650 (45%) 550 (39%) 
WHZ ≥ −2 553 (38%) 689 (49%) 
Edema (+ or ++), n (%) 23 (1%) 24 (1%) 
Other participant characteristics 
Child breastfed in last 24 hours, n (%) 1,437 (69%) 1,426 (70%) 
Caretaker reports any morbidityb in child in past 
week, n (%) 
1,320 (64%) 1,179 (58%) 
Fever 787 (38%) 714 (35%) 
Diarrhea 521 (25%) 517 (25%) 
Cough 651 (31%) 694 (34%) 
Health care sought in prior week 489 (24%) 339 (20%) 
HIV status, n (%)   
Positive 9 (0%) 5 (0%) 
Exposed (mother) 19 (1%) 17 (1%) 
Disabled (physically or mentally) 44 (2%) 38 (2%) 
Tuberculosis (+), n (%) 6 (0%) 3 (0%) 
Household characteristics 
Mother is caretaker, n (%) 1,978 (96%) 1,923 (94%) 
Maternal educational achievement, n (%)   
None 927 (47%) 837 (44%) 
Pre-primary 9 (1%) 13 (1%) 
Primary 475 (24%) 485 (25%) 
Secondary 566 (29%) 585 (30%) 
College tertiary 0 (0%) 1 (0%) 
Number of children under 5 years in the home, 
mean (SD) 
1.5 (1.0) 1.7 (0.8) 
Access to toilet, n (%) 1,314 (64%) 1,342 (66%) 
Water source, n (%)   
(Continued ) 





Table 1. (Continued) 
 
Characteristic Combined protocol (N = 12, 
n = 2,071) 
Standard protocol (N = 12, 
n = 2,039) 
Household tap 92 (4%) 174 (9%) 
Community tap/tap stand 684 (33%) 742 (36%) 
Hand pump/borehole 746 (36%) 518 (25%) 
Borehole (private) 162 (8%) 452 (22%) 
Vendors 227 (11%) 77 (4%) 
Open water 152 (7%) 67 (3%) 
Livelihood/main source of income, n (%)   
No income 10 (1%) 112 (6%) 
Sale of items (grass, firewood, livestock) 324 (16%) 97 (5%) 
Fishing/farming 649 (31%) 559 (27%) 
Business/shopkeeper 226 (11%) 586 (29%) 
Casual labor 529 (26%) 586 (29%) 
Salaried work 301 (15%) 284 (14%) 
Other 21 (1%) 29 (1%) 
Ever no food to eatc, n (%)   
Never 1,022 (49%) 1,294 (64%) 
Rarely 550 (27%) 380 (19%) 
Sometimes 407 (20%) 309 (15%) 
Often 73 (4%) 43 (2%) 
Don’t know 2 (0%) 7 (0%) 
Ever go to sleep without enough foodc, n (%)   
Never 1,205 (50%) 1,189 (58%) 
Rarely 543 (26%) 490 (24%) 
Sometimes 454 (22%) 291 (14%) 
Often 39 (2%) 43 (2%) 
Don’t know 2 (0%) 20 (1%) 
Any household member go whole day without 
eating anythingc, n (%) 
  
Never 1,097 (53%) 1,238 (61%) 
Rarely 507 (25%) 438 (22%) 
Sometimes 421 (20%) 279 (14%) 
Often 37 (2%) 43 (2%) 
Don’t know 1 (0%) 35 (2%) 
 
N = number of clusters; n = individual children eligible for treatment. 
aRecumbent length was taken for children 6–23 months, and standing height was taken for children 24 months and 
older. 
b“Any morbidity” includes diarrhea, fever, cough, vomiting, skin infection, and other illness. 
cFrom Household Hunger Scale. 






Kaplan–Meier plots showing the time to recovery are presented in S1–S6 Figs. Median time 
to recovery in the per-protocol analysis was approximately 10 weeks, with similar time to 
recovery in both arms. 
Data from research grant accounts, NGO operational accounts, 83 key informant inter- 
views, and 64 caregiver interviews were used to compute the total economic costs per 





Table 2. Primary and secondary outcomes (per-protocol and intention-to-treat analyses). 
 
Outcome Standard protocol Combined protocol Unadjusted Adjusted 



















Unadjusted: all children with outcome measures, not adjusted for any demographic or study design characteristics. Adjusted: adjusted for age, sex, and country. N = 
number of clusters; n = number of children eligible for follow-up. 
§Standard errors adjusted for clustering within facilities. 
aStandard protocol: N = 12, n = 1,202; combined protocol: N = 12, n = 1,286. 




treatment arm and country (Table 4). To reach recovery in Kenya, SAM children in the stan- 
dard protocol arm received on average 148 sachets of ready-to-use food (RUTF and RUSF), 
and SAM children in the combined protocol arm received on average 105 sachets of RUTF. To 
reach recovery in South Sudan, SAM children in the standard protocol arm received on aver- 
age 209 sachets of RUTF and RUSF, and SAM children in the combined protocol arm received 
on average 133 sachets of RUTF. Overall, the average amount of ready-to-use food required 
for a child with SAM to reach full recovery (MUAC ≥ 12.5 cm and no edema for 2 consecutive 
visits) was lower in the combined protocol arm than in the standard protocol arm (122 versus 
193 sachets). Combining mean costs and recovery rates across countries, per the statistical 
power of the study, the combined protocol costs US$123 less per child recovered than the stan- 
dard protocol (Table 5). The input costs partially include the added costs of running a research 
trial, as these could not be fully separated from treatment program costs. 
Among the 1,127 children who defaulted, 1,103 (97.9%) were followed up with home visits. 
Of these, only 386 (35.0%) were home at the time of the defaulter tracing visit and had their 
status verified. Among children traced with status verified, 157 (69.2%) in the standard proto- 
col arm and 83 (52.2%) in the combined protocol arm were found to be still malnourished 
(with a MUAC < 12.5 cm and/or edema), 63 (27.8%) in the standard protocol arm and 72 
(45.3%) in the combined protocol arm had recovered, 6 (2.6%) in the standard protocol arm 
and 2 (1.3%) in the combined protocol arm had died, and 1 (0.4%) in the standard protocol 
arm and 2 (1.3%) in the combined protocol arm were unknown. Among children with SAM, 
284/641 (44.3%) defaulted in the standard protocol arm, and 209/617 (33.8%) defaulted in the 
Recovery 884 73.5% 981 76.3% 0.03 (−0.06 to 0.11) 0.52 0.03 (−0.05 −0.10) 0.52 
 
Death 21 1.8% 23 1.8% 0.00 (−0.01 to 0.01) 0.95 0.00 (−0.01 to 0.01) 0.87 
Non-response 297 24.7% 282 21.9% −0.03 (−0.11 to 0.05) 0.49 −0.03 (−0.10 to 0.05) 0.48 
 
Recovery 884 43.8% 981 47.6% 0.04 (−0.06 to 0.14) 0.46 0.03 (−0.06 to 0.13) 0.47 
 
Death 21 1.0% 23 1.1% 0.00 (−0.01 to 0.01) 0.84 0.00 (−0.01 to 0.01) 0.79 
Non-response 297 14.7% 282 13.7% −0.01 (−0.06 to 0.04) 0.66 −0.01 (−0.05 to 0.04) 0.73 
Defaulting 619 30.7% 508 24.7% −0.06 (−0.15 to 0.03) 0.20 −0.06 (−0.15 to 0.03) 0.20 
Transfer 51 2.5% 77 3.7% 0.01 (−0.01 to 0.04) 0.38 0.01 (−0.01 to 0.03) 0.17 
Inpatient 23 1.1% 35 1.7% 0.01 (−0.01 to 0.02) 0.51 0.01 (−0.01 to 0.02) 0.42 
New facility 28 1.4% 42 2.0% 0.01 (−0.01 to 0.02) 0.44 0.01 (−0.01 to 0.02) 0.30 
Early discharge 145 7.2% 190 9.2% 0.02 (−0.04 to 0.08) 0.53 0.02 (−0.02 to 0.06) 0.36 
 










combined protocol arm. Among children with MAM, 348/1,376 (25.3%) defaulted in the stan- 
dard protocol arm and 308/1,444 (21.3%) defaulted in the combined protocol arm. 
In exploratory analyses of sub-groups, children with SAM, children with MAM, children 
aged <24 months, children aged ≥24 months, SAM children weighing ≥8 kg, children with a 
MUAC 11.5 to <12.5 cm but WHZ < −3, children in Kenya, and children in South Sudan 




ComPAS compared a simplified, combined protocol for acute malnutrition to standard care, 
and found non-inferior nutritional recovery in the combined protocol arm relative to the 
 
Table 3. Secondary outcomes among recovered children. 
 
Outcome Standard protocol 
(N = 12, n = 884) 
Combined protocol 
(N = 12, n = 981) 
Unadjusted Adjusted 
Mean SE Mean SE Mean difference p-Value Mean difference p-Value 
Length of stay (days) 65.0 2.31 65.4 2.24 0.42 (−6.19 to 7.04) 0.90 −0.55 (−5.75 to 4.65) 0.83 
Average daily weight gain (g/kg/day) 1.9 0.08 1.9 0.08 0.06 (−0.17 to 0.29) 0.61 0.08 (−0.13 to 0.29) 0.42 
Average daily MUAC gain (mm/day) 0.2 0.01 0.2 0.01 −0.01 (−0.05 to 0.02) 0.39 −0.01 (−0.04 to 0.02) 0.45 
 
Unadjusted: all children with outcome measures, not adjusted for any demographic or study design characteristics. Adjusted: adjusted for age, sex, and country. N = 
number of clusters; n = number of children eligible for follow-up. 
MUAC, mid-upper arm circumference. 
https://doi.org/10.1371/journal.pmed.1003192.t003 
 





Table 4. Input costs by country setting and treatment arm. 
 
Cost category Input costs—South Sudan Input costs—Kenya 
Combined protocol Standard protocol Combined protocol Standard protocol 
Treatment (includes product) $237,887 $243,991 $176,251 $174,164 
Product only $34,863 $40,967 $22,897 $20,196 
SAM $15,132 $26,492 $6,576 $6,678 
MAM $19,731 $14,474 $16,321 $13,518 
Outreach $71,329 $71,329 $20,766 $20,766 
Supply logistics $57,640 $69,220 $30,756 $30,756 
Supervision $128,917 $128,917 $14,125 $15,919 
Management $101,346 $101,346 $41,397 $41,397 
Household $8,861 $9,891 $11,563 $11,680 
Total $605,979 $624,692 $294,859 $294,683 
 
All values in US dollars. 




standard care arm. The findings of the per-protocol and intention-to-treat analyses were simi- 
lar. Clinical effectiveness was similar, with no evidence of a difference for the secondary out- 
comes death, non-response, defaulting, transfer to inpatient care, length of stay, program 
coverage, average daily weight gain, and average daily MUAC gain. Outcomes were similar 
between the study arms in exploratory analyses of sub-groups, including when disaggregated 
by SAM or MAM, and by country. The combined protocol cost less per child recovered than 
the standard protocol, especially for treatment of children with SAM and in the South Sudan 
context. 
This study contributes evidence on integrated SAM/MAM treatment protocols, MUAC- 
based programming, and novel dosage regimes, which carry certain programmatic benefits: 
simplicity, ease of use, and potential cost-effectiveness. The combined protocol tested in this 
trial was the first to our knowledge to use a simple, MUAC-based dosage. Our findings are 
consistent with previous studies on integrated management of SAM and MAM with novel dos- 
age regimes: a clinical trial in Sierra Leone that used a weight-based dosage protocol, with sim- 
ilar recovery and lower therapeutic food costs in the intervention arm of the study [21], and an 
operational trial in Burkina Faso that achieved recovery above Sphere standards and used less 
therapeutic food than standard programs [22]. 
 
 
Table 5. Base-case cost-effectiveness results of the combined versus standard protocol. 
 
Outcome Combined protocol Standard protocol 
Total cost (US dollars) $900,838 $919,376 
Number of children in program 2,071 2,039 
Recovery rate (intention-to-treat) 48% 44% 
Number of children recovered 981 884 
Cost per child treated (US dollars) $435 $451 
Cost per child recovered (US dollars) $918 $1,041 
Incremental cost (total) (US dollars) −$18,538 Ref 
Incremental cost (per child recovered) (US dollars) −$123 Ref 
 
ITT, intention-to-treat; USD, US dollars. 
https://doi.org/10.1371/journal.pmed.1003192.t005 
 




Strengths of this study included comparison against the “gold standard” of standard care: 
community-based management of acute malnutrition at health clinics offering OTP and SFP 
in the same physical location, with RUSF offered to children with MAM instead of fortified 
blended flours. ComPAS was designed this way to capture the value added by simplifying and 
combining treatment. The reality is that many standard care programs are not able to provide 
RUSF for children with MAM, or the treatments for SAM and MAM are offered in separate 
physical locations. Another strength was the inclusion of 2 different contexts contributing to a 
combined dataset. The multi-country nature of the trial increases the generalizability of the 
results, with both rural and urban settings contributing data. 
ComPAS faced several operational limitations. The contexts in Nairobi and Aweil East are 
very different, but the study sites were not large enough to be independently powered. There- 
fore, the analysis is only powered for combined multi-country estimates. Though our inclusion 
criteria included children up to 59 months, the majority were less than 24 months, so care 
should be taken in extrapolating the results to older or larger children. A non-inferiority mar- 
gin of 10% was selected in consideration of previous program data from Aweil East and Nai- 
robi. Actual proportions recovered are within a slimmer margin, with adjusted and 
unadjusted risk differences for both the per-protocol and intention-to-treat analyses within a 
5%–6% margin (Table 2; Fig 2). In Aweil East, access to 4 of the clinics during the rainy season 
(May to November) was limited. Two of these clinics implemented the combined protocol, 
and 2 of the clinics implemented the standard protocol. One of the clinics was so inaccessible 
that supplies could not be delivered for more than 3 months. In Nairobi, mothers were often 
unable to take time off work to bring their children for regular visits, and some children with 
medical complications were not admitted to inpatient care for the same reason. The health 
clinics in Kenya were affected by a national nurse’s strike from June to November 2017, which 
resulted in brief clinic closures and reduced availability of nursing staff. A national presidential 
election in August 2017, followed by a repeat election in October 2017, contributed to an 
atmosphere of uncertainty and some instability in the areas of Nairobi where the study took 
place. Many children were not able to attend their scheduled visits for several weeks during 
each election period, while families traveled to their rural homes to vote. All the factors above 
contributed to high defaulting in both contexts, reflected similarly in both arms, and may have 
negatively affected average daily weight gains. We have no reason to suspect that treatment 
acceptability had any role in defaulting. High defaulting drove down the overall recovery rates 
in the intention-to-treat analyses, which did not meet Sphere standards [40]. High defaulting 
also inflated the cost per child recovered. Defaulting did not impact our assessment of non- 
inferiority of recovery as the required number of participants completing treatment was met 
across clusters and arms. 
The same underlying factors that drove high defaulting in both arms also contributed to fre- 
quent missed visits and longer lengths of stay. We do not attribute the longer lengths of stay to 
a difference in dosage protocol, as the lengths of stay were similar between arms. Where 
defaulting and missed visits are common, extending the period in treatment allows for more 
children to reach recovery. In our analyses, many children went on to recover after the 
16- week cutoff for non-response (S1 Fig; S2 Fig). 
The cost savings assessed in this trial were limited in scope. Though our method for assess- 
ing cost-effectiveness removed many of the research-specific costs [34], it was not possible to 
fully separate research versus programming costs in the analysis, so the total cost per child is 
higher than in many program settings. The costs reflect the combined inputs of NGOs and 
ministries of health, both of which contributed to the treatment of children. Additionally, the 
settings of Nairobi, Kenya, and Aweil East, South Sudan, have unique cost implications that 
may not affect other programs, such as the high costs of rent in a capital city and the high 




logistics and security costs of operating a clinical trial in a conflict-affected context. Average 
costs in a non-research setting, although highly variable by context, are often around US$200 
per child recovered [48,49]. 
There were large differences in costs between countries. It is important to note that costing 
results reflect the caseloads and characteristics of the sample at the country level, but the study 
is not statistically powered to make conclusions about differences in effectiveness. In South 
Sudan, there were 3 main reasons for cost savings in the combined protocol: (1) higher recov- 
ery and lower length of stay in the combined protocol arm (S5 Table), (2) a higher burden of 
SAM (with a reduced dosage of RUTF compared to the standard protocol), and (3) an inde- 
pendent supply chain. In Kenya, the larger proportional burden of MAM to SAM cases (S3 
Table) and the presence of a centralized medical supply chain through the national govern- 
ment meant cost savings were not apparent. RUTF had a slightly higher price than RUSF (US 
$0.33 versus US$0.29 per sachet), which affected the cost of MAM treatment in the combined 
protocol. 
Future studies should assess whether additional savings can be achieved from increased effi- 
ciencies throughout the larger system for managing acute malnutrition in operational settings. 
Further research is needed to assess cost-effectiveness in a scaled-up system treating SAM and 
MAM in 1 protocol with 1 food product across a variety of contexts. Operational studies could 
assess the impact of a simplified, combined protocol on SAM/MAM caseloads and resource 
use across multiple years. Potential cost savings may be possible through the prevention of 
SAM, with its associated medical complications and systematic medications. In the longer 
term, cost savings from increased efficiency and a reduction in SAM caseload may spread fur- 
ther upstream, addressing more of the MAM caseload. Earlier treatment of acute malnutrition 
is likely to result in fewer long-term implications, helping children to better survive and thrive. 
Adoption of a simplified and combined protocol may simplify operations in resource-con- 
strained settings. A combined protocol reduces the need to procure 2 separate products for 
SAM and MAM treatment, streamlines program logistics and staff training, and enables a 
more holistic continuum of care for children with acute malnutrition. A simplified protocol 
may also facilitate delivery of treatment by community health workers, to improve access and 
reduce defaulting, an important area of work that calls for research. In contexts where children 
are highly vulnerable to malnutrition—particularly in crises and chronically fragile situations 
—a combined protocol may offer some protection, enabling children to benefit from treat- 
ment before they deteriorate into life-threatening SAM. The optimal diagnostic criteria and 
dosage of therapeutic foods may differ by setting, and further research should explore these 
setting-specific issues and the operational and physiological impacts of expanding treatment of 
MAM [17]. The potential benefits of a simplified protocol may be weighed against economic 
considerations including implications for the supply chain of ready-to-use foods, and the 
impact on caseload and cost when treatment is made more readily available to moderately mal- 
nourished children. Further research is also needed to assess the safety and effectiveness of a 
reduced dosage protocol in children with SAM and in older or larger children. Though our 
study did not find evidence of harm among any sub-groups, including those with SAM and 
older children, future studies could be powered to assess those populations specifically. Our 
findings are consistent with other studies that indicate that a reduced dosage for SAM does not 
lower recovery [21,22,30,31], but research is needed to understand why a reduced dosage is 
effective and the contextual factors that affect recovery. Investigating the effects of context 
(e.g., differences between African and Asian settings, differences between food-insecure set- 
tings and food-secure settings, and the impact of seasonality) is a priority. 
The reality is the current system fails to reach the majority of children who need treatment, 
and resources are already limited. If the global health community is to meet SDG nutrition 




targets, new approaches are urgently needed. This is particularly true with the emergence of 
SARS-CoV-2, which has further necessitated a consideration of simplified, easy-to-use, and 
cost-effective nutrition treatment approaches. The number of malnourished children may rise 
as a result of the pandemic due to economic and biological factors, and the ability of the health 
system to respond may be strained. Simplified protocols can be incorporated into an adapted 
approach that could be delivered by community health workers at home and that optimizes 
the use of ready-to-use foods. Further research should assess how simplified nutrition proto- 
cols can be part of the response to this need, optimizing existing resources to reach more chil- 
dren while maintaining a high level of clinical care for all sub-groups. Streamlined, cost- 
effective programs make a more persuasive case for future investment, and this in turn is more 
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Abstract: Weight-for-age z-score (WAZ) is not currently an admission criterion to therapeutic feeding 
programs, and children with low WAZ at high risk of mortality may not be admitted. We conducted 
a secondary analysis of RCT data to assess response to treatment according to WAZ and mid-upper 
arm circumference (MUAC) and type of feeding protocol given: a simplified, combined protocol 
for severe and moderate acute malnutrition (SAM and MAM) vs. standard care that treats SAM 
and MAM, separately. Children with a moderately low MUAC (11.5–12.5 cm) and a severely low 
WAZ (<−3) respond similarly to treatment in terms of both weight and MUAC gain on either 
2092 kJ (500 kcal)/day of therapeutic or supplementary food. Children with a severely low MUAC 
(<11.5 cm), with/without a severely low WAZ (<−3), have similar recovery with the combined 
protocol or standard treatment, though WAZ gain may be slower in the combined protocol. A 
limitation is this analysis was not powered for these sub-groups specifically. Adding WAZ < −3 as an 
admission criterion for therapeutic feeding programs admitting children with MUAC and/or oedema 
may help programs target high-risk children who can benefit from treatment. Future work 
should evaluate the optimal treatment protocol for children with a MUAC < 11.5 and/or WAZ < 
−3.0. 
Keywords: acute malnutrition; weight-for-age; mid-upper arm circumference; ready-to-use thera- 
peutic food; community-based management of acute malnutrition; wasting; stunting; concurrent 




Malnutrition is a major underlying cause of morbidity and mortality in children [1]. 
At any given time, stunting, defined by deficits in a child’s height-for-age, affects at least 
149 million children under five years of age, and wasting, defined by deficits in a child’s  
weight-for-height and/or a low mid-upper arm circumference, affects about 49 million 














estimates suggest [3,4]. Malnutrition contributes to approximately half of all deaths in 
children less than 5 years of age [1], and deaths associated with wasting may also be 
significantly underestimated [5]. The coronavirus pandemic is likely to further increase 
wasting and associated mortality [6]. 
Current policy and practice organize programs that focus on stunting and wasting 
separately [7–10]. Stunting is typically addressed through development programs that 
primarily focus on its prevention, whereas wasting is often addressed through humanitar- 
ian programs that primarily focus on its treatment in order to prevent near-term mortality. 
Multisectoral social and development programs aim to prevent stunting through agricul- 
ture; micronutrient supplementation; infant and young child feeding; and water, sanitation, 
and hygiene (WASH) approaches, among others [11]. The management of wasting may 
include therapeutic and supplementary feeding and treatment of underlying illnesses. 
Despite evidence of the common causal pathways for wasting and stunting [12,13] and the 
epidemiological overlap [14], programs rarely integrate objectives to address both forms of 
undernutrition simultaneously. Current funding mechanisms and organizational structures 
facilitate this division, with grants usually directed to programs addressing either stunting 
or wasting but seldom both [7]. In practice, this means programs addressing both wasting 
and stunting may not be available at the same place and time. Similar silos exist within 
wasting treatment, as severe and moderate acute malnutrition (SAM and MAM) are treated 
in separate programs [7,15]. 
Children with concurrent wasting and stunting are among the most vulnerable of all 
malnourished children, with a higher mortality risk than either wasting or stunting alone, 
and about a 12 times greater risk of mortality in the absence of treatment than those with 
normal anthropometry [16,17]. In low-income countries, 4.7% of children are affected si- 
multaneously by wasting and stunting [18]. Acknowledging the coexistence of wasting and 
stunting and the interactive effect on mortality risk, recent research has explored existing 
data to understand more about this particularly vulnerable group. Existing measures used 
at the community level were evaluated for their ability to identify concurrently wasted and 
stunted children. Weight-for-age (z-scores from the international reference median, WAZ) 
was found to have high (i.e., >90%) sensitivity and specificity for identifying children who 
are concurrently wasted and stunted across multiple settings [17]. In an analysis of cohort 
data from Senegal, different anthropometric criteria were examined for their ability to 
predict mortality. A combination of a severely low mid-upper arm circumference (MUAC 
< 11.5 cm) and a severely low WAZ (i.e., WAZ < 2.8) detected all near-term (i.e., occurring 
within 6 months of measurement) deaths associated with either a weight-for-height z-score 
(WHZ) < 3 and/or concurrent wasting and stunting (WHZ < 2 and height-for-age z-
score (HAZ) < 2) [19,20]. MUAC is already well evidenced to identify those at high risk 
for mortality and is easy to use [21–24]. Used together, these measures may be both 
practical and effective as MUAC and WAZ are already used at the community level for 
screening and for growth monitoring and promotion. 
Current therapeutic feeding programs use MUAC < 11.5 cm, WHZ < 3 and/or pres- 
ence of oedema as independent admission criteria [25,26]. Some children who are severely 
wasted and concurrently stunted are included by these criteria, but moderately wasted 
children who are concurrently stunted may not be captured for therapeutic feeding by 
these admission criteria despite their having a similar near-term mortality risk to severely 
wasted children [16,17]. Adding WAZ to the admission criterion for therapeutic feeding 
could improve the ability of these programs to identify and treat malnourished children 
most at risk of dying [19]. The intensity of treatment required by this additional group of 
children and the impact of their inclusion on therapeutic program caseloads and workload 
has yet to be evaluated in a prospective trial. There is already growing interest to simplify 
protocols for wasting treatment to reduce the silos between SAM and MAM treatment and 
optimize the use of resources to identify and treat the most vulnerable children [27–36]. 
Combining SAM and MAM treatment into a single protocol provides a holistic continuum 
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per therefore draws on data from a randomized controlled trial that tested the effectiveness 
of a simplified, combined protocol for treatment of medically uncomplicated severe and 
moderate acute malnutrition in children aged between 6 and 59 months [27,35]. 
The aim of this analysis was to contribute evidence on the value of adding WAZ to 
therapeutic feeding program admission criteria. Our objectives were to (1) assess outcomes 
and response to treatment in children admitted with a MUAC < 11.5 cm as two separate 
groups—those with a WAZ < 3 and those with a WAZ 3—both of which would be 
included in current therapeutic feeding programs, as well as children with a moderately 
low MUAC (i.e., MUAC between 11.5 cm and 12.5 cm) and a WAZ < 3, who would be 
eligible for admission into supplementary feeding programs in many settings; (2) explore 
outcomes and response to treatment by dosage protocol: a simplified, MUAC-based 
dosage in a combined treatment program compared to the weight-based dosage offered in 
standard care. 
2. Materials and Methods 
This paper reports on a secondary analysis of the intention-to-treat dataset from 
the Combined Protocol for Acute Malnutrition Study (ComPAS). ComPAS was a cluster- 
randomized controlled trial conducted in Kenya and South Sudan from May 2017–August 
2018 to evaluate whether a simplified, combined protocol was non-inferior to standard 
care for treatment of medically uncomplicated SAM and MAM in children 6–59 months. 
The trial found non-inferior recovery (76.3% in the combined protocol arm and 73.5% in 
the standard protocol arm, risk difference of 0.03, 95% CI 0.05 to 0.10, p = 0.52), with less 
ready-to-use food required for a child with severe malnutrition to reach full recovery in 
the combined protocol (122 versus 193 sachets) and improved cost-effectiveness (US$123 
less per child recovered; US$918 in the combined protocol versus US$1041 in the standard 
protocol) [35]. The methods [27,37], scientific rationale [34] and results [35] from the 
ComPAS trial have been published previously. 
This study was a secondary analysis of data from a trial conducted according to 
the guidelines laid down in the Declaration of Helsinki, and all procedures involving 
research study participants were approved by the ethics committees of the London School 
of Hygiene and Tropical Medicine (reference 11826), the Kenya Medical Research Insti- 
tute (reference non-KEMRI 551), and the Ministry of Health in South Sudan (approved 
21 November 2016). The analyses conducted for this paper comply with these ethical 
approvals. Written informed consent was obtained from the caretakers of all patients or by 
a witness who could attest to the caretaker’s verbal consent. 
In standard treatment, SAM and MAM are treated in separate programs with separate 
food products [7,15]. SAM is treated with ready-to-use-therapeutic food (RUTF) based 
on weight, and MAM can be treated with one sachet of ready-to-use supplementary food 
(RUSF) per day (Table 1). In the ComPAS intervention arm, a simplified, combined protocol 
admitted children with both SAM and MAM for treatment in a unified program, with 
eligible children receiving RUTF according to their MUAC and/or oedema status (Table 1, 
Supplementary Table S1). A simple MUAC-based RUTF dosage protocol was used because 
of evidence showing that MUAC identifies children at high-risk of mortality and is easier to 
use than weight-for-height measures [21–24], and that changes in MUAC track changes in 
weight [34,38,39]. The simplified protocol provides a reduced dosage of RUTF for children 
with a MUAC < 11.5 cm who have an admission weight of 5 kg, as these children would 






Table 1. Energy and food product given by treatment group. 
 
Group Combined Protocol Standard Protocol 
Group 1: 
MUAC < 11.5 cm and WAZ ≥ −3.0 
Group 2: 
MUAC 11.5 to <12.5 and WAZ < −3.0 
Group 3: 
MUAC < 11.5 cm and WAZ < −3.0 
Group 4: 
MUAC 11.5 to <12.5 and WAZ ≥ −3.0 
4184 kJ (1000 kcal)/day 
RUTF 
2092 kJ (500 kcal)/day 
RUTF 
4184 kJ (1000 kcal)/day 
RUTF 
2092 kJ (500 kcal)/day 
RUTF 
836.8 kJ (200 kcal)/kg/day 
RUTF 
2092 kJ (500 kcal)/day 
RUSF 
836.8 kJ (200 kcal)/kg/day 
RUTF 




MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score; RUTF, ready-to-use-therapeutic food; RUSF, ready-to-use supplemen- 
tary food. 
Clusters in the ComPAS trial were 24 health facilities stratified by country and ran- 
domized to deliver either the combined protocol or the standard protocol [27]. The dataset 
included children aged between 6 and 59 months at admission diagnosed with moderate or 
severe wasting and without medical complications in three urban sub-counties of Nairobi, 
Kenya (Embakasi North, Embakasi East and Embakasi West) and Aweil East, a rural, agro- 
pastoralist region of Northern Bahr El Ghazal state in South Sudan. Children presenting to 
any of the 24 health clinics participating in the study were eligible to enroll. Active case 
finding was also conducted to refer children with malnutrition. Participants in Kenya were 
invited to attend an appointment four-months post-discharge as part of a follow-up study. 
An anonymized dataset using only key variables from the ComPAS trial was used for 
this analysis [40]. The variables included case ID, age, sex, date of visit, anthropometric 
measurements (MUAC, weight, height, WAZ, HAZ) and oedema at each visit, outcome 
(recovered, died, defaulted, transferred or early discharge), site code, and intervention 
code (standard or combined protocol). Morbidity, hospitalization, fat mass, and fat-free 
mass variables were used from the follow-up study dataset. The following categorizations 
and anthropometric cut-offs were used: 
• Group 1: MUAC < 11.5 cm and WAZ ≥ −3; 
• Group 2: MUAC between 11.5 cm and <12.5 cm and WAZ < −3; 
• Group 3: MUAC < 11.5 cm and WAZ < −3; 
• Group 4: MUAC between 11.5 cm and <12.5 cm and WAZ ≥ −3.0. 
Groups 1–3 were the groups of interest in this analysis, and group 4 is presented for 
comparison. Groups 1 and 3 are currently included in therapeutic feeding programs for 
treatment of SAM because MUAC < 11.5 cm is a standard admission criterion. Groups 2 
and 4 are eligible for supplementary feeding for treatment of MAM where provided under 
existing guidelines because MUAC is between 11.5 and <12.5 cm [25,26]. Groups 1 and 3 
received RUTF at a fixed dose of 4184 kJ (1000 kcal) RUTF/day in the combined protocol 
and RUTF at a standard dose 836.8 kJ (200 kcal)/kg/day in the standard protocol. Groups 
2 and 4 received 2092 kJ (500 kcal) RUTF per day in the combined protocol and 2092 kJ 
(500 kcal) RUSF per day in the standard protocol (Table 1) [27]. RUTF and RUSF are similar 
in their compositions, but there are some key differences, including the proportion of total 
protein derived from dairy. RUTF typically has 50% of protein derived from dairy, and 
RUSF may have 33% of protein derived from dairy [25]. 
For each patient group, we assessed outcomes following treatment, duration of stay, 
and velocity of weight and MUAC change from admission until discharge. Outcomes in- 
cluded recovery (MUAC of 12.5 cm and no oedema for two consecutive visits), defaulting 
(failure to attend for three consecutive visits), death (including deaths that occurred after 
defaulting), transfers to other facilities, transfers to inpatient care, non-response (i.e., still 
under treatment but without recovery at or before the 17th week of treatment, and defined 
as “non-recovered” in this analysis) and early discharges (i.e., discharges made in error by 






as non-responders before the 17th week time limit). These issues are described in detail 
in the main trial paper [35]. We use the term “non-recovered” instead of “non-response” 
in this paper because there are some children who gained weight or MUAC and thus did 
“respond” to treatment but ultimately do not reach the recovery criteria. All outcome 
categories in the analysis were mutually exclusive. 
In Kenya only, caregivers of all study participants were asked to return for a follow- 
up visit at four months following discharge. The outcomes assessed at this visit were 
anthropometry (weight, height, MUAC, and oedema), recent history of illness, and body 
composition using bioelectrical impedance analysis (BIA) [41]. For the body composition 
analysis, raw impedance data were converted to fat and fat-free mass (FFM) values (kg) 
using a calibration equation derived from healthy children aged 3 to 18 months in The 
Gambia [42]. 
Because the data came from a cluster-randomized controlled trial, outcome analyses 
were adjusted for clustering of observations within health facilities using a cluster-robust es- 
timator of variance. We used binomial regression for binary outcomes and linear regression 
for continuous outcomes. Adjusted analyses accounted for country, age, and sex. Analyses 
were conducted using Stata IC v.13.1 (StataCorp LLC: College Station, TX, USA). Stata’s  
zscore06 module was used to calculate weight-for-age z-scores and flags, using WHO 
2006 Growth Standards [43]. Children with biologically implausible WAZ values as deter- 
mined by WHO flagging criteria (WAZ > 5 or < 6) at admission were excluded [44,45], 
and children with oedema on admission were not included in this analysis because their 
weight-for-age on admission would be unduly high due to the oedema. 
To develop individual growth curves, MUAC and weight-for-age were plotted at each 
visit and examined. One set of growth curves looks only at children who achieved recovery 
within 17 weeks, to allow for a closer examination of how these children recovered. cmAM 
programs typically report average weight and MUAC gains among recovered children 
only; therefore, this first set of growth curves is meant to align with cmAM reporting stan- 
dards [46]. Another set of growth curves inclusive of all children was generated to assess 
overall trends in the study dataset. The overall pattern of growth was visualized using ag- 
gregate growth curves. Median MUAC or WAZ at admission and at each subsequent visit 
up to and including discharge were estimated using a non-parametric percentile bootstrap 
procedure with 10,000 bootstrap replicates. These estimates were plotted, and a summary 
growth curve fitted using a LOWESS smoother [47] that weighted the weekly median esti- 
mates by the square root of the sample size at each week in each group. Summary growth 
curves were made for groups 1–3 for both the combined and standard protocol programs. 
3. Results 
Of the 4078 children included in the ComPAS trial dataset [35], 58 were excluded. Of 
these, 47 did not have an admission WAZ calculated due to the presence of oedema (which 
would have biased weight and WAZ upwards), and 11 were excluded because they had 
implausible WAZ values [44,45]. A total of 4020 children were available for the outcome 
analyses. The growth curve analyses presented in Figure 1 included the 647 children in 
groups 1–3 who recovered within 17 weeks. Of these 4020 children, 1962 were in Kenya, 
and 780 (39.8%) returned for a four-month follow-up visit, of whom 225 were in groups 











Figure 1. Analysis flow chart. MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score. 
 
Half of the children in this analysis were either severely underweight (WAZ < 3) 
and/or severely wasted (MUAC < 11.5 cm) at admission. Of the 4020 children, 1674 (41.6%) 
had a WAZ < 3. Of the 1200 children with MUAC < 11.5 cm, 71.9% had a WAZ <  3. 
Among those with a WAZ < 3863, 51.6% had a MUAC < 11.5 cm, and 811 (48.4%) had a 
MUAC   11.5 cm. Of the 2820 children with MUAC   11.5 cm, 28.8% had a WAZ <   3. 
Twice as many children in South Sudan (66.9%) were either severely underweight and/or 
severely wasted than in Kenya (32.4%). A total of 21.5% of children were both severely 
underweight by weight-for-age and severely wasted by MUAC (Table 2). 
Table 2. Numbers of children by category at admission. 
 
By Intervention Arm By Country 
Admission Groups 
Total by
 Combined Standard 
 
Kenya South Sudan 
 
MUAC < 11.5 cm and WAZ ≥ −3.0 
MUAC 11.5 to <12.5 cm and WAZ < −3.0 
MUAC < 11.5 cm and WAZ < −3.0 
MUAC 11.5 to <12.5 cm and WAZ ≥ −3.0 
MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score. 
 Protocol Protocol  
Group 1 
337 (8.4%) 142 (7%) 195 (9.8%) 126 (6.4%) 211 (10.3%) 
Group 2 
811 (20.2%) 482 (23.7%) 329 (16.6%) 294 (15%) 517 (25.1%) 
Group 3 
863 (21.5%) 447 (22%) 416 (20.9%) 215 (11%) 648 (31.5%) 
Group 4 











Overall, 1150 (89.5%) of children with a WHZ < −2.0 and HAZ < −2.0 (i.e., concur- 
rently wasted and stunted) also had a WAZ < −3.0. In Kenya, fewer children with a WHZ 
< −2.0 and HAZ < −2.0 also had a WAZ < −3.0 (80.9%). In South Sudan, more children 
with a WHZ < −2.0 and HAZ < −2.0 also had a WAZ < −3.0 (93.3%) (Table 3). 
Table 3. Numbers of children at admission with a WHZ < −2.0 and HAZ < −2.0 identified by a WAZ < −3.0. 
 
Country Criterion WAZ < −3.0 WAZ ≥ −3.0 Total 
Kenya WHZ < −2 and HAZ < −2 322 (80.9%) 76 (19.1%) 398 
South Sudan WHZ < −2 and HAZ < −2 828 (93.3%) 59 (6.7%) 887 
Both WHZ < −2 and HAZ < −2 1150 (89.5%) 135 (10.5%) 1285 
WHZ, weight-for-height z-score; HAZ, height-for-age z-score; WAZ, weight-for-age z-score. 
 
Group 1 were younger (median age 10 months) than the other groups and had the 
highest proportion of females. Group 2 were the oldest (median age 20 months), and 
Group 3 had a median age of 15 months (Table 4). 
 






MUAC < 11.5 cm and 
WAZ ≥ −3.0 (n = 337) 
Group 2 
MUAC 11.5 to <12.5 cm and 
WAZ < −3.0 (n = 811) 
Group   3 
MUAC < 11.5 cm and 
WAZ < −3.0 (n = 863) 
Combined 
(m § = 12, 
n † = 142) 
Standard 
(m = 12, 
n = 195) 
Combined 
(m = 12, 
n = 482) 
Standard 
(m = 12, 
n = 329) 
Combined 
(m = 12, 
n = 447) 
Standard 
(m = 12, 
n = 416) 
 
 






Weight (kg), mean (SD) 7.00 (1.54) 6.97 (1.62) 7.30 (1.42) 7.52 (1.39) 6.39 (1.34) 6.50 (1.31) 
 
Height (cm) *, mean (SD) 72.6 (9.28) 72.0 (9.29) 74.0 (8.34) 74.9 (8.06) 70.8 (8.07) 71.5 (8.09) 
MUAC (cm), mean (SD) 11.2 (0.23) 11.2 (0.29) 12.0 (0.27) 12.0 (0.26) 11.0 (0.44) 11.0 (0.49) 
 
WAZ, mean (SD) −2.4 (0.56) −2.4 (0.52) −3.6 (0.47) −3.6 (0.52) −4.1 (0.67) −3.9 (0.66) 
HAZ, mean (SD) −0.91 (1.07) −0.99 (1.16) −3.05 (1.02) −3.07 (1.03) −3.13 (1.25) −2.82 (1.17) 
 
WHZ, mean (SD) −2.61 (1.01) −2.52 (0.73) −2.72 (0.79) −2.62 (0.81) −3.23 (0.83) −3.24 (0.86) 
MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score; HAZ, height-for-age z-score; WHZ, weight-for-height z-score.§ m = 
number of clusters; † n = individual children eligible for treatment. * Length if child is <24 months. 
 
In general, children with a MUAC < 11.5 cm (groups 1 and 3) had lower recovery 
and higher defaulting and non-response than children with a MUAC between 11.5 and 
<12.5 cm (groups 2 and 4) at admission. Within MUAC categories, severely underweight 
children had poorer outcomes than those without severe underweight. Of the three patient 
groups of interest, children in group 2 had the highest recovery (53.9%) and shortest length 
of stay (median 64 days), though recovery was lower and length of stay longer than for 
children in the comparator group 4 who had neither WAZ <    3.0 nor MUAC < 11.5 cm 
(of whom 59.5% recovered with a median length of stay of 57 days). Recovery in group 1 
was 19.6%, and this group had the longest median length of stay (94 days). Children in 
group 3 had the lowest recovery (16.7%), despite being 5 months older on average than 
group 1. Children in group 3 also had the highest proportion of defaulters (39.4%) and 
deaths (1.9%). Defaulting and non-recovery was high in all groups studied [35], though 
Males, n (%) 31 (21.8%) 45 (23.1%) 258 (53.5%) 194 (59%) 221 (49.4%) 196 (47.1%) 
Age at admission (months), 
10 (8, 14)
 
10 (7, 14) 18 (12, 30) 21 (14, 30) 14 (9, 24) 15 (10, 24) 











group 2 had lower non-recovery (8.5%) and defaulting (21.7%) than groups 1 or 3. Among 
children with a MUAC between 11.5 cm and <12.5 cm, those with a WAZ < 3.0 had 
lower recovery (Table 5) 
 
Table 5. Outcomes of children, by admission category. 
 






MUAC < 11.5 cm and 
WAZ 3.0 
(n = 337) 
 
Group 3 
MUAC < 11.5 cm and 
WAZ <    3.0 
(n = 863) 
Group 2 
MUAC 11.5 to 
<12.5 cm and 
WAZ <    3.0 
(n = 811) 
 
Group 4 
MUAC 11.5 to <12.5 cm 
and WAZ 3.0 
(n = 2009) 
 
 n % n % n % n % 
Recovered * 66 19.6 144 16.7 437 53.9 1196 59.5 
Died 3 0.9 16 1.9 7 0.9 18 0.9 
Defaulted 131 38.9 340 39.4 176 21.7 480 23.9 
Non-recovered † 102 30.3 225 26.1 69 8.5 176 8.8 
Transfer-inpatient 9 2.7 29 3.4 10 1.2 8 0.4 
Transfer-new 
facility 
8 2.4 33 3.8 15 1.9 13 0.7 
Early discharge 18 5.3 78 9.0 102 12.6 130 6.5 
 Median IQR Median IQR Median IQR Median IQR 
Length of stay 
(days) ‡ 
94 73, 106 89.5 68, 101 64 43, 85 57 43, 76 
MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score.* Recovery is defined as MUAC      12.5 cm and no oedema for 
2 consecutive visits. † Non-recovered is defined as not reaching recovery criteria after 17 weeks in treatment, even though some of 
these children achieved recovery after 17 weeks [35]. ‡ Length of stay among recovered children only, following global cmAM reporting 
standards [46]. 
In exploratory analyses of the sub-groups by type of protocol given, there was no 
evidence of a difference between the combined and the standard protocols for groups 1 
or 2 for any of the outcomes (Supplementary Tables S4–S6). There was weak evidence 
of a difference by type of protocol given in group 3 in terms of recovery and defaulting. 
Recovery in group 3 was 19.5% in the combined protocol compared to 13.7% in the standard 
protocol (adjusted risk ratio = 1.36, 95% CI 0.90, 1.82, p = 0.07). Defaulting in group 3 was 
33.6% in the combined protocol compared to 45.2% in the standard protocol (adjusted risk 
ratio = 0.74, 95% CI 0.57, 0.97, p = 0.03) (Supplementary Table S6). There was no evidence 
of a difference in mortality for children when treated with either the combined or standard 
protocol in any of the three groups (Supplementary Tables S4–S6). 
Relapse to acute malnutrition at the four-month post-discharge follow-up visit in 
Kenya among children who were discharged as recovered in the three patient groups 
(n = 142) ranged from 8% to 25%. A high proportion of children who were admitted with 
MUAC < 11.5 cm and/or oedema reported an illness in the week before their post-discharge 
follow-up appointment (20–47%). Body composition (lean and fat mass) was similar for 
those treated with the combined and the standard protocol in each of the admission groups 
(Supplementary Table S3). 
Growth curve analyses were conducted among recovered children in the three patient 
groups of main interest (Figure 2) and among all children (Supplementary Figure S1). The 
samples at each time point in the growth curves are small, and the 95% confidence bands 
between the combined and standard protocols mostly overlap, though there are some 
potential differences to highlight. Of children who recovered, WAZ gain appears slower 
and lower in Group 1 among children treated with the combined protocol (Figure 2a). 
There is no evidence of a difference in MUAC gain in this group. In Group 3, children in 





some of the difference in Figure 2e. As with Group 1, there is no evidence of a difference in 
MUAC gain between the protocols in Group 3 (Figure 2f). In Group 2, the 95% confidence 
bands overlap for both WAZ and MUAC gain with no significant differences between 
the protocols. 
 
Figure 2. Panel of WAZ and MUAC response among recovered children by admission group. MUAC, mid-upper arm 
circumference; WAZ, weight-for-age z-score. (a) WAZ plotted against week in program for Group 1; (b) MUAC plotted 
against week in program for Group 1; (c) WAZ plotted against week in program for Group 2; (d) MUAC plotted against 
week in program for Group 2; (e) WAZ plotted against week in program for Group 3; (f) MUAC plotted against week in 
program for Group 3. The shaded areas represent a 95% confidence band around each curve (i.e., the area between the 









Similar trends can be seen in the growth curves of all children, with lower WAZ gain 
in children treated with the combined protocol in Group 1 (Supplementary Figure S1a), 
though 95% confidence bands overlap at many time points, and there is no evidence of 
a difference in MUAC gain (Supplementary Figure S1b). In Group 2, the children in the 
combined protocol appear to start at a lower baseline and the overall shape, and trajectory 
of WAZ gain is similar to the standard protocol, with mostly overlapping 95% confidence 
bands (Supplementary Figure S1c). There is no evidence of a difference in MUAC gain 
between the protocols in Group 2 (Supplementary Figure S1d). In Group 3, children in the 
combined protocol start at a lower baseline WAZ (Table 3), and the curve remains lower at 
all time points (Supplementary Figure S1e). MUAC gain appears slower and lower among 
children in the combined protocol in Group 3 (Supplementary Figure S1f). 
To assess how well a combination of WAZ < 3.0 and MUAC < 12.5 cm performs in 
capturing near-term deaths (i.e., within 6 months), we adapted an analysis of data presented 
in a previous paper [19] to assess a cut-off of WAZ <    3.0 instead of WAZ <    2.8 (Figure 3). 
A combination of MUAC and WAZ case definitions detect 39 (97.5%) of the 40 deaths 
associated with a WHZ < −3.0 and 62 (95.4%) of 65 deaths associated with concurrent 
wasting and stunting, as defined by WHZ < −2.0 and HAZ < −2.0 (WaSt). 
 
Figure 3. Venn diagram showing the number of deaths among treated children with different 
combinations of anthropometric deficits (adapted from Myatt et al., 2019 [19]). MUAC, mid-upper 
arm circumference; WAZ, weight-for-age z-score; WHZ, weight-for-height z-score; HAZ, height-for- 
age z-score; WaSt, both wasted and stunted. 
 
4. Discussion 
Children with a MUAC between 11.5 cm and <12.5 cm who would be admitted to 
therapeutic feeding programs if WAZ < 3.0 is added as an independent criterion had 
higher recovery and lower lengths of stay than either of the groups with a MUAC < 11.5 cm, 
despite receiving only a supplementary dose of RUTF or RUSF instead of a therapeutic 
dose based on weight. Recovery in this group remained lower than children with the 
same MUAC (between 11.5 to <12.5 cm) but a higher WAZ (i.e., WAZ 3.0), which may 
reflect the increased severity of their anthropometric deficits. Children who recovered in 
this group also achieved rapid growth under both the combined and standard protocols, 
suggesting we may expect good response to treatment with 2092 kJ (500 kcal)/day of 
either RUTF or RUSF. Children with severely low MUAC (<11.5 cm), with and without 









also had the longest lengths of stay and the highest defaulting. Children with both a 
MUAC < 11.5 cm and a WAZ <  3.0 had the lowest recovery of any patient group, with 
the greatest number of deaths. There was no evidence of a difference in mortality for 
children when treated with either the combined or standard protocol in any of the three 
groups (Supplementary Tables S4–S6). This analysis indicates some potential differences 
in the way severely malnourished children respond to treatment between the combined 
and standard protocols, though these differences were mixed. There was weak evidence 
of higher recovery and lower defaulting among children with a MUAC < 11.5 cm and a 
WAZ < 3.0 treated with the combined protocol. Among children with a MUAC < 11.5 cm 
and a WAZ 3.0, there was some indication that WAZ gain was slower and lower in the 
combined protocol, though MUAC gain was similar. These mixed results in children with 
the most severe deficits in MUAC and WAZ warrant further investigation to understand 
the growth patterns and optimal dosage protocol for these groups. 
Limitations to this analysis included both statistical and operational constraints. Cau- 
tion should be exercised when extrapolating these results as these are exploratory analyses 
of small sub-groups. This is a secondary analysis of data from a trial that was not powered 
for sub-group analyses but for combined multi-country estimates of overall recovery in 
each treatment arm. The majority of children in the ComPAS trial were aged 6–24 months, 
thus limiting generalizability to older children. The eligibility criteria for this trial were 
focused on MUAC and/or oedema; therefore, we cannot assess how WAZ would perform 
as an independent criterion if we had admitted all those with WAZ < 3 but normal MUAC 
and oedema status. Operationally, the ComPAS trial faced multiple challenges. Study 
operations were disrupted by a nurse’s strike and repeated national elections in Kenya in  
2017, and the rainy season interfered with the accessibility of some clinic sites in South 
Sudan [35]. These operational factors affected both study arms equally and contributed to 
frequent missed visits, longer lengths of stay, and higher numbers of children discharged 
as non-responders or defaulters. An outcome of “non-response” (defined as non-recovered 
in this analysis) was strictly applied to all children still in treatment after the cut-off of 
17 weeks, though some of these children went on to recover after 17 weeks [35]. Low 
overall recovery was reported in the intention-to-treat analyses of the ComPAS trial due 
to high defaulting, though the main per-protocol analysis reported higher recovery than 
the intention-to-treat analysis (76.3% in the combined protocol and 73.5% in the standard 
arm) [35]. The high defaulting reduced the number of recovered children that could be 
analyzed in each of the three admissions groups in this analysis. 
Strengths of this analysis included the multi-country nature of the trial, which con- 
tributes to the generalizability of results. Both rural and urban settings are included. 
Additionally, the data analyzed comes from a randomized controlled trial, with quality 
control measures in place to ensure high accuracy of data. The ComPAS trial provided a 
unique opportunity to evaluate WAZ response in different settings and in children with 
both SAM and MAM in the same dataset and to explore their outcomes by intensity of 
dosage and type of food product given [27]. 
This analysis contributes to a growing body of evidence on the utility of adding 
WAZ as an admission criterion for therapeutic feeding programs alongside MUAC and 
oedema [17,19,48]. As humanitarian and development actors and governments study 
the impacts of combined and simplified SAM and MAM programming [27–36], debate 
continues over which anthropometric indicators and cut-offs are likely to admit the highest- 
risk children that can be treated successfully with currently available therapeutic feeding 
products [21,49]. Given that a combination of low WAZ and/or low MUAC captures 
nearly all near-term mortality associated with anthropometric deficits including low WHZ 
and concurrent wasting and stunting, their combined use is an inclusive approach to 
therapeutic feeding admissions (Figure 3) [17,19]. In addition to being good predictors of 
near-term mortality, WAZ and MUAC are practical to use [19,22,23,50]. It is difficult to 
identify children with concurrent wasting and stunting and prioritize them for treatment 












feasible community-based alternative. Community-level programs can use WAZ to identify 
children with a severely low WHZ who are at high risk of mortality without needing to 
measure height [17,19]. WAZ and MUAC are already widely used in community programs 
(such as Expanded Program on Immunization (EPI), Integrated Management of Childhood 
Illnesses (IMCI), Growth Monitoring and Promotion (GMP), and community screening).  
WAZ integrates multiple anthropometric dimensions of malnutrition, thus bridging the 
current divide in programming between wasting and stunting. The use of WAZ and MUAC 
also aligns with recent recommendations for the identification of SAM in infants less than 
6 months [51]. 
These potential benefits must be weighed against potential drawbacks, including 
the difficulties assessing age in feeding programs and the likely increase in caseload. 
Age may be challenging to assess objectively, as it may be based on reporting using 
seasonal or cultural event calendars. This may affect the ability to accurately assess WAZ 
for some children. Current treatment programs, particularly those including moderate 
wasting, may already capture many low weight-for-age cases (41.6% of children admitted 
in the ComPAS trial had a WAZ <     3.0) (Table 2). Based on the numbers in this analysis, 
if WAZ < 3.0 (with a MUAC < 12.5 cm) is added as a criterion to a cmAM program 
admitting children with a MUAC < 11.5 cm only, the caseload would increase by 1.68 times 
(in this program, from 1200 children with a MUAC < 11.5 cm to 2011 children with either 
a MUAC < 11.5 cm and/or a WAZ <      3.0). This is similar to caseload change estimates 
made from simple simulations using population, prevalence survey, and program coverage 
data reported previously [19]. However, the exploratory analyses presented in this paper 
indicate this additional group of children appear to respond well to 1 sachet of either 
RUTF or RUSF a day and a clinic visit every other week instead of weekly, thus making 
this a potentially cost-effective approach. In emergencies or resource-constrained settings, 
either RUTF or RUSF could be selected based on availability. If this group of children 
identified by WAZ < 3 is added into a program using a simplified and combined protocol, 
additional cost savings may be seen. In this analysis, out of the 589 children with a 
MUAC < 11.5 cm (groups 1 and 3) treated with the combined protocol, 535 (90.8%) had 
an admission weight of    5 kg and thus received a reduced dosage of RUTF compared 
to standard care (Supplementary Table S2). Our prior research on this dosage protocol 
indicated it is sufficient to meet the theoretical energy needs of children 6–59 months 
recovering from uncomplicated acute malnutrition [34], and recovery was non-inferior 
to the standard protocol in an RCT [35]. The reduced dosage and other cost savings seen 
in a simplified protocol [30,35,36] may make it more feasible to treat additional children 
identified using WAZ and maintain the overall cost-effectiveness of the program. 
Future work should evaluate how to treat children with the highest risk of mortality 
efficiently and effectively. This includes prospectively testing appropriate treatment regi- 
mens for the severely low MUAC and WAZ groups, assessing how adding WAZ to the 
admission criteria for therapeutic feeding affects caseload, resource use and workload, and 
evaluating outcomes of low weight-for-age and concurrently wasted and stunted children 
under treatment. Existing cmAM cohort data could be used for this purpose, as many 
SAM cases are likely to have a WAZ < 3.0 (Table 2). Future work could look at whether 
children who do not ultimately reach recovery criteria nonetheless improve their WAZ and 
MUAC. Different WAZ and MUAC cut-offs for admission and management can be tested 
according to context and in consideration of aggravating factors such as food insecurity 
and prevalence of disease.  A WAZ <   3.0 identified different proportions of children 
with concurrent wasting and stunting in Kenya and South Sudan in this analysis (Table 3). 
Studies should build in adequate follow-up time post-treatment to assess longer-term 
growth trends and health outcomes of children with a low WAZ. 
5. Conclusions 
Preventing mortality and achieving optimal long-term health outcomes should be the 






to avoid the silos created by SAM/MAM or wasted/stunted classifications. Adding WAZ 
as an admissions criterion may help programs target children at higher risk of adverse 
outcomes who may benefit from treatment. The optimal dosage protocol for the most 
severely malnourished (MUAC < 11.5 cm, with and without a WAZ < 3.0) should be 
evaluated further. 
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ready-to-use therapeutic food dosage table (based on 200 kcal/kg/day using 92 g packets containing 
500 kcal). Table S3. Relapse, body composition, and morbidity at four months post-discharge, by 
admission category and protocol type (Kenya sample only). Table S4. Outcomes of children in group 
1, unadjusted and adjusted risk ratios. Table S5. Outcomes of children in group 2, unadjusted and 
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Chapter 5: Discussion 
 
5.1 Summary of research findings 
 
 
The aim of this thesis was to generate evidence on a simplified, combined SAM and MAM approach 
to treat uncomplicated acute malnutrition in children 6-59 months, using a MUAC-based RUTF 
dosage protocol. Each stage of the research contributed different findings to our understanding of 
managing uncomplicated acute malnutrition in children 6-59 months. Below is a summary of key 
findings as they relate to the three objectives of this thesis. 
Objective 1: Assess MUAC and weight gain trends in children recovering from acute 
malnutrition and estimate energy requirements correlated with MUAC category, to inform 
the development of a simplified, MUAC-based dosage protocol for SAM and MAM. 
In the first stage of the research, we found that children with a MUAC <12.5 cm need approximately 
1,000 kcal/day to achieve optimal growth during treatment. The rate of MUAC and weight gain 
appear to slow when children reach a MUAC of approximately 11.5 cm, and thus we proposed a 
reduction in the dosage from 1,000 kcal/day (2 sachets) of RUTF to 500 kcal/day (1 sachet) of RUTF 
when children reached a MUAC of 11.5 cm and no oedema for two consecutive visits, in line with 
global guidance on the management of MAM.23, 24 These findings were theoretical, and the next 
stage was to test this protocol in a field setting. 
Objective 2: Evaluate if the simplified, combined protocol is non-inferior to the standard 
protocol in terms of recovery and assess whether it improves cost-effectiveness. 
In the second stage of the research, we found that a simplified, combined protocol is as effective as 
standard treatment and saves money. A MUAC-based dosage protocol providing 1,000 kcal/day (2 
sachets) of RUTF for children with a MUAC <11.5 cm and/or oedema, and 500 kcal/day (1 sachet) of 
RUTF for children with a MUAC between 11.5 cm and <12.5 cm, is as good as the standard weight- 
based dosage protocol in terms of anthropometric recovery. Less RUTF is required to fully recover 
a child admitted with SAM (122 vs. 193 sachets). Stream-lined logistics and program management 
introduces additional cost savings, particularly in the South Sudan context, where the RUTF and 




Objective 3: Explore the outcomes of subgroups of children with severely low weight-for- 
age and/or severely low MUAC, to contribute evidence on the optimal dosage required by 
children who may be at a high risk of near-term mortality. 
In the final stage of the research, we found that children with a MUAC between 11.5 and <12.5 cm 
and a WAZ <-3.0 respond similarly to either 500 kcal of RUTF or 500 kcal of RUSF. This group with a 
WAZ <-3.0 but a MUAC ≥11.5 cm is currently excluded from therapeutic feeding programs, and 
evidence from this analysis indicates they benefit from a low intensity treatment. Children with a 
severely low MUAC <11.5 cm, with or without a WAZ <-3.0, have the poorest outcomes, with similar 
recovery, MUAC gain and mortality between the combined and standard protocol groups. Among 
children with a MUAC <11.5 cm and a WAZ ≥-3.0, there is some indication WAZ gain may be slower 
in the combined protocol. The optimal dosage protocol for children with a MUAC <11.5 cm, with or 
without a WAZ <-3.0, should be confirmed with further research. 
 
 
5.2 Research in context 
 
 
These findings are similar to related trials.31, 32, 87 The simplified and combined management of SAM 
and MAM in a single protocol achieves similar numbers of recovered children and contributes to 
cost savings.31, 32, 132 When used at a larger scale over a longer timeframe in an operational study, a 
combined SAM/MAM treatment protocol may reduce the SAM caseload, by preventing children 
with MAM from deteriorating into SAM.32 Reduced dosages of RUTF provided to children with SAM 
results in similar recovery, average daily weight and MUAC gains,31, 32, 86, 87, 132 though one trial 
indicated a negative impact on height gain.87 The ComPAS follow-up study (Annex J) found no 
difference in relapse among children treated with the simplified, combined protocol compared to 
the standard protocol, or in body composition four months post-discharge, similar to findings from 





5.3.1 Technical strengths 
 
The design of ComPAS with multiple stages allowed for an extensive development and theoretical 




research stages, ComPAS comprised multiple sub-studies including the cost-effectiveness analysis, 
the follow-up study on body composition and relapse, and a policy landscaping analysis.133 
Objective 1 was answered with a large database from five countries, allowing for greater confidence 
in the choice of RUTF rations as the MUAC-based dosage protocol was developed. 
Objectives 2 and 3 were answered with data from the RCT, which is considered as a strong source 
of evidence according to the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) Working Group.134 
The ComPAS RCT was designed to compare against the ‘gold standard’ of standard care for CMAM: 
integrated OTP and SFP services offered in the same physical location, with RUSF offered for MAM 
instead of fortified blended flours. In many situations, the reality of ‘standard care’ is that treatment 
for MAM is not available, or only fortified blended flours are available for MAM, or treatment for 
SAM and MAM are not offered in the same location. ComPAS was designed to compare against the 
ideal implementation of CMAM to assess the value added of simplifying and combining treatment, 
and not just providing MAM treatment. This may also be seen as a limitation to the trial, as the true 
effect of offering a combined SAM and MAM protocol may be underestimated when the reality in 
many situations is that there is no MAM treatment at all. 
 
 
5.3.2 Contextual strengths 
 
 
The study benefited from the inclusion of data from multiple countries across several settings. The 
first stage drew on data from five countries in multiple regions: Chad, South Sudan, Kenya, Yemen 
and Pakistan. The RCT was conducted in two countries with very different contexts: rural South 
Sudan and urban Kenya. The diversity of data increased the generalizability and applicability of the 
results across both rural and urban contexts. 
 
 
5.3.3 Research into policy and practice 
 
 
The ComPAS research benefited from a global coalition of research partners, an expert scientific 
committee and the engagement of key policy stakeholders, including UN agencies, institutional 
donors and Ministries of Health. The engagement of key stakeholders helped position the research 
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to directly inform future policy discussions. The global coalition of partners that supported ComPAS 










5.4.1 Secondary analysis of routine program data 
 
 
In the first stage, the analysis of rate of growth and energy requirements was based on 
retrospectively collected routine program data from three different agencies, across multiple 
countries and years. Children in the dataset were treated in different types of feeding programs, but 
we did not have information on the type or amount of food product offered to children with MAM. 
In South Sudan, only children with SAM were admitted, though these children were treated until 
they recovered from MAM (MUAC >12.5 cm). Therefore, for children with a MUAC between 11.5 
to <12.5 cm, the type of treatment they received differed according to context. For example, a child 
in South Sudan admitted to a SAM-only treatment program would be treated with a weight-based 
dosage (175-200 kcal/kg/day) even after their MUAC qualified them as MAM (11.5 to <12.5 cm). A 
child with a similar MUAC admitted to a MAM treatment program in one of the other four countries 
may have been treated with a single sachet of RUSF/day, or with fortified blended flours. Data on 
specific subgroups were limited in the stage 1 database- particularly older, larger children with SAM 
(defined as ≥24 months and/or ≥8kg with a MUAC <11.5 cm and/or oedema), and therefore care 
should be taken in extrapolating results to these subgroups. 
 
 
5.4.2 Randomized controlled trial in Kenya and South Sudan 
 
 
The RCT took place in two countries, but neither country-specific sample size was powered to be 
large enough for an independent country subgroup analysis of results. This was due to funding 
restrictions. The original donor for the trial wanted to see results from different countries to 
increase generalizability, but there was not enough funding to increase the size of the trial. Multiple 




affected the trial; these are described in detail in Paper III. These factors contributed to high 
defaulting across both arms of the trial, and likely also increased the average length of stay and 
decreased the average weekly weight and MUAC gains. 
As with the secondary analysis of routine program data in first stage of research, the majority 
(approximately 75%) of children in the RCT were between 6-24 months. The results are therefore 
less generalizable to older children >24 months, as there were not enough of them to specifically 
explore or compare the outcomes for this group. The results are generalizable to CMAM programs 
overall as the age of participants was similar to many programs globally, but caution should be taken 
assuming the dosage tested will work across all age ranges equivalently. 
Similarly, the RCT was conducted in two East African contexts, and more research is needed to assess 
the effectiveness of a reduced dosage protocol in other geographic contexts. Different dosage 
protocols, using different anthropometric cut-offs, may be appropriate in African vs. Asian or food 
insecure vs. food secure contexts.88 Paper II of this thesis found that the amount of energy required 
for recovery of children with a MUAC <11.5 cm in the Asian countries may be lower than in the 
African countries included in the analysis, consistent with research indicating SAM may be different 
in children in Asian vs. African contexts.135 
 
 
5.4.3 Cost-effectiveness analysis 
 
 
The cost-effectiveness results were limited in scope, varying significantly by context and by severity 
of acute malnutrition. In South Sudan, with a higher proportion of SAM children, greater cost savings 
were seen due to the reduced dosage of RUTF provided to some children with SAM. In Kenya, these 
savings due to RUTF costs were not apparent due to a smaller proportion of SAM. Similarly, in Kenya 
a national logistics system, the Kenya Medical Supplies Agency (KEMSA) manages both the supply 
of RUTF and RUSF, reducing the potential of a single product to improve cost efficiencies. In South 
Sudan, where RUTF and RUSF are supplied through separate UN agencies (UNICEF for RUTF and 
WFP for RUSF), the effect of a combined protocol with a single food product improved cost savings. 
The cost results were limited by these country-specific differences because the overall intention-to- 
treat recovery rate was used to assess cost-effectiveness, but a country-specific estimate of 




5.4.4 Secondary analysis of children with low weight-for-age 
 
 
Limitations to the secondary analysis of children with low weight-for-age included the operational 
constraints for the trial described above, as well as the statistical constraints of analyzing a subgroup 
of children that the sample size was not powered to investigate. The eligibility for the ComPAS trial 
was based on MUAC and oedema, therefore we cannot evaluate the outcomes of children who may 
have had a WAZ <-3.0 but a MUAC >12.5 cm and no oedema. We are not able to contribute evidence 
on the use of WAZ <-3.0 as an independent criterion for admissions to therapeutic feeding 
programs, nor do we know how many children might have qualified under such a criterion as this 
data is not routinely collected. 
 
 
5.5 Current context and policy implications 
 
 
5.5.1 Inspiring new research 
 
 
The ComPAS research and related studies31, 87, 129 contributed to a shift in thinking about SAM and 
MAM treatment, helping to inform and inspire new and related research 20, 32-35, 136-140 and a 
community of practice on simplified approaches.141 A Simplified Approaches Working Group, led by 
UN and NGO nutrition partners, was formed in 2019 to support the uptake of the simplified, 
combined protocol and related approaches globally. New studies have looked at optimizing the 
dosage of RUTF offered to children during SAM treatment,32, 83, 87, 132 combining SAM and MAM 
treatment,31, 32, 34, 132 and simplifying treatment overall.31-34, 59, 132, 138, 142 Some elements of the 
protocol studied in ComPAS remain debated, particularly MUAC-only programming,58 the 
appropriate dosage83 and the extension of treatment to all children with MAM.25 Overall, there is a 
drive towards better understanding which children need what kind of treatment and how to 
optimally identify and support them.142-146 
 
 
5.5.2 Informing UN and institutional donor guidelines 
 
 
As a result of ComPAS and related research, several UN agencies and institutional donors have 
released guidelines encouraging the use of simplified and combined programming, particularly in 




Tool for Emergencies, which included an adapted version of the ComPAS protocol for use in 
exceptional circumstances.24 ECHO issued a technical issue paper on the simplified protocol in 2017 
and OFDA incorporated guidance on simplifying and combining SAM and MAM treatment in their 
proposal guidelines in 2018.147, 148 UNICEF released a statement outlining plans to shift treatment of 
wasting to use elements of the simplified, combined protocol, in combination with complementary 
interventions.149 The COVID-19 pandemic accelerated the use of the simplified, combined protocol. 
UNICEF and the WHO released guidelines on the management of wasting in communities affected 
by COVID, recommending elements of the ComPAS protocol, such as MUAC-only programming, 
expanded admissions to all children with a MUAC <12.5 cm and/or oedema, and the use of a single 
RUTF product for both SAM and MAM.150 UNICEF, the IRC and NGO partners published a 
complementary toolkit to support implementation of community health worker delivery of the 
simplified, combined protocol in the context of COVID-19.151 
 
 
5.5.3 Piloting the simplified, combined protocol 
 
 
UN agencies and institutional donors have also funded operational research of the ComPAS 
protocol. In 2018, UNICEF, WFP and ECHO organized operational research of the ComPAS protocol 
in West and Central Africa.139 Pilots of the ComPAS protocol were initially implemented by the IRC 
in Mali and Chad in 2018 and 2019. These pilots were followed by more operational research run by 
UN agencies and NGO’s in different countries and regions. According to the Simplified Approaches 
Working Group in February 2021, the ComPAS protocol was being tested or planned for use by seven 
different NGO’s (IRC, AAH, MSF, Alliance for International Medical Action (ALIMA), Save the 
Children, GOAL, and Concern Worldwide) in more than 12 countries, including in Burkina Faso, Mali, 
Senegal, Afghanistan, South Sudan, Ethiopia, Chad, Somalia, Kenya, Niger, Mauritania and the 
Central African Republic.139 The ComPAS protocol has been used in emergency responses in South 
Sudan, Nigeria, and Uganda among other countries.152-154 UNICEF and WFP have committed to 
introducing simplified approaches in the Sahel and Horn of Africa regions, with a strong learning 
agenda to inform expansion to new regions.155 
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5.5.4 Reviewing the evidence in global consultations 
 
 
The World Health Organization hosted a meeting to review the evidence on combined and simplified 
protocols in March 2019 and issued a statement.143 The Field Exchange, a technical publication on 
nutrition and food security in emergencies, produced a special issue in 2019 focusing on the 
continuum of care, which highlighted research on simplified and combined protocols and 
approaches to improve SAM and MAM treatment along a continuum.146, 156 In 2020, the UN released 
the Global Action Plan on Child Wasting with an extensive research agenda that included a call for 
more research on specific elements of simplified and combined protocols, including the optimal 
dosage and simplifications aimed at improving the cost-effectiveness and coverage of 
programming.140 UNICEF published a rapid review of the evidence on simplified approaches in 2020, 
finding that the protocol used in ComPAS was the most widely used dosage adaptation, likely due 
to its simplified calculation of dosage based only on MUAC.139 As part of the Global Action Plan on 
Wasting, the WHO committed to reviewing the evidence and revising the guidelines for treatment 
and prevention of wasting by the end of 2021.140 The WHO commissioned scoping reviews and 




5.5.5 Advocating for policy change 
 
 
As researchers and programmers began to test simplified and/or combined CMAM programs that 
treated SAM and MAM in a single program, complementary advocacy efforts emerged to promote 
a more enabling global and national policy environment. Research addressing the continuum of 
care contributed to a wave of advocacy, driven by non-governmental organizations seeking a more 
efficient and effective UN system for managing acute malnutrition.143, 157-160 A system that divides 
UN agency responsibility along SAM/MAM lines is no longer fit for purpose as the evidence for 
simplified, combined protocols increases in different contexts.139, 161 Responding to the evidence 
and advocacy for improved coordination between the UN agencies on SAM and MAM, UNICEF and 
WFP committed in November 2020 to a new partnership agreement for the streamlined delivery of 
wasting treatment with a single agency lead.162 Under the new system, UNICEF will take the lead on 
the management of wasting (both SAM and MAM) and WFP will provide support by providing food 








5.5.6 National uptake 
 
 
Despite the growing evidence and the momentum at a global level, national policies remain largely 
unchanged. In many emergencies, separate SAM and MAM programming remains the only option 
to remain in line with national protocol. Simplified, combined approaches are still primarily used at 
a small-scale in the context of operational research settings or short-term emergency responses.24, 
152-154 A review of national perspectives and policy on the combined protocol in 2018 indicated that 
though national government stakeholders generally agreed on the logic of offering SAM and MAM 
treatment in the same location and that using a single food product made logistical sense, there 
were concerns about using MUAC and oedema as the sole anthropometric admissions criteria and 
concerns about maintaining the supply chain for RUTF. Interest in a simplified and combined 
SAM/MAM protocol is increasing from Ministries of Health and nutrition partners in countries with 
a high burden of acute malnutrition, and national policy makers have sought more evidence and 
formal guidance from the WHO.133, 163 
 
 
5.5.7 A shifting paradigm 
 
 
Overall, the paradigm is shifting towards a greater acceptance of simplifying treatment and 
combining SAM and MAM programming, as evidenced by new research,139 operational 
programming, UN and donor guidance,24, 149, 150 and UN commitments.140, 162 The national policy 
environment is shifting more slowly, and formal guidance from the WHO remains pending.133 The 
United Nations agencies involved in nutrition are evaluating the evidence on simplified 
approaches139, 143 and undergoing administrative re-alignments that may accommodate the 
simplified, combined protocol and other innovations in the sector through the Global Action 
Plan,140, 162 though it remains to be seen whether this will translate into improved coverage of 




5.6 Further research 
 
 
The optimal protocol will achieve a balance between simplifying CMAM to improve cost- 
effectiveness and coverage, while ensuring programs meet the needs of the most vulnerable 
children and adapting to the context. 
 
 
5.6.1 Ensuring the protocol works for high-risk children 
 
 
Children at an increased risk of mortality and long-term adverse outcomes should be the priority for 
treatment, and future research should focus on how best to identify and treat them. Malnutrition 
treatment programs should aim to prevent child mortality, and not just treat ‘thinness.’144 
Malnourished children at the highest risk of mortality may include the youngest children (<24 
months), those with concurrent wasting and stunting, multiple severe anthropometric deficits, 
severely low weight-for-age, and underlying medical conditions.27-29, 45, 48, 59, 144 Future studies of the 
simplified, combined protocol should be powered to evaluate specific subgroups- particularly 
children at high risk of adverse outcomes and older, larger children with SAM- to ensure the dosage 
provided in a simplified protocol is sufficient for optimal growth and supports longer-term health 
and development outcomes. 
There is also the question of how the dosage provided in ComPAS impacts indicators related to 
stunting, such as WAZ and HAZ. Though this research did not find any evidence of a difference 
between the simplified, combined protocol and standard treatment in terms of wasting response, 
the potentially slower WAZ gain found in Paper IV raises the possibility that other factors, such as 
stunting or age, may influence treatment response. 
 
 
5.6.2 Adapting to the context 
 
 
Contextual issues should also drive the identification and targeting of high-risk children, as children 
living in communities affected by chronic food insecurity, conflict, climate change and disease 
outbreaks are more vulnerable to malnutrition.164 Identifying children who are physiologically 
vulnerable, as well as targeting children who live in geographically vulnerable contexts, may help 
programs direct resources where they are needed the most. 
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Future work will need to test adaptations of the protocol to fit the local context and circumstances. 
Operational research programs may adjust the protocol to add flexibility according to the context, 
using different ready-to-use food products, such as new formulations of RUTF of RUSF76, 136 and/or 
integrating different cut-offs for admissions criteria.57 
Though RUTF was used for the ComPAS research, future work could look at the operational and 
economic implications of using RUTF, RUSF or both in a simplified, combined approach. In early 
2017, when the ComPAS trial was set to start, near-famine conditions were declared in four 
countries, including in South Sudan. The ComPAS research teams in both Kenya and South Sudan 
were unable to procure a sufficient supply of RUSF for several months due to a global supply 
shortage in RUSF. Unpredictable contextual and supply chain issues necessitate flexibility in 
humanitarian situations, and evidence on the optimal product(s) to use as part of this approach will 
help inform decision-making. 
 
 
5.6.3 Adjusting the admissions criteria 
 
 
Weight-for-age may be added as an independent criterion to improve detection of the highest-risk 
children.28, 29 MUAC cut-offs may be adjusted to capture more or fewer children depending on the 
resources available.152 Weight for-height may also be integrated in a simplified protocol, following 




5.6.4 Moving towards long-term and large-scale operational research 
 
 
A next step is to pilot the ComPAS protocol at a large-enough scale and over a long-enough time to 
see how it works operationally in different contexts, among different subgroups of children, and 







A simplified, combined SAM and MAM approach, using a MUAC-based RUTF dosage protocol, shows 
promise to maintain a high quality of treatment, save money, and thus potentially reach more 
children for similar resources. However, a simplified and combined protocol is just one solution 
among many to improve the coverage of treatment globally. The greatest impact will likely be seen 
when used in combination with complementary interventions, like the delivery of treatment 
through community health workers,165-167 the training of caregivers to screen and refer their own 
children using MUAC and other tools,72, 73, 168 and linkages to approaches that prevent malnutrition. 
A treatment approach that integrates caregiver screening and a treatment delivery model that 
utilizes community health workers at the village level may empower families and communities to 
identify and address malnutrition in children before it becomes severe. These approaches enable 
care to be delivered outside of health facilities, reducing the opportunity cost of seeking treatment 
for families that live far from medical care. A simplified, cost-effective, and community-empowered 
approach to treatment is crucial in an era when a global pandemic threatens the health and 
economies of vulnerable communities worldwide.7 There are many challenges to scaling up a more 
community-centered approach to treatment, including ensuring a consistent and localized supply 
chain of ready-to-use foods, but these challenges can be surmounted with strategic partnerships 
that make use of strengths from the humanitarian, public and private sectors. 
Ultimately, by making treatment simpler and more cost-effective to deliver, health systems may be 
better able to provide treatment at scale. If we can reach more children with MAM before they 
deteriorate into SAM, we can get further upstream of the problem- saving more money as a less 
intensive, less medicalized approach works well for children when they are less severely 
malnourished. With each step further upstream, we free up more resources to address malnutrition 
before it begins- investing more in prevention and working more on the underlying and systemic 
causes that cause malnutrition to begin with. Treatment is just the tip of the iceberg but remains 
crucial to unlocking the extraordinary potential of millions of lives saved- children who may one day 








A: Narrative review search strategy 
 
Table A-1: Search terms 
A. 
Integrated Treatment of Acute 
Malnutrition 










RUF/Treatment for MAM 
C1+C2 
Or D. 
Energy needs during 






































































































































Ms Jeanette Bailey 
LSHTM 
 
13 December 2016 
Dear Jeanette, 
Study Title: Combined Protocol for Acute Malnutrition Study (ComPAS) Stage 1: Secondary Data Analysis 
 
LSHTM Ethics Ref: 11820 
 
 
Thank you for responding to the Observational Committee’s request for further information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 




The final list of documents reviewed and approved by the Committee is as follows: 
 
 
Document Type File Name Date Version 
Investigator CV Rachel Chase_CV_Sept 2015 30/09/2015 final 
Investigator CV CV Dr Marko Kerac_2016_07 03/07/2016 1 
Protocol / Proposal Statistical Analysis Plan_Stage 1_LEO 26/07/2016 3 
Protocol / Proposal OFDA Research Proposal Revised_July 30 26/07/2016 final 
Investigator CV Jeanette Bailey- CV 27/07/2016 final 
Investigator CV Mark Manary_CV 27/07/2016 final 
Investigator CV Andre Briend_CV 27/07/2016 final 
Investigator CV Charles Opondo_CV 30/07/2016 final 
Local Approval MSF France Data Sharing Agreement 14/09/2016 1 
Local Approval ACF-USA Sub-grant Agreement 14/09/2016 1 
Local Approval Attachment 2 Scope of Work 14/09/2016 1 
Covering Letter Cover letter_Response to LEO Stage 1_15 Sep_Signed 15/09/2016 2 
Covering Letter Cover letter_Response to LEO Stage 1_6 Dec 06/12/2016 1 
Local Approval MSF Data Sharing Policy 06/12/2016 1 
Local Approval MSF Research Ethics Framework 06/12/2016 1 
Local Approval MSF Ethics Review Board exemption letter for ComPAS 06/12/2016 1 
Local Approval MSF Ethics Review Board Standard Operating Procedures 06/12/2016 1 
Local Approval MSF France Written Permission to use Dataset 06/12/2016 1 
 





The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application. These must be submitted to the Committee for review 
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee. 
 
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project 
by submitting a Serious Adverse Event form. 
 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk 
Additional information is available at: www.lshtm.ac.uk/ethics 
Yours sincerely, 
 




















Ms Jeanette Bailey, 
LSHTM 
 
28 November 2016 
Dear Jeanette, 
Study Title: Combined Protocol for Acute Malnutrition Study (ComPAS) Stage 2: Cluster Randomized Controlled Trial 
 
LSHTM Ethics Ref: 11826 
 
 
Thank you for responding to the Interventions Committee’s request for further information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 




The final list of documents reviewed and approved by the Committee is as follows: 
 
 
Document Type File Name Date Version 
Protocol / Proposal ComPAS data collection matrix_1 June 2016_v2 01/06/2016 2 
Protocol / Proposal ComPAS_Analysis Plan Stage 2_v4_20 July 20/07/2016 4 
Investigator CV Jeanette Bailey- CV 27/07/2016 final 
Investigator CV Andre Briend_CV 27/07/2016 final 
Investigator CV Mark Manary_CV 27/07/2016 final 
Investigator CV Pamela Onyoo_CV 28/07/2016 1 
Investigator CV Bethany Marron_CV 28/07/2016 1 
Investigator CV CV Dr Marko Kerac_2016_07 03/08/2016 1 
Investigator CV Charles Opondo_CV 03/08/2016 final 
Advertisements Recruitment procedures 29/08/2016 1 
Safety Information RUTF product characteristics v2 29/08/2016 2 
Sponsor Letter QA912_ComPAS Study 01/09/2016 1 
Covering Letter Cover letter_Response to LEO Stage 2_ 24 Oct 2016 24/10/2016 1 
Information Sheet Participant Info Sheet_Kenya_v3_24 Oct 24/10/2016 3 
Information Sheet Participant Info Sheet_South Sudan_v3_24 Oct 24/10/2016 3 
Information Sheet Health Facility Info Sheet_Kenya_v3_24 Oct 24/10/2016 3 
Information Sheet Health Facility Info Sheet_South Sudan_v3_24 Oct 24/10/2016 3 
Information Sheet Participant consent form_v3_24 Oct 24/10/2016 3 
Information Sheet Health facility consent form_v3_24 Oct 24/10/2016 3 




After ethical review 
 
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application. These must be submitted to the Committee for review 
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee. 
 
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project 
by submitting a Serious Adverse Event form. 
 
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk 
 



















  KENYA MEDICAL  RESEARCH INSTITUTE  
P.O. Box 54840-00200, NAIROBI, Kenya 
Tel:(254)(020)2722541,2713349,0722-205901,073 3,Fax:(254)(020)2720030 
E-mail: dlrector@kemrt.org, lnfo@kemrt.org, Webalte. www.kemrt.org 
KEMRI/RES/7 /3/1 January OS, 2017 
TO: VIDDAH OWINO (PRINCIPAL INVESTIGATOR), 
viddah,owino@rescue,org 




RE: PROTOCOL NO. NON-KEMRI 551 (RESUBMISSION OF INITIAL 
SUBMISSION): COMBINED PROTOCOL FOR ACUTE MALNUTRITION STUDY 
  (ComPAS),( VERSION 2.0 DATED 1ST DECEMBER, 2016) 
 
Reference is made to your letter dated 1st December, 2016. The KEMRI/Sc!entific and Ethics 
Review Unit (SERU) acknowledges receipt of the revised study documents on 20th 
December, 2016. 
This is to inform you that the Committee notes that the issues raised during the 2srti 
KEMRI/Ethics Review Committee (ERC) held on 15th November, 2016 have been 
adequately addressed. 
 
Consequently, the study is granted approval for implementation effective this day, 5th 
January, 2017 for a period of one year. Please note that authorization to conduct this 
study will automatically expire on January 4, 2018. If you plan to continue data collection 
or analysis beyond this date, please submit an application for continuation approval to SERU 
by 24th November, 2017. 
 
You are required to submit any proposed changes to this study to SERU for review and the 
changes should not be initiated until written approval from SERU is received. Please note 
that any unanticipated problems resulting from the implementation of this study should be 
brought to the attention of SERU and you should advise SERU when the study is completed 
or discontinued. 
 
You may embark on the study. 
 
Yours faithfully, 
Q(Jl( Ht ,i _ 
- - DR. EVANS AMUKOYE, 
ACTING HEAD, 



















PARTICIPANT CONSENT FORM 
 
Title of Project: Combined Protocol for Acute Malnutrition Study (ComPAS) 
Name of PI/Researcher responsible for project: Jeanette Bailey 
 
Statement Please initial or 
thumbprint* each box 
I confirm that I have read the information sheet dated 24-October-16 (version 3) for the above 
named study. I have had the opportunity to consider the information, ask questions and have 
these answered satisfactorily. 
OR 
I have had the information explained to by study personnel in a language that I understand. I 




I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
 
I understand that relevant sections of my medical notes and data collected during the study 
may be looked at by authorised individuals from the London School of Hygiene and Tropical 
Medicine, International Rescue Committee and Action Against Hunger, where it is relevant to 




I agree to take part in the above named study 
 
 
   
Printed name of participant Signature of participant Date 
 
   
Printed name of impartial witness* Signature of impartial witness* Date 
 
I attest that I have explained the study information accurately in to, and was understood to the best of my 
knowledge by, the participant and that he/she has freely given their consent to participate* in the presence of the above 
named impartial witness (where applicable). 
 
Printed name of person obtaining consent Signature of person obtaining consent Date 







A copy of this informed consent document has been provided to the participant. 
Centre Number: 
Study Number: 
Participant Identification Number: 





D: Data collection forms 
Research Officer Name:    
ComPAS ID: 
Form 1 Group A 





















Child’s Name:        
First Name Last Name 
 
Section A: Biographic Information 
 
 Please circle your response or enter integer 
1. Child Information 
Do you know the child’s exact date of birth? 
(Circle one) 
Yes 
No→ go to 1c 
 1a. Child Information 
Enter Date of Birth 
 
  
     
DD MM YYYY 
 1b. Child Information 




For both responses, go to 1d 
Taken from documentation 
(example: MIYCN booklet) 
 1c. Child Information 
Enter child’s age in months as reported by 
caregiver (min 6 months, max 59 months) 
 
 
 1d. Child Information 




    
 
Research Officer Name:    
ComPAS ID: 
Form 1 Group A 






2. Admission Anthropometry Extract data from OTP / SFP patient card or register 
 
Weight in kg : 
(min 04.00, max 30.00) 
Height in cm: 
(min 025.0, max 135.0) 
   
  
Weight-for-height z-score (check one): ☐ ≥ -2z 
☐ < -2z to ≥ -3z 
☐ <-3z 
MUAC in cm:(min 06.0, max 16.0) 
 
 
 2a. Does the child have oedema (+/++)? (Circle one) 
Yes 
No 
 2b. Did child pass appetite test? (Circle one) 
Yes 
No→ STOP. Child is not eligible for study. This child will 
not be registered and should be referred to the SC. 
 2c. Did clinician identify any medical 
complications requiring referral to SC? 
(Circle one) 
 
Yes→ STOP. Child is not eligible for the study and should be 
referred to the SC. 
 
No→ Child is eligible for the study. 
3. Caregiver Information 




No → Child is not eligible for the study. 
4. Consent Information 
Did Research Officer go through the participant 




 4a. Consent Information 
Did caregiver agree to participate in the 
study and sign the consent form? 
(Circle one) 
Yes → Proceed to section B 
No→ STOP 
    
 
Research Officer Name:    
ComPAS ID: 
Form 1 Group A 






Section B: Admission Caregiver Questionnaire 
 
 Please circle your response, enter text, or enter integer 
1. Child Information 
Give / Enter ComPAS registration number 
 
      
 
2. Caregiver Information 
What is the name of the primary caregiver? 
 
 
First Name:    
 
 
Last Name:    
 2a. Caregiver information 






Other (please specify)    
 2b. Caregiver Information 




 2c. Caregiver’s mobile number 
(or other number where we can 
contact) 
 
 2d. Address of caregiver  
    
 
Research Officer Name:    
ComPAS ID: 
Form 1 Group A 






3. Medical History 






 3a. Medical History 
In the past week, has the child sought 
care from a medical clinic or health 
facility? 






 3b. Medical History - Diarrhea 
In the past week, did the child suffer 
from diarrhea (have watery stool 3 or 
more times in one day)? 
(Circle one) 
Yes 
No→ go to 3d 
 
Don’t know→ go to 3d 
 3c. If yes, how many days has the child 
suffered from diarrhea in the past 
week? 
Enter days 1-7 
Enter 9 if don’t know 
 3d. Medical History – Vomiting 




No→ go to 3f 
 
Don’t know→ go to 3f 
 3e. If yes, how many days has the child 
suffered from vomiting in the past 
week? 
 
Enter days 1-7 
Enter 9 if don’t know 
 3f. Medical History - Fever 




No→ go to 3h 
 
Don’t know→ go to 3h 
    
 
Research Officer Name:    
ComPAS ID: 
Form 1 Group A 






 3g. If yes, how many days has the child 
suffered from fever in the past week? 
Enter days 1-7 
Enter 9 if don’t know 
 3h. Medical History - Cough 




No→ go to 3j 
 
Don’t know→ go to 3j 
 3i. If yes, how many days has the child 
suffered from cough in the past week? 
Enter days 1-7 
Enter 9 if don’t know 
 3j. Medical History - Other 
In the past week, did the child have 














4. Breastfeeding information 




No→ go to 5 
Child is older than 36 months→ go to 5 
Don’t know→ go to 5 
 4a. Breastfeeding information 




No→ go to 5 
 
Don’t know→ go to 5 
    
 
Research Officer Name:    
ComPAS ID: 
Form 1 Group A 






 4b. Breastfeeding information 
How many times was the child 
breastfed in the last 24 hours? 
 
0-20 times 
99 if don’t know 
 4c. Breastfeeding information 
Was this child fed any solid, semi- 





  No 
  
Don’t know 
5. Family Characteristics 
For the past month, how many people have 
been living in this child’s household? 
 
0-20 
99 if don’t know 
 5a. Family Characteristics 
How many children under five years 
of age live in the child’s household? 
(including the child) 
 
0-20 
99 if don’t know 
 5b. Family Characteristics 
What is the highest level of the 












6. Household Characteristics 
What is the occupation of the main 





Sale of livestock 
  
Sale of crops 
  
Petty trading (e.g. sale of firewood, hawking) 
  
Casual labor (waged) 
  
Permanent job (salaried) 
  
Sale of personal assets 
  
Remittance 
    
 
Research Officer Name:    
ComPAS ID: 
Form 1 Group A 






  Government assistance 
Business/shopkeeper 
Don’t know 
Other (specify)    
 6a. Household Characteristics 
What is the household’s primary 









 6b. Household Characteristics 
Where does the household defecate 







Other (please specify)    
7. Household Hunger 
In the past 4 weeks or (30 days): Was there 
ever no food to eat of any kind in your 
house because of lack of resources to get 
food? 
(Circle one) 
Never – 0 times 
Rarely – 1 to 2 times 
 
Sometimes – 3 to 10 times 
Often – greater than 10 times 
Don’t know 
 7a. Household Hunger 
In the past 4 weeks or (30 days): Did 
you or any household member go to 
(Circle one) 
 
Never – 0 times 
    
 
Research Officer Name:    
ComPAS ID: 
Form 1 Group A 






  sleep at night hungry because there 
was not enough food? 
 
Rarely – 1 to 2 times 
 
Sometimes – 3 to 10 times 
 
Often – greater than 10 times 
 
Don’t know 
 7b. Household Hunger 
In the past 4 weeks or (30 days): Did 
you or any household member go a 
whole day and night without eating 
anything at all because there was not 
enough food? 
(Circle one) 
Never – 0 times 
Rarely – 1 to 2 times 
  Sometimes – 3 to 10 times 
  
Often – greater than 10 times 
  
Don’t know 
 7c. Household Hunger 
In the past 4 weeks or (30 days): Has 
the household received food 







    
 
Research Officer Name:    
ComPAS ID: 
Form 1 Group A 






Section C: Admission Child Status Form 
 
 Please circle your response, enter text, or enter integer 
1. Admission Criteria for Combined 
Protocol Children 
How was the child admitted? 
(Circle one) 
 
Direct from community (CHV or self referral) 
From Stabilization Center (SC) 
Discharged from OTP (SAM child became MAM) 
 1a. What admission criteria did the 
child meet? 
(Circle all that apply) 
  Oedema (+/++) 
  
MUAC < 11.5 cm 
  
MUAC ≥ 11.5cm < 12.5cm 
  
WHZ score <-3 SD 
  
WHZ score <-2SD ≥ -3SD 
  
Other, please specify:   
2. Medical History 




Exposed (biological mother is HIV positive) 
 
Unknown 
 2a. Medical History 









3. Therapeutic Food 
Number of RUTF sachets provided 
 
Enter 00-14 sachets 
 
END OF FORM 
Provide caregiver the sachets and next return date. 
    
 
Research Officer Name:    
ComPAS ID: 
Form 2 Group A 
Page 1 of 5 
 
 
Instructions: The Research Officer will fill out this form for all children who are enrolled in the study and 













Visit week #: 
MM 
 
Child’s Name:         





Section A: Caregiver questions 
 
 Please circle your response, enter text, or enter integer 
1. Caregiver information 






Other (please specify)    
 1a. Caregiver information 
Is the respondent a responsible caregiver 
or guardian of the child? 
(Circle one) 
Yes 
No → Skip all remaining caregiver questions. 
2. Breastfeeding information 
If the child is <36 months, was the child 
breastfed in the last 24 hours? 
(Choose one) 
Yes 
No→ go to 3 
 
Don’t know→ go to 3 
 2a. Breastfeeding information 
How many times was the child breastfed 
in the last 24 hours? 
 
0-20 times 
99 if don’t know 
    
 
    
 
Research Officer Name:    
ComPAS ID: 
Form 2 Group A 





 2b. Breastfeeding information 
Was this child fed any solid, semi-solid, 






3. Medical History 
In the past week, has the child sought care from 
a medical clinic or health facility? 






 3a. Medical History-Diarrhea 
In the past week, did the child suffer from 




No→ go to 3c 
 
Don’t know→ go to 3c 
 3b. If yes, how many days has the 
child suffered from diarrhea? 
(Enter days 1-7) 
 3c. Medical History-Vomiting 




No→ go to 3e 
 
Don’t know→ go to 3e 
 3d. If yes, how many days has the 
child suffered from vomiting? 
(Enter days 1-7) 
 3e. Medical History-Fever 




No→ go to 3g 
 
Don’t know→ go to 3g 
 3f. If yes, how many days has the 
child suffered from fever? 
(Enter days 1-7) 
    
 
Research Officer Name:    
ComPAS ID: 
Form 2 Group A 





 3g. Medical History-Cough 




No→ go to 3i 
 
Don’t know→ go to 3i 
 3h. If yes, how many days has the 
child suffered from cough? 
(Enter days 1-7) 
 3i. Medical History 
In the past week, did the child have any 






4. RUTF/RUSF Usage 







 4a. RUTF Usage 
How many sachets do you have remaining 
from the last distribution? 
 
0-42 sachets → If 0, go to 4b, all other 
99 if don’t know integers, go to 4c 
 4b. RUTF Usage 




 4c. RUTF Usage 




99 if don’t know 
5. Household Food Security 
In the past month, has the household received 







    
 
Research Officer Name:    
ComPAS ID: 
Form 2 Group A 





Section B: Child Status 
 
 Please circle your response, enter text, or enter integer 
1. Anthropometry  
Weight in kg : 
(min 04.00, max 30.00) 
 
Weight-for-height z-score (check one): ☐ ≥ -2z 
☐ < -2z to ≥ -3z 
☐ <-3z 
MUAC in cm: 
(min 06.00, max 16.00) 
 1a. Anthropometry 
Was height taken this week? 
(Circle one) 
Yes→ go to 1b 
No→ go to 1c 
 1b. Anthropometry 
Enter height taken this week. 
Extract from OTP / SFP patient card or register 
Height in cm: 
(min 025.0, max 135.0) 
   
go to 1d 
 
 1c. Anthropometry 
Enter most recent height 
recorded. 
Extract from OTP / SFP patient card or register 
Height in cm: 
(min 025.0, max 135.0) 
   
  
 
 1d. Admission Anthropometry 





2. Treatment Outcome for 
Combined Protocol 
Is the MUAC measurement ≥ 12.5 
cm? 
(Circle one) 
Yes→ got to 2a 
No→ go to 2b 
 2a. Treatment Outcome for 
Combined Protocol 
Did the child have 2 
consecutive visits with a 
MUAC ≥ 12.5cm? 
(Circle one) 
 
Yes→ This child can now be discharged. Generate 4 month follow up 
date to give caregiver and begin Form 3-Caregiver Cost Questionnaire. 
 
No→ go to 2b 
    
 
Research Officer Name:    
ComPAS ID: 
Form 2 Group A 





    
 2b. Treatment Outcome for 
Combined Protocol 




Child is still in treatment 
 
  Outcome attained: cured from 
malnutrition 
 
Begin Form 3-Caregiver 
Cost Questionnaire 
  Outcome attained: Non-Response  
   
Outcome attained: Referred 
If cured → provide 4 
month follow-up date 
3. Therapeutic Food for Combined 
Protocol 





END OF FORM 
Provide caregiver the sachets and next return date. 
    
 
Page 1 of 2 
 
 
Instructions: The Research Officer will fill out this form for every child who is enrolled in our study and is being 
discharged from the program. 
ComPAS Kenya 
Form 3 – Caregiver Cost Questionnaire 
 
 





Visit week #: 
MM 
 
Child’s Name:        






1. What is the name of the 
village/neighborhood/block you are coming 
from? 
 
Enter Text:   







Other (specify ) 
3. How long did it take you to get here (from the 








1 - <2 hours 
 
2- <4 hours 
 
≥ 4 hours 
4. How much did it cost for transportation to get 
to the health facility today (one way)? Estimate 
cost of fuel if your own transport or cost of hire. 
(Enter KSH) 
     Write “0000” if they 
walked 
 
    
 
Page 2 of 2 
 
 







Other (specify ) 
6. How long will it take you to return home (from 








1 - <2 hours 
 
2- <4 hours 
 
≥ 4 hours 
4. How much will it cost for transportation to get 
home today (one way)? Estimate cost of fuel if 
your own transport or cost of hire. 
(Enter KSH) 
     Write “0000” if they 
walked 
 





E: Supplementary materials for Paper I 
 
 
Procedures for taking anthropometric measurements 
 
 
Protocol for taking weight measurements: 
 
The child’s weight will be measured and documented at admission as well as at each 
follow-up visit. 
 
1. Record weight using the ComPAS-designated SECA 385 scale, only 
2. Ensure scale is on level floor or table top and set to zero (baby tray can be 
removed for children who are able to stand on their own) 
3. Press ‘start’ button for first use or ‘reset’ button between each measurement; wait 
for ‘00.0000’ to appear 
4. Child removes any shoes and heavy clothing 
5. Child is placed on tray or child stands on center of the scale, sitting/standing still 
(caregiver or clinician may have to persuade child to remain calm) 
6. Clinician records measurement once reading is stable (digits will flash once and 
then stabilize) 
7. Measurement is recorded to the nearest 0.01kg 
 
Protocol for taking height/length measurements: 
 
The child’s height/length will be measured and documented at admission as well as on 
a monthly basis thereafter. Length is measured for those aged <2, height for those ≥2 
years. This measurement will be taken by two operators, and measurements compared. 
 
1. Child should remove shoes and any hair ornaments that may interfere with 
reading 
2. Child is laid or stands straight with heels against height/length board, toes 
directly in the air (feet at 90°angle standing position) or feet flat on floor 
3. Ensure back, shoulders, head, buttocks are flat against height board and heels 
are flat against heel plate 
4. Ensure the head in line with neck and shoulders (chin level) 
5. Clinician moves foot board against child’s feet or head board onto child’s head 
6. Clinician places hands under the subjects ears to assist with posture and then 
asks child to breath in and then relax but stay tall 
7. Measurement is recorded to the nearest 0.1cm 
8. The two measurements should be within 0.5cm of each other. If they are not, 
both operators should repeat the measurements. If they are within 0.5cm of each 
other, the final value should be mid-way between the two (ie. added together and 
divided by 2) 
 
Protocol for taking MUAC measurements: 
 
The child’s mid upper arm circumference will be measured and documented at 




1. Shirt should be removed 
2. Take the left arm of the child 
3. Place the left arm of the child across his chest and ask the caregiver to keep the 
arm in this position. 
4. Use the MUAC tool to determine the mid-point between the shoulder and tip 
(bone) of elbow 
5. Strap the MUAC tool around the arm of the child at the identified mid-point, be 
sure tape is level and tension is correct (no skin bulging from the top or bottom of 
the MUAC tape) 
6. With the arm of the child hanging down, record the digits that are shown at the 
arrow in the hole of the MUAC tool (round to the nearest 1 mm). 
7. When recording on the form, use two digits to the left of the decimal place, and 
one digit to the right. 
 
Protocol for checking for oedema: 
 
A condition of bilateral pitting oedema (level + or ++) meets the criteria for admission 
into the study. Do not force the appearance of a pit by pushing too hard, especially with 
a fingernail. It is not accurate to report nutritional oedema if only one foot has oedema. 
Oedema level +++ should be immediately referred for inpatient care. 
1. While child’s foot is limp, press firmly with the pad (not tip) of thumb on the top of 
the child’s feet for 5 seconds, then release 
2. Check each for a pit or indentation that lasts as least 2 seconds after release 
163  
 
F: Supplementary materials for Paper III 
 
 
Supplemental materials to accompany “A simplified, combined protocol versus standard 
treatment for acute malnutrition (ComPAS trial): a cluster randomized controlled non- 
inferiority trial” 
Supplemental table 1: Comparison of Combined and Standard Protocols 
 




Eligibility criteria Age 6-59 months, MUAC <12∙5cm and/or 
edema (+/++), and clinically uncomplicated 
(i.e.  passes    appetite   test,    no   Integrated 
Management of Childhood Illness (IMCI) 
danger signs/ no serious medical complications) 
Age 6-59 months, MUAC <12∙5cm and/or edema 
(+/++), and clinically uncomplicated (i.e. passes 
appetite   test,   no   Integrated   Management   of 
Childhood Illness (IMCI) danger signs/ no serious 
medical complications) 
Admission criteria OTP • <125mm MUAC 
AND/OR 
• Bilateral pitting edema (+/++) 
AND 
• clinically uncomplicated 
• WHZ < -3 
AND/OR 
• MUAC < 115mm 
AND/OR 
• Bilateral pitting edema (+/++) 
AND 
• clinically uncomplicated 
SFP 
• Discharged from OTP 
AND/OR 
• WHZ <-2 to WHZ >-3 
AND/OR 
• MUAC 115mm- < 125mm 
AND 
• clinically uncomplicated 
Treatment frequency OTP MUAC <115mm and/or edema (+/++) 
Weekly Weekly 
SFP MUAC 115-<125mm 
14 days 14 days 
Treatment transition criteria • Child meets OTP ‘cured’ definition 
as described below 
• Two consecutive MUAC measurements at 
or above 115mm 
AND 
• No edema 
Dosage OTP MUAC <115mm and/or edema (+/++) 
RUTF 200kcal/kg/day RUTF 1000 kcal/day (2 sachets/day) 
SFP MUAC 115-<125mm 
RUSF 500 kcal/day (1 sachet/day) RUTF 500 kcal/day (1 sachet/day) 
Cured OTP ≥125mm for 2 consecutive measurements and no 
edema • Child maintains MUAC ≥115mm 
fo r two consecutive visits** 
AND/OR 
• WHZ >-3 Z-score fo r two 
consecutive visits** 
AND 
• No edema for two consecutive visits 
SFP 
Child maintains WHZ >-2 Z-score and/or 




Supplemental table 2: Admission characteristics of children by country 
 
Characteristic Kenya (n=1,988) South Sudan (n=2,122) 
Sex and age 
Males, n (%) 742 (37%) 940 (44%) 
Age in months, mean (SD) 12∙0 (7∙0) 21∙7 (12∙0) 
Age categories, n (%)   
6-<24 months 1,880 (94∙6%) 1,164 (54∙9%) 
≥ 24 months 105 (5∙3%) 954 (45∙0%) 
Anthropometrics 
Weight (kg), mean (SD) 6∙8 (1) 7∙7 (2) 
Height (cm), mean (SD) 69∙5 (6) 76∙2 (10) 
MUAC (cm), mean (SD) 11∙8 (∙5) 11∙6 (∙6) 
WHZ, mean (SD) -2∙1 (1∙0) -2∙7 (3∙3) 
HAZ, mean (SD) -1∙7 (1∙5) -2∙3 (1∙6) 
WAZ, mean (SD) -2∙5 (1∙0) -3∙2 (1∙0) 
MUAC <11∙5cm, n (%) 354 (18%) 881 (42%) 
and WHZ ≥-3 to <-2 123 (35%) 274 (31%) 
and WHZ <-3 160 (45%) 538 (61%) 
and WHZ >=-2 71(20%) 69(8%) 
MUAC 11∙5-<12∙5cm, n (%) 1,631(82%) 1,227 (58%) 
and WHZ ≥-3 to <-2 586 (36%) 614 (50%) 
and WHZ <-3 173 (11%) 243 (20%) 
and WHZ >=-2 872(54%) 370(30%) 
Edema (+ or ++), n (%) 18 (1%) 29 (1%) 
Household and other characteristics 
Mother is caretaker, n (%) 1,915 (96%) 1,986 (94%) 
Maternal educational achievement, n(%)   
None 29(2%) 1735(87%) 
Pre-primary 22(1%) 0(0%) 
Primary 726(38%) 234(12%) 
Secondary 1135(59%) 16(1%) 
College tertiary 0(0%) 1(0%) 
Number of children under five in the home, 
mean (SD) 
1∙1 (∙7) 2∙1 (∙8) 
Children breast fed in last 24 hours, n(%) 1,636 (82%) 1,227 (58%) 
Caretaker reports any morbidity in past 
week*, n (%) 
870 (44%) 1,629 (77%) 
Fever 337 (17%) 1,164 (55%) 
Diarrhea 275 (14%) 763 (36%) 
Cough 479 (24%) 866 (41%) 
Healthcare sought in prior week 367(19%) 521(25%) 
HIV Status   
+ 14(1%) 0(0%) 
Exposed (Mother) 36(2%) 0(0%) 
Disabled (physically or mentally) 29(2%) 53(3%) 
Tuberculosis (+), n(%) 9(1%) 0(0%) 
Access to toilet 1978(100%) 678(32%) 
Water source   
Household tap 266 (13%) 0(0%) 
Community tap/ tap stand 1381(70%) 45(2%) 
Hand pump/ borehole 0(0%) 1264(60%) 
Borehole (private) 26 (1%) 588(28%) 
Vendors 304(15%) 0(0%) 
Open water 1(0%) 218(10%) 
Livelihood/ main source of income   
No income 121(6%) 1(0%) 
Sale of items (grass, firewood, livestock) 81(4%) 340(16%) 
Fishing/ farming 0(0%) 1208(57%) 
Business/ shopkeeper 821(41%) 93(4%) 
Casual labor 425(21%) 294(14%) 
Salaried work 31(2%) 160(8%) 
Other 6(0%) 19(1%) 
Household Hunger Score   
Ever no food to eat?   
Never 1541(78%) 775(37%) 
 
 
Rarely 286(14%) 653(31%) 
Sometimes 126(6%) 590(28%) 
Often 23(1%) 93(4%) 
Don’t know 2(0%) 7(0%) 
Ever go to sleep without enough food?   
Never 1560(79%) 654(31%) 
Rarely 280(14%) 753(36%) 
Sometimes 114(6%) 631(30%) 
Often 21(1%) 61(3%) 
Don’t know 3(0%) 19(1%) 
Any HH member go whole day without 
eating anything? 
  
Never 1581(80%) 754(36%) 
Rarely 257(13%) 688(32%) 
Sometimes 122(6%) 578(27%) 
Often 16(1%) 64(3%) 
Don’t know 2(0%) 34(2%) 




 Standard Protocol Combined Protocol 




(39∙1% - 66∙2%) 
47∙3% 
(37∙1% - 58∙0%) 
54∙9% 
(41∙2% - 68∙0%) 
48∙6% 
(38∙0% - 59∙4%) 










Definition of SAM: MUAC<11∙5cm and/or edema (+/++); definition of MAM: MUAC 11∙5-<12∙5cm and no edema 









n % N % Risk difference§ 
(95% CI) 
p-value Risk difference§ 
(95% CI) 
p-value 
Recovery among sub-groups by admission status 
SAM 111/294 37∙8% 121/291 41∙6% 0∙04 (-0∙06-0 ∙13) 0∙43 0∙03 (-0∙05-0 ∙12) 0∙42 
MAM 773/ 908 85∙1% 860/995 86∙4% 0∙01 (-0∙07-0 ∙10) 0∙77 0∙00 (-0∙07-0 ∙07) 0∙97 
Age <24 
months 
654/930 70∙3% 667/928 71∙9% 0∙02 (-0∙08- 0∙11 ) 0∙75 0∙02 (-0∙07-0 ∙11 ) 0∙62 
Age ≥24 
months 
230/272 84∙6% 314/358 87∙7% 0∙03 (-0∙06-0 ∙13) 0∙52 0∙04 (-0∙06-0 ∙13) 0∙46 




84/111 75∙7% 134/190 70∙5% -0∙05 (-0∙19 -0∙08 ) 0∙46 -0∙05 (-0∙16 -0∙07 ) 0∙44 
Kenya 516/686 75∙2% 458/627 73∙1% -0∙02 (-0∙13 -0∙09 ) 0∙71 -0∙02 (-0∙13 -0∙09)  0∙70 
South Sudan 368/516 71∙3% 523/659 79∙4% 0∙08 (-0∙03- 0∙19 ) 0∙16 0∙08 (-0∙02-0 ∙18) 0∙13 





 Mean SE Mean SE Mean difference§ 
(95% CI) 
p-value Mean difference§ 
(95% CI) 
p-value 
Length of stay by country 
Kenya 58∙9 2∙36 63∙5 2∙35 4∙62 (-2∙35-11 ∙59) 0∙17 4∙73 (-2∙07-11 ∙52) 0∙15 
South Sudan 73∙5 2∙52 67∙0 2∙38 -6∙45 (-13∙53 -0∙63 ) 0∙07 -6∙37 (-13∙17 - 0∙43) 0∙06 
Unadjusted: All children with outcome measures, not adjusted for any demographic or study design characteristics; 
Adjusted: for age, sex and country; N= number of clusters; n=number of children eligible for follow up; §standard 
errors adjusted for clustering within facilities 
 
Supplemental table 5: RUTF Dosage Table (based on 200 kcal/kg/day using 92g packets containing 500 kcal) 
 
Child’s weight (kg) Packets per day Packets per week 
4∙0*-4∙9 2 14 
5∙0-6∙.9 2∙.5 18 
7∙0-8∙4 3 21 
8∙5-9∙4 3∙.5 25 
9∙5-10∙.4 4 28 
10∙5-11∙.9 4∙5 32 
≥12 5 35 
*Infants≥6 months and <4kg are referred to in-patient care 






Supplemental figure 2: Time to recovery for all children in intention-to-treat analysis 
 






Supplemental figure 4: Time to recovery for SAM children in intention-to-treat analysis 
 










Supplemental document 1: Procedures for taking anthropometric measurements 
 
 
Protocol for taking weight measurements: 
 
The child’s weight will be measured and documented at admission as well as at each follow-up visit. 
 
1. Record weight using the ComPAS-designated SECA 385 scale, only 
2. Ensure scale is on level floor or table top and set to zero (baby tray can be removed for children who are 
able to stand on their own) 
3. Press ‘start’ button for first use or ‘reset’ button between each measurement; wait for ‘00∙0000’ to appear 
4. Child removes any shoes and heavy clothing 
5. Child is placed on tray or child stands on center of the scale, sitting/standing still (caregiver or clinician 
may have to persuade child to remain calm) 
6. Clinician records measurement once reading is stable (digits will flash once and then stabilize) 
7. Measurement is recorded to the nearest 0∙01kg 
Protocol for taking height/length measurements: 
 
The child’s height/length will be measured and documented at admission as well as on a monthly basis thereafter∙ 
Length is measured for those aged <2, height for those ≥2 years This measurement will be taken by two operators, 
and measurements compared. 
 
1. Child should remove shoes and any hair ornaments that may interfere with reading 
2. Child is laid or stands straight with heels against height/length board, toes directly in the air (feet at 
90°angle standing position) or feet flat on floor 
3. Ensure back, shoulders, head, buttocks are flat against height board and heels are flat against heel plate 
4. Ensure the head in line with neck and shoulders (chin level) 
5. Clinician moves foot board against child’s feet or head board onto child’s head 
6. Clinician places hands under the subjects ears to assist with posture and then asks child to breath in and 
then relax but stay tall 
7. Measurement is recorded to the nearest 0∙1cm 
8. The two measurements should be within 0∙5cm of each other. If they are not, both operators should repeat 
the measurements. If they are within 0∙5cm of each other, the final value should be mid-way between the 
two (ie. added together and divided by 2) 
 
Protocol for taking MUAC measurements: 
 
The child’s mid upper arm circumference will be measured and documented at admission to determine eligibility for 
treatment as well as at each follow-up visit. 
 
1. Shirt should be removed 
2. Take the left arm of the child 
3. Place the left arm of the child across his chest and ask the caregiver to keep the arm in this position. 
4. Use the MUAC tool to determine the mid-point between the shoulder and tip (bone) of elbow 
5. Strap the MUAC tool around the arm of the child at the identified mid-point, be sure tape is level and 
tension is correct (no skin bulging from the top or bottom of the MUAC tape) 
6. With the arm of the child hanging down, record the digits that are shown at the arrow in the hole of the 
MUAC tool (round to the nearest 1 mm). 
7. When recording on the form, use two digits to the left of the decimal place, and one digit to the right. 
 
Protocol for checking for oedema: 
 
 
A condition of bilateral pitting oedema (level + or ++) meets the criteria for admission into the study. Do not force 
the appearance of a pit by pushing too hard, especially with a fingernail. It is not accurate to report nutritional 
oedema if only one foot has oedema. Oedema level +++ should be immediately referred for inpatient care. 
 
1. While child’s foot is limp, press firmly with the pad (not tip) of thumb on the top of the child’s feet for 5 
seconds, then release 









Supplementary Table S1. Comparison of Combined and Standard Protocols * 
 
Standard Protocol (CONTROL) Combined Protocol (INTERVENTION) 
Age 6–59 months, MUAC < 12.5 cm and/or oedema Age 6–59 months, MUAC <12.5cm and/or 












test, no Integrated Management of Childhood Illness 
(IMCI †)Error! Bookmark not defined. danger signs/ no 
serious medical complications) 
OTP 
 
•  WHZ < −3 
AND/OR 
•  MUAC < 11.5 cm 
AND/OR 
• Bilateral pitting oedema (+/++) 
AND 
• clinically uncomplicated 
 
  SFP  
• Discharged from OTP 
AND/OR 
• WHZ < −2.0 to WHZ > −3 
AND/OR 
• MUAC ≥ 11.5 cm and < 12.5 cm 
AND 
• clinically uncomplicated 
passes appetite test, no Integrated Management 
of Childhood Illness (IMCI) danger signs/ no 






•  <12.5 cm MUAC 
AND/OR 
• Bilateral pitting oedema (+/++) 
AND 
• clinically uncomplicated 
 
Treatment frequency 
OTP MUAC <11.5 cm and/or edema (+/++) 
Weekly Weekly 
SFP MUAC ≥ 11.5 and < 12.5cm 
14 days 14 days 
• Two consecutive MUAC measurements at or 
Treatment transition 
criteria 
• Child meets OTP ‘recovered’ definition as 
described below 
above 11.5 cm 
AND 
• No edema 
 
Dosage 
OTP MUAC < 11.5 cm and/or edema (+/++) 
 
RUTF 200 kcal/kg/day RUTF 1000 kcal/day (2 sachets/day) 
 
SFP MUAC ≥ 11.5 and < 12.5 cm 
 
RUSF 500 kcal/day (1 sachet/day) RUTF 500 kcal/day (1 sachet/day) 
OTP 
 




• WHZ > −3 z-score for two consecutive visits 
AND 
• No edema for two consecutive visits 
 
  SFP  
Child maintains WHZ > −2.0 z-score and/or MUAC ≥ 
12.5 cm for a period of two consecutive visits 
≥ 12.5 cm for 2 consecutive measurements and no 
edema 
 
MUAC, mid-upper arm circumference; IMCI, Integrated Management of Childhood Illness; WHZ, weight-for-height z-score; OTP, 
outpatient therapeutic program; SFP, supplementary feeding program; RUTF, ready-to-use therapeutic food; RUSF, ready-to-use 
supplementary food. * Adapted from Bailey et al. 2018 [27] and Bailey et al. 2020 [35]. † Integrated Management of Childhood Illness 






Supplementary Table S2. Standard ready-to-use therapeutic food dosage table (based on 200 kcal/kg/day using 92 g 
packets containing 500 kcal) * 
 
Child’s Weight (kg) Packets per Day Packets per Week 
4.0 †–4.9 2 14 
5.0–6.9 2.5 18 
7.0–8.4 3 21 
8.5–9.4 3.5 25 
9.5–10.4 4 28 
10.5–11.9 4.5 32 
≥12 5 35 





Supplementary Table S3. Relapse, body composition and morbidity at four months post-discharge, by admission 






MUAC < 11.5 cm and WAZ ≥ −3.0 
(n = 29) 
Group 2 
MUAC 11.5 to < 12.5 cm and 
WAZ < −3.0 (n = 140) 
Group 3 
MUAC < 11.5 cm and WAZ < −3.0 
(n = 56) 
Combined 
(N = 6, n = 10) 
Standard 
(N = 6, n = 19) 
Combined 
(N = 6, n = 87) 
Standard 
(N = 6, n = 53) 
Combined 
(N = 6, n = 30) 
Standard 












MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score. N = number of clusters; n = individual children eligible for 
treatment. † At 4-month follow-up visit. ‡ Among those discharged as cured. § Data collected on reported diarrhea, vomiting, fever 
or cough in past week. 





20 5 26 15 17 10 19 7 23 5 19 
Relapse to acute 
1/4
 
25 1/10 10 10/68 15 6/35 17 1/12 8 1/13 8 
Illness reported in past 
2
 
20 9 47 21 24 12 23 6 20 8 31 
Hospitalization reported 
0 0 1 5 5 6 3 6 1 3 2 8 
mean SD mean SD mean SD mean SD mean SD mean SD 
Fat free mass (kg) 6.29 0.54 6.26 0.62 6.08 0.82 6.22 0.88 6.18 0.66 6.16 0.70 
Fat mass (kg) 2.26 0.61 2.43 0.63 2.15 0.84 2.31 0.93 2.44 1.14 2.10 0.77 
 
Supplementary Table S4. Outcomes of children in group 1, unadjusted and adjusted risk ratios 
  Group 1 MUAC < 11.5 cm and WAZ ≥ −3.0 (n = 337)  
Intention-to-Treat Combined 
(N = 12, n = 142) 
Standard 
(N = 12, n = 195) 
Unadjusted Risk Ratio † Adjusted Risk Ratio † 
 
 
 n % n % Risk ratio (95% CI) p-Value ‡ Risk ratio (95% CI) p-Value ‡ 
Recovered 25 17.6 41 21.0 0.84 (0.52, 1.35) 0.47 0.87 (0.54, 1.40) 0.56 
Died 1 0.7 2 1.0 0.69 (0.07, 6.45) 0.74 0.57 (0.05, 6.55) 0.65 
Defaulted 48 33.8 83 42.6 0.79 (0.57, 1.11) 0.18 0.81 (0.58, 1.12) 0.20 
Non-recovered § 46 32.4 56 28.7 1.13 (0.75, 1.70) 0.57 1.16 (0.77, 1.74) 0.48 
Transfer-inpatient 7 4.9 2 1.0 3.20 (0.68, 15.04) 0.14 3.13 (0.76–12.96) 0.12 
Transfer-new facility 6 4.2 2 1.0 4.12 (0.74, 22.87) 0.11 4.08 (0.75, 22.13) 0.10 
Early discharge 9 6.3 9 4.6 1.53 (0.61, 3.80) 0.36 1.54 (0.68, 3.45) 0.30 
Median IQR Median IQR 
Common Language Effect Size statistic 
(control > intervention) * (95% CI) 
 
Length of stay (days) a 80         59, 94         94         85, 108 0.63 (0.49, 0.78) 
 
MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score. N = number of clusters; n = individual children eligible for 
treatment. † Both unadjusted and adjusted results account for the effect of clustering. The adjusted model also includes adjustment 
for country, age and sex. ‡ Analyses use the Generalized Linear Model, reporting Pearson chi-squared p-values. § Non-recovered 
defined as not reaching recovery criteria after 17 weeks in treatment. a Length of stay among recovered children only, per global 
CMAM reporting standards [46]. * Probability that a randomly selected control length of stay is greater than a randomly selected 
intervention length of stay. 
Supplementary Table S5. Outcomes of children in group 2, unadjusted and adjusted risk ratios 
  Group 2 MUAC 11.5 to <12.5cm and WAZ < −3.0 (n=811)  
Intention-to-Treat Combined 
(N = 12, n = 482) 
Standard 
(N = 12, n = 329) 




n % n % Risk Ratio (95% CI) p-Value ‡ Risk Ratio (95% CI) p-Value ‡ 
Recovered 274 56.9 163 49.5 1.15 (0.85, 1.55) 0.37 1.18 (0.90, 1.54) 0.24 
Died 4 0.83 3 0.91 0.91 (0.16, 5.25) 0.92 0.75 (0.15, 3.86) 0.73 
Defaulted 92 19.1 79 24.0 0.78 (0.45, 1.37) 0.39 0.78 (0.51, 1.19) 0.25 
Non-recovered § 41 8.5 28 8.5 1.0 (0.40, 2.50) 1.0 0.82 (0.41, 1.63) 0.58 
Transfer-inpatient 5 1.0 5 1.5 0.68 (0.13, 3.59) 0.65 0.68 (0.14, 3.28) 0.63 
Transfer-new facility 9 1.9 6 1.8 0.98 (0.37, 2.60) 0.96 1.06 (0.45, 2.48) 0.90 
Early discharge 57 11.8 45 13.7 0.89 (0.46, 1.72) 0.73 0.95 (0.57, 1.61) 0.86 
Median IQR Median IQR 
Common Language Effect Size Statistic 
(control > intervention) * (95% CI) 
 
Length of stay (days) a 57         43, 85         71 57, 85 0.52 (0.46, 0.58) 
 
MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score. N = number of clusters; n = individual children eligible for 
treatment. † Both unadjusted and adjusted results account for the effect of clustering. The adjusted model also includes adjustment 
for country, age and sex. ‡ Analyses use the Generalized Linear Model, reporting Pearson chi-squared p-Values. § Non-recovered 
defined as not reaching recovery criteria after 17 weeks in treatment. a Length of stay among recovered children only, per global 
CMAM reporting standards [46]. *Probability that a randomly selected control length of stay is greater than a randomly selected 
intervention length of stay. 
Supplementary Table S6. Outcomes of children in group 3, unadjusted and adjusted risk ratios 
  Group 3 MUAC < 11.5 cm and WAZ < −3.0 (n = 863)  
Intention-to-Treat Combined 
(N = 12, n = 447) 
Standard 
(N = 12, n = 416) 
Unadjusted Risk Ratio † Adjusted Risk Ratio † 
 
 
 n % n % Risk ratio (95% CI) p-Value ‡ Risk ratio (95% CI) p-Value ‡ 
Recovered 87 19.5 57 13.7 1.42 (0.89, 1.95) 0.06 1.36 (0.90, 1.82) 0.07 
Died 9 2.0 7 1.7 1.20 (0.30, 4.78) 0.25 0.91 (0.36, 2.33) 0.85 
Defaulted 150 33.6 188 45.2 0.74 (0.56, 0.98) 0.03 0.74 (0.57, 0.97) 0.03 
Non-recovered § 111 24.8 114 27.4 0.90 (0.70, 1.15) 0.40 0.91 (0.73, 1.15) 0.45 
Transfer-inpatient 18 4.0 11 2.6 1.40 (0.34, 5.69) 0.47 1.58 (0.38, 6.56) 0.53 
Transfer-new facility 21 4.7 12 2.9 1.43 (0.64, 3.17) 0.38 1.51 (0.68, 3.35) 0.31 
Early discharge 51 11.4 27 6.5 1.80 (0.95, 3.40) 0.07 1.95 (1.10, 3.43) 0.02 
Median IQR Median IQR 
Common Language Effect Size statistic 
(control > intervention) * (95% CI) 
 
Length of stay (days) a 81        66, 101        94         71, 108 0.56 (0.46, 0.67) 
 
MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score. N = number of clusters; n = individual children eligible for 
treatment. †Both unadjusted and adjusted results account for the effect of clustering. The adjusted model also includes adjustment for 
country, age and sex. ‡ Analyses use the Generalized Linear Model, reporting Pearson chi-squared p-values. § Non-recovered defined 
as not reaching recovery criteria after 17 weeks in treatment. a Length of stay among recovered children only, per global CMAM 
reporting standards [46]. * Probability that a randomly selected control length of stay is greater than a randomly selected intervention 







Supplementary Figure S1. Panel of WAZ and MUAC response among all children by admission group. 
MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score. (a) WAZ plotted against week in 
program for Group 1; (b) MUAC plotted against week in program for Group 1; (c) WAZ plotted against 
week in program for Group 2; (d) MUAC plotted against week in program for Group 2; (e) WAZ plotted 
against week in program for Group 3; (f) MUAC plotted against week in program for Group 3. The shaded 
areas represent a 95% confidence band around each curve (i.e., the area between the upper and lower 95% 
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STUDY PROTOCOL Open Access 
Abstract 
Background: Acute malnutrition is currently divided into severe (SAM) and moderate (MAM) based on level of 
wasting. SAM and MAM currently have separate treatment protocols and products, managed by separate international 
agencies. For SAM, the dose of treatment is allocated by the child’s weight. A combined and simplified protocol for 
SAM and MAM, with a standardised dose of ready-to-use therapeutic food (RUTF), is being trialled for non-inferior 
recovery rates and may be more cost-effective than the current standard protocols for treating SAM and MAM. 
Method: This is the protocol for the economic evaluation of the ComPAS trial, a cluster-randomised controlled, 
non-inferiority trial that compares a novel combined protocol for treating uncomplicated acute malnutrition 
compared to the current standard protocol in South Sudan and Kenya. We will calculate the total economic costs 
of both protocols from a societal perspective, using accounting data, interviews and survey questionnaires. The 
incremental cost of implementing the combined protocol will be estimated, and all costs and outcomes will be 
presented as a cost-consequence analysis. Incremental cost-effectiveness ratio will be calculated for primary and 
secondary outcome, if statistically significant. 
Discussion: We hypothesise that implementing the combined protocol will be cost-effective due to streamlined 
logistics at clinic level, reduced length of treatment, especially for MAM, and reduced dosages of RUTF. The findings of 
this economic evaluation will be important for policymakers, especially given the hypothesised non-inferiority of the 
main health outcomes. The publication of this protocol aims to improve rigour of conduct and transparency of data 
collection and analysis. It is also intended to promote inclusion of economic evaluation in other nutrition intervention 
studies, especially for MAM, and improve comparability with other studies. 
Trial Registration: ISRCTN 30393230, date: 16/03/2017. 
Keywords: Cost-effectiveness, Severe acute malnutrition, Moderate acute malnutrition, Community management 
of acute malnutrition, Cost-consequence analysis 





The "ComPAS Trial" combined treatment 
model for acute malnutrition: study 
protocol for the economic evaluation 
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Tackling undernutrition in all its forms is a major global 
health priority demonstrated by its inclusion in the recent 
Sustainable Development Goals [1]. Stunting, severe acute 
malnutrition (SAM) and intrauterine growth restriction 
together are responsible for 21% of disability-adjusted life- 
years for children under 5 years [2]. Annually, acute mal- 
nutrition specifically affects 52 million children aged under 
5 years and is associated with a high mortality rate if un- 
treated as well as multiple long-term implications [3, 4]. 
Acute malnutrition is currently defined as low weight-for- 
height, low mid upper arm circumference (MUAC), and/or 
presence of bilateral oedema. It can be either moderate 
   (MAM) or severe (SAM), depending on the extent of wast- 
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2Department of Population Health, London School of Hygiene and Tropical 
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ing. SAM cases, without medical complications, are treated 
through outpatient therapeutic programmes, where they 
receive routine medical care and a weekly take-home 
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ration of ready-to-use therapeutic food (RUTF). Although 
there is currently no consensus on how best to manage 
MAM cases, they are often treated in food-insecure set- 
tings through supplementary feeding programmes (SFP), 
where they receive bi-weekly take-home rations of ready- 
to-use supplementary food [5, 6]. When discussing SAM 
and MAM in combination, the term ‘global acute malnu- 
trition’ (GAM) is applied. 
The current system of two parallel malnutrition treat- 
ment programmes  and  product  supply  chains  means 
that SAM programmes are often  prioritised  over  those 
for MAM, resulting in no services for MAM children in 
many settings. In contexts where the treatment of both 
SAM and MAM are available, the parallel systems may 
be resulting in an inefficient use of resources. In 
addition, current dosage of RUTF for treatment of SAM 
is based on the weight of the child, requiring multiple 
calculations by health workers and, in some cases, chil- 
dren are provided with a higher dose and for a longer 
period of time than required [7]. 
ComPAS (Combined Protocol for Acute Malnutrition 
Study) aims to assess whether unifying and simplifying 
the treatment of uncomplicated SAM and MAM for 
children aged 6–59 months into one programme would 
have an impact on the effectiveness of treatment. The 
‘combined protocol’ will treat all SAM and MAM cases 
with RUTF using a simple MUAC-based dosage proto- 
col, and this will be compared to the ‘standard protocol’ 
in a non-inferiority, cluster-randomised controlled trial. 
Further details of the ComPAS trial study design are 
published elsewhere [7, 8]. 
Few studies have assessed the cost-effectiveness of nutrition 
interventions, particularly with regard to treatment of MAM 
and changes in acute malnutrition protocols. Since the intro- 
duction of the current standard community-based protocol 
for treatment of SAM in 2001, studies have found this model 
to be cost-effective compared to the previous model of in- 
patient treatment [9–11]. Treatment for SAM is estimated to 
cost between USD$26 and USD$53 per disability-adjusted life 
year averted [9–11], and between USD$100 and USD$203 
per child treated [11, 12]. It has also been estimated that costs 
can be as high as USD$500 per child treated by non- 
government organisations in fragile or emergency contexts 
[13]. The cost per MAM child treated is not widely published, 
perhaps due to the current lack of recommended protocols. 
One previous study has trialled a combined protocol, 
using RUTF to treat MAM and SAM, and found it to have 
a comparable recovery rate (83% vs. 79%) for GAM and 
higher coverage (71% vs. 55%, P = 0.0005) than the stand- 
ard protocol [14]. This clinical trial was conducted in Si- 
erra Leone in 2013 and tested the efficacy of  an 
integrated, MUAC-only protocol for the treatment  of 
SAM and MAM using one product (RUTF) at different 
standardised doses for children with a height < 115 mm 
 
(175 kcal/kg/day) and 115–125 mm (75 kcal/kg/day), 
against the standard protocol, which used corn-soy 
blended flour (CSB++) for children with MAM. The study 
also presents the cost of therapeutic food from a 
programme perspective. The cost of RUTF was US$4/kg, 
which was the local producer’s price in 2013, and US$1. 
30/kg for CSB++ [14]. The cost of RUTF used to treat a 
SAM case was US$36 in the combined protocol, com- 
pared to US$68 in the standard programme. The cost of 
food products to treat a case of MAM was US$12 in both 
the combined and standard management arms. 
Despite the higher price of RUTF compared to CSB+ 
+, the study found that the integrated protocol was less 
costly due to the lower dose of RUTF provided to SAM 
cases and faster recovery rates of children with MAM. 
The authors theorised that,  due  to  the  reduced  food 
costs and simpler logistical  requirements,  it  seemed 
likely that the integrated management would  be  less 
costly to implement per child treated than the standard 
protocol [14]. They also found a lower  proportion  of 
SAM in their combined protocol arm, which they 
hypothesised might be due to SAM cases averted by 
earlier treatment of MAM with RUTF. The need for a 
more complete economic analysis of the combined 
protocol was highlighted. 
Our study builds on this previous work, and aims to 
estimate the full economic cost of the ComPAS com- 
bined protocol, compared to the standard protocol, from 
a societal perspective. We hypothesise that  the  com- 
bined protocol will be more cost-effective than the 
standard protocol as overall costs will be lower and an 
equivalent recovery rate from GAM will be achieved. 
Many cost-effective health interventions have better 
health outcomes but at a greater  cost;  we  hypothesise 
that the  combined protocol will have as high recovery 
rates as the standard protocol, at a lower cost (Fig. 1). 
Based on the literature, we hypothesise that cost reduc- 
tions will come from the streamlining of logistics and 
personnel, the potential for provision of lower weekly 
dosages of RUTF, and the faster recovery of children. 
As few protocols have been published for economic 
evaluations in child health, this article follows a call for 
publication of complex economic protocols [15]. The 
publication  of  economic  protocols,  such  as  this,  aims 
to improve the rigour of conduct  among  costing  stud- 
ies, improve comparability, and familiarise  researchers 
and programme implementers  in  global  health  nutri- 
tion  with the methodologies  of   economic   evaluation 
in order to encourage its inclusion in more nutrition 
intervention trials. 
 
Aims and objectives 
The aim of the ComPAS economic evaluation is to 
measure the cost and cost-effectiveness of a ‘combined 








This study is a cost-consequence and cost-effectiveness 
analysis of the ComPAS trial, a multi-country, cluster- 
randomised, controlled trial taking place between May 
2017 and July 2018. We will estimate the total costs of 
both protocols from a  societal  perspective,  including 
both service provider and household costs. Data collec- 
tion for the costing study will take  place  at  the  mid- 
point of recruitment  for the main trial, and accounting 
data will be accessed at the end of the study implemen- 
tation. Time horizons for the  costing  study  are  within 
the trial period only. 
Ethical approval for the trial was obtained from the 
Kenya Medical Research Institute (KEMRI) (5/1/2017, 
ref.: 551), the South Sudan Ministry of Health Internal 
Review Board (21/11/2016), and the London School of 
Hygiene and Tropical Medicine (28/11/2016, ref: 11826). 
This protocol describes the methods specific to the 
economic study alongside the ComPAS randomised 
controlled trial, following the SPIRIT checklist  format 
(see Additional file 1); further details  of  the  protocol 
have been published elsewhere [8]. 
 
protocol’ for treatment of SAM and  MAM compared to 
the standard protocol, which separates SAM and MAM 
treatment into an outpatient therapeutic   programme 
and SFP. The primary marker of effectiveness will be re- 
covery from GAM, defined as achieving a MUAC ≥ 125 
mm. The secondary markers of effectiveness will be 
programme coverage, length of treatment, treatment 
adherence, average weekly weight gain and average 
weekly MUAC gain. 
The specific  objectives  of  the  economic  evaluation 
are to: 
 
1. Quantify the economic cost of implementing the 
combined protocol (intervention) and the standard 
protocol (control), using a combination of activity- 
based costing and ingredients approach. 
2. Quantify the economic cost to households partaking 
in the combined protocol and the standard protocol. 
3. Estimate any incremental costs to the wider health 
system by the implementation of the combined 
protocol compared to the standard protocol using 
programme referral data and published literature. 
4. Compute the incremental cost per child recovered 
for the combined protocol compared to the 
standard protocol. 
5. Present the costs and any significant differences in 
the primary and secondary outcomes (i.e. recovery 
rate, coverage, defaulting, average weight gain, 
average MUAC gain and length of treatment) as a 
cost-consequence analysis. 
Target population 
The target population for the ComPAS trial is children 
aged 6–59 months who are diagnosed with uncomplicated 
acute malnutrition and are eligible for outpatient treat- 
ment. Acute malnutrition is defined in the trial as a MUAC 
< 125 mm and/or bilateral pitting oedema only. Children 
with a weight-for-height < −2 z-score will be treated, how- 
ever, they will not be included in the primary analysis. The 
only reason for non-inclusion will be if the child is receiv- 
ing SAM or MAM treatment at another facility. 
All caregivers of children presenting with acute malnu- 
trition at participating health facilities, who meet the 
inclusion criteria, are approached  for  consent  to  take 
part in the trial. Details of the informed consent process 
can be found in the trial protocol [8]. If the caretaker 
chooses not to participate in the trial, their child  is 
enrolled for treatment only and their information is not 
recorded for study purposes. 
For the economic  evaluation,  the  target  populations 
for the collection of resource-use data are (1) carers of 
children receiving treatment for  acute  malnutrition  as 
part of the trial; (2) staff working to treat children en- 
rolled in the trial; (3) support, supervision, management 
and  logistics  staff  relevant  to the  treatment of children 
in the trial; and (4) partner organisations supporting any 
aspect of care provision to children enrolled in the trial. 
 
Setting and randomisation 
The study will take place in 12  health  facilities  in 






















Fig. 1 Depiction of hypothesised economic outcome of the ‘combined 
protocol’ on the cost-effectiveness matrix. We hypothesise that the 
‘combined protocol’ for treatment of severe and moderate acute 
malnutrition will have as high recovery rates as the standard 
treatment protocol, but at a lower cost 







Aweil East County, South Sudan. Six health facilities in 
each country have been randomised to the  control  arm 
and six to the intervention arm using a random 
sequence generated and applied to a pre-written list of 
participating clinics. Health facility staff are not blinded 
to the trial, as they are required to follow the specific 
protocol to which their facility is allocated. 
Nairobi County is an urban area where more than 60% 
of residents live in informal settlements, in which the es- 
timated prevalence of wasting (GAM) is 2.8% [16]. The 
2014 Kenya Demographic and Health Survey estimated 
that 17% of children aged under 5 years in Nairobi were 
stunted, and 4% were underweight; further 60.4% of chil- 
dren were fully immunised and 93.6% of women living 
in urban areas were literate [17]. The 12 health  facilities 
in Nairobi are operated by the Ministry of Health with 
support from International Rescue Committee specific- 
ally for treatment of malnutrition. These facilities were 
selected as study sites by the Ministry of Health based 
on the high burden of malnutrition; they are approxi- 
mately 3–5 km apart. 
Aweil East is a rural setting in Northern Bahr el Ghazal 
State in South Sudan. Children under 5 years of age are 
thought to account for 19% of the population and 76% of 
the population in the State live below the  poverty line 
[18]. A Standardized Monitoring and Assessment of Relief 
and Transitions survey conducted in Aweil East in April 
2014 reported a GAM prevalence of 26% [19]. Coverage 
of measles immunisations is thought to be 27%, and the 
2009 National Baseline Household Survey found national 
female literacy rates to be 16% [20]. The 12 health facilities 
included in this study are operated by an international non-
government organisation (Action Against Hunger), are 
approximately 20–30 km apart from each other and 
provide malnutrition services only. 
 
Intervention 
The control arm follows  the  standard  protocol  defined 
by national guidelines for the treatment of SAM and 
MAM, and the intervention arm follows a combined 
protocol for SAM and MAM. The RUTF dosage for the 
intervention was developed based on a retrospective 
analysis of acute malnutrition treatment data in order to 
propose a physiologically appropriate, simplified dosage 
that meets the energy requirements for acutely malnour- 
ished children defined by MUAC [7]. Children treated in 
the control arm receive 200 kcal/kg/day of RUTF if they 
are classified as SAM (MUAC < 115 mm or bilateral pit- 
ting oedema), and 500 kcal/day of ready-to-use supple- 
mentary food if they are classified as MAM (MUAC 115 
to < 125 mm), as per national protocols. Children treated 
in the intervention arm receive 1000 kcal/day of RUTF 
if they  have SAM and 500 kcal/day  of RUTF in they 
have MAM. Further details of the two protocols can be 
 
found in Table two of Bailey et al. [8] and in the online 
trial registration (ISRCTN 30393230) [21]. 
 
Health outcomes 
The primary outcome of the ComPAS trial is ‘proportion 
of children recovered’; however, as a non-inferiority trial, 
it is expected that this outcome will not be statistically 
significantly different between intervention and control 
arms. For the purposes of analysis, recovery will be 
defined as two consecutive measurements with a MUAC 
≥ 125 mm and no oedema for both control and interven- 
tion arms. 
The secondary outcomes will be treatment coverage, 
defaulter rate, length of treatment, average weight  gain 
and average MUAC gain. Coverage is defined as propor- 
tion of children eligible for  treatment  (MUAC  < 125 
mm) who receive treatment, assessed by a standardised 
Semi-Quantitative Evaluation of Access and Coverage 
survey [22]. Defaulting is defined as absence from treat- 
ment appointments for 3 consecutive weeks. Further 
details of health outcomes can be found in the trial 
protocol [8]. Statistically significant secondary outcomes 
will be presented in the cost-consequence analysis  and 
unit costs presented where appropriate, e.g. cost per unit 
coverage, although the conservative  a priori hypothesis 
for all outcomes is non-inferiority. 
Maust et al. [14] found a reduced caseload of SAM 
in their version of the combined protocol and 
hypothesised that this could be due to more intensive 
treatment of  MAM  resulting  in  prevention  of  SAM. 
We will also explore any adjusted differences in SAM 
caseloads  between  the  intervention  and  control  arm 
and, if a significant difference is found,  the  cost  per 
SAM case averted will be estimated.  They  also  found 
that SAM children who received the intervention re- 
covered  more  rapidly   and  therefore  had  a  reduced 
cost of RUTF [14]. We will also present the  cost  of 
RUTF per SAM case simply  using  the  number  of 
sachets  prescribed  and  the  local  unit  cost  per  sachet, 
in order to compare with previously published values. 
Nevertheless, it is important to note that the study by 
Maust  et  al.   [14]  compared  their   combined  protocol 
to routine control clinics, whereas this study will 
compare a combined protocol to fully supported, ‘op- 
timal’ control sites. Exploration of differences in 
defaulting rates and relapse rates between the two 
protocols will also be considered in  relation  to  their 
effect on total programme costs. 
Recent health seeking and referrals to external medical 
care will also be assessed in a sub-set of study partici- 
pants in order to estimate differences in health seeking 
behaviour and utilisation of wider health services, which 
will inform the estimated cost of the intervention to the 
wider health system. 








There will be 12 health facilities (clusters)  in  South 
Sudan and 12 in Kenya; in each country, six health facil- 
ities will be randomly allocated as intervention and six 
as control, with 150 children per clinic. The sample size 
for the main trial outcome was calculated using an ex- 
pected recovery rate of 85% based on the average 
programme statistics for each site, allowing for a 10% 
non-inferiority margin, with 80% power at the 5% level 
of significance. 
As the study is only statistically powered for determin- 
ing effectiveness across both countries rather than 
within each country, the economic evaluation will be 
conducted using pooled costs and outcomes from both 
sites. Pooled and site-specific costs and outcomes  will 
also be presented in the cost-consequence analysis. 
Cost data collection will be carried out at all 24 health 
facilities participating in the study. For beneficiary costs, 
an exhaustive sample will be asked  a  simple  survey 
about cost and time implications of participating in the 
programme as part of the main trial exit interview. In 
addition, more in-depth group interviews with benefi- 
ciary carers will take place with between four and six 
purposively selected participants at each clinic (i.e. ~72 
participants for each country) (Table 1). Interview sample 
sizes will be determined by data saturation. Survey sample 
sizes will be dictated by the trial sample size; however, 
post-hoc sample size calculations for differences in cost 
and time data will be calculated where possible. 
 
Measuring resources and costs 
The economic evaluation will be conducted from  a 
societal perspective, measuring programme and 
household costs. A combination of  activity-based cost- 
ing and ingredients approach will be used to estimate 
programme costs. See Table 1 for list of activities and 
ingredients.  The  timing  of  data  collection  points  can 
be seen in Fig. 2. Full start-up costs will not  be  col- 
lected as protocol development has been on-going 
across previous years and previous studies; however, 
simple start-up costs relevant for future use, such as 
stakeholder meetings, trainings,  community  sensitisa- 
tion and translation  of  resources,  will  be  estimated. 
Note that cost of inpatient  treatment  for  SAM  will 
not be collected as it is not part of the intervention. 
 
Measuring programme costs 
Major activities guiding the programme costs have been 
derived from other community management of acute mal- 
nutrition costing analyses [9, 23], namely treatment, out- 
reach, supply logistics, training, supervision and 
management. The ingredients within each activity will be 
quantified and costed using a clinic audit, key informant 
interviews with clinic staff, Ministry of Health regional 
 
level staff and relevant partner organisations, and account- 
ing data, where available (Table 1). Capital costs will be 
annualised over their expected useful life (3 years for com- 
puters, 5 years for cars and other equipment, 10 years for 
communal land) and discounted at a rate of 3%. The allo- 
cation of joint costs will be divided by activity and by 
study arm, informed by the weekly clinic survey and 
study-midpoint staff time-use interview. 
As programme costs are the primary area where we 
anticipate the main differences to lie between interven- 
tion and control, we will collect primary  resource  use 
data for all activity areas rather than rely on assumptions 
applied to accounting data. Specifically, we hypothesise 
differences in therapeutic food and staff costs. 
 
Measuring household costs 
Basic travel time and costs will be measured using sur- 
vey questions to all study participants during the main 
trial exit interview. In Kenya, survey data will be col- 
lected electronically and stored on a secure server. In 
South Sudan, survey  data  will  be  collected  on  paper 
and entered using the same electronic data collection 
system as in Kenya, which includes appropriate  skip 
logic, value restrictions and data checks. Group inter- 
views with a sub-sample of participants during their en- 
rolment in the study will also be undertaken to 
consider any hidden or abstract costs to  households as 
well as to calculate potential lost earnings due to time 
spent at the programme. Participants  will  be  purpos- 
ively selected to represent both SAM and  MAM  chil- 
dren as well as a range of travel times. 
 
Estimating costs to the wider health system 
Wider health system costs will be estimated using the 
number and nature of referrals of participating children 
as well as any differences in health-seeking behaviour. 
Referral nature and number will be estimated based on 
quarterly clinic surveys  and  health-seeking  behaviour 
will be discussed in participant group interviews.  Cost 
will be estimated using existing published data on costs 
of treating common referrals, for instance WHO 
CHOICE cost estimates [24]. 
 
Analytical methods 
Incremental cost-effectiveness ratios will  be  calculated 
for the primary outcome (i.e. incremental cost per add- 
itional child recovered) and for secondary  outcomes 
where a statistically significant difference is found. 
Potential secondary outcomes for inclusion  are  treat- 
ment coverage, defaulter rate, length of treatment, aver- 
age weight gain and average MUAC gain. Univariate and 
multivariate sensitivity analyses will be performed  in 
order to assess the potential best case and worse case 
variability in costs and outcomes. Areas of potential 







Table 1 Outline of data categories and sources 
Activity Ingredients Data sources Sample size 
Programme costs 








2. Clinic audit 
3. KII with partners (UN agencies) 
4. Time allocation questionnaire 
2. All clinics (12 per country) 
3. One from each partner 
4. Purposive sample representing all types of clinic staff involved 
in treatment 




2. Clinic audit 2. All clinics (12 per country) 




2. KII with partners and clinic 
staff 
3. Time allocation questionnaire 
2. Purposive sample representing all partners 
3. Purposive sample representing all types of clinic staff 




2. Clinic audit 2. All clinics (12 per country) 







1. MoH/partner accounting data 
2. KII with MoH/partner support 
staff 
3. Time allocation questionnaire 
1. N/A 
2. Purposive sample 
3. All support staff involved in the programme 
Household costs 
Participating in treatment Supplies 1. GIs with beneficiaries 
 




Wider health system costs 
Time 
Transport 
2. Beneficiary exit survey 2. All beneficiaries 





2. Literature estimates 2. N/A 
 
 
aNote that this does not include SAM inpatient treatment 
KII key informant interview, MoH Ministry of Health, GIs group interviews, N/A not applicable 
 
variability will be determined through exploration of the 
effectiveness data and the researcher’s evaluation of cost 
data uncertainty following data collection. For example, 
there could be  variability in costs or time-use informa- 
tion provided by staff and other key informants due to 
recall error. 
In addition to incremental cost-effectiveness ratios, the 
economic evaluation will be presented as a cost- 
consequence analysis where all costs and outcomes will 
be listed, including the multiple secondary trial 
outcomes, allowing policymakers to compare costs with 
health gains for the combined protocol. 
Costs will be presented in 2017 prices in local currency 
(Kenyan shillings and South Sudanese Pounds) as well as 
2017 US dollars, which will allow for comparison across 
the two country sites as well as comparison with other 
studies. Costs and outcomes will not be discounted as the 
intervention does not span more than 1 year. 
Results are expected to be generalisable to multiple Afri- 
can contexts, particularly within the range of the 
Lelijveld et al. Trials (2018) 19:252 Page 7 of 9 
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sensitivity analyses. Household food security estimates for 
each site will aid identification of where results may be 
generalisable to (i.e. food insecure settings). In addition, as 
treatment in one study site is government-led and in the 
other it is partner-led, results from each should be of 
interest to implementers with a variety of programme 
structures. One limitation of the study is that the main 
analysis will present an average of the two sites, therefore 
masking some of the heterogeneity between sites. 
Anonymised hardcopies of data will be stored in ap- 
proved, secured locations in the respective countries; 
anonymised electronic data for the economic evaluation 
will be stored on a secure server in the UK, assessable 
only by the research team. No  participant  identifiable 
data will be recorded. Results will be reported following 
the consolidated health economic evaluation reporting 
standards (CHEERS) checklist [25]. 
 
Discussion 
This economic evaluation will provide  key information 
for policymakers when considering alterations to  the 
GAM treatment protocols. As a non-inferiority trial, the 
recovery rates are expected to be statistically similar 
between each protocol, hence the comparative cost- 
effectiveness will likely play a larger role in policy 
decision-making. 
With regard to limitations, this study will not be able 
to assess the cost impact of the combined protocol on 
international logistics and supply chain, which may be 
further streamlined if the combined protocol were to be 
scaled-up. In addition, the full extent of the hypothesised 
cost savings of the combined protocol is unlikely to be 
realised during the period of this study (8–10 months). 
A longer time horizon is necessary to reveal the impact 
of an improved treatment protocol on the reduction in 
acute malnutrition caseload through prevention of 
deterioration from MAM to SAM. Finally, as is the case 
with many controlled trials, the extra support offered to 
both the combined and standard protocols will  likely 
result in higher costs, which should be noted when gen- 
eralising the results to routine programmes. 
This publication aims to  improve  rigour  in  conduct 
and transparency of data collection and analysis. The 
publication of this protocol also intends to promote 
Lelijveld et al. Trials (2018) 19:252 Page 8 of 9 
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inclusion of economic evaluation in other nutrition inter- 
vention studies, particularly for MAM, and improve com- 
parability with other studies. Regardless of whether the 
new protocol is more cost-effective than the standard 
protocol or not, the evidence provided by this evaluation 
will contribute significantly to the currently limited evi- 




This is protocol version number 1, finalised on 01/06/2017. 
Recruitment of trial participants began on 15/05/2017 and 
is expected to be completed on 01/06/2018, at which point 
accounting data and survey data will be analysed. Inter- 
views for the economic evaluation began on 20/06/2017 






ComPAS: Combined Protocol for Acute Malnutrition Study; CSB++: corn-soy 
blend (fortified); GAM: global acute malnutrition; MAM: moderate acute 
malnutrition; MUAC: mid upper arm circumference; RUTF: ready to use 
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Severe and moderate acute malnutrition (SAM and MAM) affect more than 50 million chil- 
dren worldwide yet 80% of these children do not access care. The Combined Protocol for 
Acute Malnutrition Study (ComPAS) trial assessed the effectiveness of a simplified, com- 
bined SAM/MAM protocol for children aged 6–59 months and found non-inferior recovery 
compared to standard care. To further inform policy, this study assessed post-discharge 
outcomes of children treated with this novel protocol in Kenya. 
 
Methods 
Six ‘combined’ protocol clinics treated SAM and MAM children using an optimised mid- 
upper arm circumference (MUAC)-based dose of ready-to-use therapeutic food (RUTF). 
Six ‘standard care’ clinics treated SAM with weight-based RUTF rations; MAM with ready- 
to-use supplementary food (RUSF). Four months post-discharge, we assessed anthropom- 
etry, recent history of illness, and body composition by bioelectrical impedance analysis. 
Data was analysed using multivariable linear regression, adjusted for age, sex and allowing 
for clustering by clinic. 
 
Results 
We sampled 850 children (median age 18 months, IQR 15–23); 44% of the original trial 
sample in Kenya. Children treated with the combined protocol had similar anthropometry, 
fat-free mass, fat mass, skinfold thickness z-scores, and frequency of common illnesses 4 
months post-discharge compared the standard protocol. Mean subscapular skinfold z- 
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scores were close to the global norm (standard care: 0.24; combined 0.27). There was no 
significant difference in odds of relapse between protocols (SAM, 3% vs 3%, OR = 1.0 p = 
0.75; MAM, 10% vs 12%, OR = 0.90 p = 0.34). 
 
Conclusions 
Despite the lower dosage of RUTF for most SAM children in the combined protocol, their 
anthropometry and relapse rates at 4 months post-discharge were similar to standard care. 
MAM children treated with RUTF had similar body composition to those treated with RUSF 
and neither group exhibited excess adiposity. These results add further evidence that a 
combined protocol is as effective as standard care with no evidence of adverse effects post- 
discharge. A simplified, combined approach could treat more children, stretch existing 





Severe and moderate acute malnutrition (SAM and MAM) affect more than 50 million chil- 
dren worldwide and result in increased risk of illness, reduced physical and mental develop- 
ment, and death [1, 2]. While treatment for SAM has made huge strides in the past decade, 
with the introduction of ready-to-use therapeutic food (RUTF) and community management 
(CMAM), there is currently no consensus on how best to manage children with MAM. The 
lack of evidence in this area has prevented development of international guidelines, hence 
urgent research is needed. In addition, treatment coverage for both SAM and MAM remains 
low, with at least 80% of children 6–59 months old with acute malnutrition not accessing care 
[3]. In many settings, children with MAM receive no support, or they receive ready-to-use 
supplementary food (RUSF), which is dependent on a dedicated team to deliver this service 
and an independent supply chain [4, 5]. One option to improve the reach of treatment services, 
as well as potentially improve outcomes for MAM children, is combining the treatment of 
SAM and MAM into one protocol, using one ready-to-use food product. 
The ComPAS trial (Combined Protocol for Acute Malnutrition Study) was a single- 
blinded, cluster randomised, controlled, non-inferiority trial to compare recovery rates of a 
combined protocol for uncomplicated SAM and MAM in children 6–59 months in South 
Sudan and Kenya against the standard treatment protocols in each country [6, 7]. It used a 
simplified dosage scheme based on mid-upper arm circumference (MUAC) and provided 
ready-to-use food (RUTF) for both SAM and MAM patients. The simplified dosage provided 
2 sachets of RUTF per day for SAM children and 1 sachet per day for MAM children; this was 
often a lower dosage than what was provided by the standard weight-based dosage calculations 
for SAM. The combined protocol had non-inferior recovery rates compared to standard treat- 
ment (76.3% vs 73.5%), as well as a reduced overall economic cost [8]. 
To better inform future policy, there is also a need to understand post-discharge outcomes 
for children treated with a simplified, combined protocol. Outstanding questions include: (1) 
Do children treated with the combined protocol have comparable sustained recovery and risk 
of post-discharge morbidity? (2) Are MAM children treated with RUTF rather than RUSF at 
increased risk of excess adiposity? It is possible that the provision of RUTF could promote 
the accretion of fat mass rather than lean mass, potentially leading to excess adiposity, which 
might track into adulthood. This is particularly important to rule out given the rise of non- 
communicable disease in low-income countries and concerns over the “double burden” of 
malnutrition [9, 10]. (3) Does the reduced dosage of RUTF for SAM patients in the combined 
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protocol affect the relapse rate after treatment? There have been few studies conducting post- 
discharge follow-up of acute malnutrition survivors [11], especially for MAM treatment. 
Hence our current understanding of predictors of post-discharge relapse, in general, is also 
limited [12]. 
This study aimed to answer the above questions by following-up children treated for SAM 
and MAM with either the standard protocol or a novel combined protocol, four months post- 




This was a follow-up study for a subset of participants in the ComPAS trial; the methods 
and results of which have been described elsewhere [6, 8] (registered protocol at ISRCTN 
(ISRCTN30393230)). Briefly, the intervention arm of the trial treated all uncomplicated chil- 
dren whose MUAC was <12.5cm with RUTF: those with MUAC < 11.5cm and/or mild or 
moderate oedema (+/++) received 2 sachets of RUTF per day and those with MUAC between 
11.5 and <12.5cm (and no oedema) received 1 sachet of RUTF per day. The control arm 
received the standard weight-based dose of RUTF for SAM and RUSF for MAM. Ethical 
approval for this follow-up study was granted as an amendment to the original study approval 
by the London School of Hygiene and Tropical Medicine (reference 11826) and the Kenya 
Medical Research Institute (reference non-KEMRI 551). Informed, written consent from a 
parent or guardian was required prior to participation in the study. 
 
Setting 
The original trial took place in 12 clinics in Kenya and 12 in South Sudan. This follow-up was 
only conducted for participants in the Kenya clusters. This was due to logistical constraints in 
South Sudan of following-up patients in a highly mobile population, as well as vast distances 
between communities and lack of mobile phone infrastructure. The Kenyan setting was urban 




Participants comprised surviving children who had been treated for uncomplicated SAM or 
MAM, defined as mid-upper arm circumference <12.5cm and/or presence of nutritional 
oedema (+/++), at any of the 12 participating health clinics, and who attended a follow-up 
appointment four months post-discharge. Children who presented after 6 months post-dis- 
charge were not included. To be eligible for treatment, children had to be between the ages of 




At discharge from treatment, caregivers were given an appointment date for their four month 
follow-up. If participants failed to attend this appointment, a community health worker tele- 
phoned the participant, if possible, or attempted to find the participant at home, and encour- 
aged them to attend. Once at their appointment, anthropometry and body composition were 
measured and a questionnaire completed (see questionnaire in S1 File). Any children who 
were found to have relapsed into SAM or MAM were readmitted for standard treatment. Any 
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children who relapsed prior to their four-month appointment and sought care were recorded 
as a relapse case and still measured at four-months post the original discharge date. 
 
Outcomes 
Anthropometric assessments (weight, height, MUAC, oedema) were done following standard 
WHO procedures and were subject to quality control, which involved a trained study team 
member taking two readings within an allowable difference [13]. Weight for height (WHZ), 
weight for age (WAZ), and length for age (LAZ) z-scores were computed using the WHO 2006 
growth standards [14]. Relapse was defined as SAM cases that relapsed back to SAM, or MAM 
cases that relapsed back to GAM (“global acute malnutrition”, i.e. either MAM or SAM). 
Bioelectrical Impedance Analysis (BIA) was used to estimate fat and fat-free mass using a 
BodyStat™ 1500 measuring at 50khz (Bodystat, Douglas, Isle of Man) [15]. Two consecutive 
readings were taken for each child; readings that were not within 10 ohms of each other were 
repeated after checking the child’s position. Only repeatable BIA measures (<10 ohms differ- 
ence in impedance) were included in analysis. Height-adjusted vectors (resistance index (R/H) 
and reactance index (Xc/H)) were computed using the approach of Piccoli et al., [16], while 
raw impedance (Z) was divided by the square of height to give the impedance index, from 
which fat-free mass (FFM) values (kg) were predicted using a calibration equation derived 
from healthy children aged 3 to 18 months in The Gambia [17]. A second equation, from mal- 
nourished children in Ethiopia aged 6 months to 14 years, was also used as a check, and yielded 
similar values [18]. Fat mass (FM) was calculated as the difference of FFM and weight. Phase 
angle was measured as a composite marker of cell mass and cellular health [19]. 
Subcutaneous fat levels and fat distribution were measured using skinfold thickness at the 
tricep and subscapular sites (Holtain Tanner/Whitehouse callipers, Holtain Ltd, Pembroke- 
shire, UK), representing peripheral and core body fat stores. Measurements were converted to 
z-scores for age and sex using the WHO 2006 growth standards [14]. Skinfold thickness ratios 
(subscapular/tricep) were calculated to represent peripheral vs central adiposity. 
Food insecurity was assessed by the FAO Food Insecurity Experience Scale (FIES), an 
8-question questionnaire which has been widely validated [20]. Other questions included 
those about any common morbidities suffered by the child in the past week and past 4 months, 
as reported by the caregiver (see questionnaire in S1 File). 
 
Sample size 
The ComPAS trial in Kenya enrolled 1,973 eligible children. Allowing for 30% loss to follow- 
up and excluding children discharged after February 2018 (due to logistical constraints), our 
potential sample size was approximately 840 children for this study. A previous study using 
BIA [21], reported mean resistance indices of 567 ohm/m (SD 130) and 603 ohm/m (SD 105) 
in SAM survivors and control children. We estimated that a sample of 840 children across 12 
clusters would be sufficient to detect 36 ohm/m difference in Resistance index (R/H) based 
on mean values in that previous study, with 90% power at the 5% level of significance, and 
assumed intra-cluster correlation coefficient of 0.05, based on a previous trial [22]. 
 
Statistical analysis 
We used hierarchical, multivariable regression analysis in Stata v14 software (StataCorp LP, 
College Station, Texas USA) to assess differences in continuous outcome data between com- 
bined protocol and control arms (anthropometry and body composition). Age and sex were 
adjusted for in the regression model, as well as accounting for clustering at clinic level. Differ- 
ences in proportion of children with morbidities post-discharge were compared using logistic 
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regression, accounting for clustering. The odds of relapsing for the combined protocol chil- 
dren vs standard protocol children, and for children with various potential risk factors (includ- 
ing food security status, age, sex, MUAC at admission, MUAC at discharge, weight gain 
during treatment) was assessed using univariate and multivariable logistic regression. As well 
as comparing combined protocol to standard protocol, results were disaggregated by SAM 
and MAM status at treatment enrolment. This was due to differences in treatment protocol 
for SAM and MAM children; namely, MAM combined-protocol children were treated with 
RUTF, whereas MAM standard-protocol children received RUSF. Both arms treated SAM 
children with RUTF, but the dosage was lower on average for the combined protocol vs the 
standard protocol (105 vs 148 sachets to recovery (MUAC>12.5cm)); 81% in SAM cases 
received a reduced dosage compared to standard care [8]. 
 
Results 
We recruited 850 children into the four-month follow-up study, which met our sample size 
requirements and was 43% of the original trial sample for ComPAS in Kenya (Fig 1). Children 
lost to follow-up were similar at baseline to those in our sample, except that this sample had 
fewer children with oedema and does not represent the small (2%) who died during treatment 
(S1 Table in S1 File). Children who were SAM based on weight-for-height z-score but not 
MUAC were excluded from the analysis. Due to several elections and political unrest during 
the implementation period of the ComPAS trial, many participants moved back to rural areas 
and were unable to attend their follow-up appointment [8]. Table 1 presents the demographic 
data for the follow-up sample disaggregated by study arm and SAM/MAM admission status. 
At admission, in this sub-sample, children in the combined protocol clinics in Kenya were 
significantly more wasted (WHZ p<0.0001), underweight (p<0.0001) and stunted (p = 0.042) 
than children in the standard protocol clinics (Table 1). Mean MUAC at admission was similar 
between the two groups (p = 0.053). The cohort of children in the combined protocol had a 
greater proportion of females than the standard protocol, and had slightly greater proportion 
of oedematous SAM cases. 
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Table 1. Demographic information for the follow-up sample. 
 
 Combined protocol (N = 6, n = 382) Standard protocol (N = 6, n = 468) 
 Total SAM MAM Total SAM MAM 
n = 73 n = 268 n = 64 n = 375 
Median age at follow up (months) 18 (IQR 15–23) 17.5 18 18 (IQR 15–23) 18 18 
Males 38% 37% 37% 42% 36% 43% 
HIV positive 1% 1% 1% 0% 0% 0% 
Weight at admission (kg) 6.9 (1.4) 5.9 (0.9) 6.9 (1.2) 7.1 (1.2) 6.0 (0.7) 7.2 (1.3) 
Height at admission (cm) 70.4 (7.6) 66.8 (4.7) 70.0 (6.7) 70.7 (6.7) 66.2 (4.6) 70.9 (6.1) 
MUAC at admission (cm) 12.0 (0.6) 11.1 (0.5) 12.1 (0.2) 12.0 (0.5) 11.2 (0.4) 12.1 (0.2) 
Oedema at admission 0.8% - - 0.2% - - 
WHZ at admission -2.32 (0.8) -3.01 (0.8) -2.12 (0.7) -1.91 (0.9) -2.42 (0.9) -1.77 (0.8) 
WAZ at admission -2.69 (0.9) -3.39 (0.9) -2.53 (0.8) -2.29 (0.9) -3.11 (0.9) -2.14 (0.8) 
LAZ / HAZ at admission -1.85 (1.2) -2.16 (1.2) -1.79 (1.3) -1.65 (1.4) -2.31 (1.3) -1.53 (1.5) 
MUAC at discharge (cm) 13.0 (0.5) 12.8 (0.7) 12.9 (0.4) 13.0 (0.5) 12.6 (0.7) 13.0 (0.5) 
Weight gain (g/kg/day) 2.17 (1.3) 2.80 (1.2) 2.00 (1.2) 1.79 (1.3) 2.06 (1.4) 1.73 (1.3) 
 
�N = number of clusters; n = number of children. Data is presented as mean (SD) unless % is stated or age, which is median (IQR). WHZ = weight for height z-score; 






Comparing anthropometry between the two protocols at four-month follow-up (Table 2), 
weight, height, MUAC, WHZ and WAZ were similar between the two groups at this point. 
This was true for the groups as a whole, and when disaggregated by SAM and MAM children 
at admission. There was also no statistical difference in LAZ at follow-up between the two 
protocols when comparing both groups as a whole, nor when comparing SAM admissions. 
However, there was a difference in LAZ when comparing the MAM children in the standard 
protocol to the MAM children in the combined protocol (Table 2). When comparing the 
mean change in LAZ for children between admission and 4-month follow-up, there was no 
significant difference between the protocols (change in LAZ since admission, MAM standard 
vs MAM combined, coefficient = -0.02, 95% CI -0.20 to 0.16, p = 0.83) (Fig 2). 
When comparing morbidity outcomes at the four-month follow-up for the standard vs 
combined protocol (Table 3), we found no association between frequency of diarrhoea, vomit- 
ing, fever or cough in the past week and treatment protocol. This was true for both SAM and 
MAM admissions. There was also no association between the proportion of children admitted 
to hospital in the 4 months since discharge and treatment protocol. 
As seen in Fig 1, 76% of children assessed at follow-up had repeatable BIA measurements 
that could be included in the analysis. There was no significant difference in body composition 
outcomes four months post-discharge between those treated with the combined and those 
treated with the standard protocol (Table 4 & whole sample comparison in S2 Table in S1 
File). This includes FFM and fat mass levels (S1 Fig in S1 File), determined by BIA, as well 
as raw BIA outcomes (height-adjusted vectors, phase angle) (S2 Fig in S1 File) and skinfold 
thickness z-scores and ratio. Since this question was especially important for MAM cases, we 
present analysis for both groups as a whole and for MAM admissions only. Regarding adipos- 
ity levels at follow-up in general, 0.9% of the sample had triceps skinfold thickness above 2 z- 
scores, and 6.5% had a subscapular skinfold thickness above 2 z-score (see histograms in S3 
and S4 Figs in S1 File). FFM comprised 73.5% of children’s body weight for SAM survivors 
and 72.7% for MAM survivors. 
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Table 2. Anthropometry at four-month follow-up for combined vs standard protocol, disaggregated by SAM and MAM status. 
 
 SAM cases MAM cases 














mean (SD) mean (SD) (95% CI)� mean (SD) mean (SD) (95% CI)� 
n = 64 n = 73 n = 375 n = 268 
Weight (kg) 8.1 (1.2) 8.5 (1.1) 0.24 (-0.1, 
0.6) 
0.18 8.7 (1.1) 8.6 (1.3) -0.15 (-0.4, 0.1) 0.29 
Weight change since admission 
(kg) 
2.1 (1.0) 2.6 (0.9) 0.44 (0.0, 0.9) 0.04 1.5 (0.7) 1.7 (0.8) 0.2 (0.0, 0.4) 0.02 
Weight change since discharge 
(kg) 
0.9 (0.6) 0.9 (0.7) 0.01 (-0.2, 
0.3) 
0.94 0.8 (0.6) 0.9 (0.6) 0.07 (-0.0, 0.2) 0.22 
Height (cm) 74.4 (4.4) 75.4 (3.8) 0.49 (-0.7, 
1.7) 
0.43 77.2 (5.5) 76.6 (6.3) -0.85 (-2.1, 0.4) 0.20 
MUAC 13.0 (1.1) 13.2 (0.9) 0.14 (-0.3, 
0.6) 
0.53 13.4 (0.7) 13.3 (0.7) -0.10 (-0.3, 0.1) 0.41 
WHZ -1.55 (1.3) -1.25 (1.3) 0.18 (-0.3, 
0.6) 
0.44 -1.37 (0.9) -1.40 (0.94) -0.01 (-0.2, 0.2) 0.90 
WAZ -2.30 (1.2) -2.00 (0.9) 0.13 (-0.2, 
0.5) 
0.50 -1.84 (0.9) -2.01 (0.9) -0.20 (-0.4, 
0.03) 
0.09 
LAZ -2.36 (1.2) -2.17 (1.2) 0.04 (-0.4, 
0.5) 




n = number of children. 
�adjusted for age and sex, allowing for clustering. Unadjusted weight is significantly smaller in standard arm due to younger age, difference is not present after adjusting. 






We examined the proportion of children that relapsed following treatment (Table 5). For 
those successfully discharged as cured, 3% of SAM cases and 11% of MAM cases relapsed 
within four months. There was no significant difference in odds of relapse for those in the 
combined protocol and those in the standard protocol (Table 5). 
We assessed whether food security score might be a useful predictor of relapse, however, 
we found no association (Table 6). Being female, having a lower MUAC at admission, having a 
lower MUAC at discharge, and having a lower weight gain per day were all significantly associ- 
ated with odds of relapsing in the whole sample. For those who were discharged as cured, 
being female and having a lower MUAC at discharge remained positively associated with odds 
of relapsing (Table 6). 
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Table 3. Morbidity at four months post-discharge. 
 














% % (95% CI) % % (95% CI) 
n = 64 n = 73 n = 375 n = 268 
Diarrhoea in past week 10.9% 5.6% -0.71 (-2.4, 1.0) 0.41 8.0% 9.2% 0.05 (-0.9, 1.0) 0.91 
Vomiting in past week 7.8% 8.5% 0.09 (-1.2, 1.3) 0.89 4.8% 7.6% 0.21 (-1.4, 1.8) 0.80 
Fever in past week 9.4% 9.9% 0.24 (-1.1, 1.5) 0.72 10.2% 12.6% 0.34 (-0.9, 1.6) 0.59 
Cough in past week 23.4% 16.9% -0.29 (-1.8, 1.3) 0.72 18.2% 14.9% -0.41 (-1.7, 0.9) 0.53 
Hospitalised in past 4 
months 
4.7% 5.6% 0.19 (-1.3, 1.7) 0.81 2.4% 3.8% 0.52 (-1.8, 2.9) 0.66 
 





This follow-up study aimed to assess whether acutely malnourished children treated with a 
simplified, combined protocol have similar anthropometry, sustained recovery and morbidity 
risk as children treated with the standard protocol at four months post-discharge. We were 
particularly interested in outcomes of SAM children in the combined protocol who have, on 
average, a reduced dosage of RUTF compared to the standard protocol, and MAM children 
treated with RUTF in the combined protocol, rather than RUSF as per the standard protocol. 
Despite the children in the combined protocol having more severe anthropometric deficits 
at admission, we found no significant difference in weight, height, MUAC, WHZ and WAZ at 
 
Table 4. Body composition at four-month follow-up. 
 
 SAM cases MAM cases 
















n = 53 n = 56 (95% CI)� n = 276 n = 198 (95% CI)� 
Fat free mass (kg) 
§ 
6.03 (0.68) 6.12 (0.62) 0.07 (-0.22, 
0.35) 
0.63 6.33 (0.78) 6.25 (0.89) -0.10 (-0.31, 
0.11) 
0.37 
Fat mass (kg) § 2.2 (0.68) 2.35 (0.94) 0.13 (-0.15, 
0.42) 
0.37 2.37 (0.86) 2.33 (0.97) -0.07 (-0.33, 
0.20) 
0.63 
R/h 1247.3 (182.9) 1223.4 (151.0) -19.5 (-88.6, 
49.5) 
0.58 1195.3 (155.5) 1210.9 (162.6) 13.73 (-29.8, 
57.2) 
0.54 
Xc/h 72.65 (16.1) 73.29 (16.1) 0.10 (-8.71, 
8.92) 
0.84 72.87 (15.8) 75.32 (21.2) 2.27 (-2.10, 
6.65) 
0.31 
Phase angle ˚ 3.46 (0.78) 3.55 (0.79) 0.09 (-0.20, 
0.39) 





1.14 (0.21) 1.07 (0.19) -0.06 (-0.15, 
0.02) 
0.13 1.14 (0.21) 1.15 (0.22) 0.005 (-0.08, 
0.09) 
0.91 
Tricep skinfold z 
score 
-0.47 (1.43) -0.34 (1.19) 0.04 (-0.96, 
1.03) 





0.07 (1.46) 0.49 (1.17) 0.33 (-0.53, 
1.20) 




n = number of children. 
�adjusted for, age and sex; allowing for clustering. § fat-free and fat mass calculated using an equation from healthy children in The Gambia (17). Skinfold thickness 
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Table 5. Relapse at four months post-discharge and comparison between treatment arms. 
 
All follow-ups Discharged as cured 
From SAM to SAM From MAM to GAM From SAM to SAM From MAM to GAM 
Combined Standard Combined Standard Combined Standard Combined Standard 
4/71 6/64 33/261 50/373 1/34 1/34 21/218 39/318 
(6%) (9%) (13%) (13%) (3%) (3%) (10%) (12%) 
OR = 0.52 p = 0.31 OR = 0.08 p = 0.78 OR = 1.0 p = 0.75 OR = 0.90 p = 0.34 
 






four months post-discharge between the two protocols. We did find that LAZ was significantly 
lower for MAM survivors in the combined protocol than the standard protocol, however this 
reflects significant differences that existed at admission as “change in LAZ” since admission 
was similar between the groups. Weight gain was also higher in the combined vs standard pro- 
tocol, which is again likely due to greater severity of weight deficits at admission, and either 
faster catch-up or possibly some regression to the mean. Morbidity since discharge was also 
similar; importantly, this was likewise true for SAM children in the combined protocol who on 
average received a lower dosage of RUTF than those in the standard protocol. These outcomes 
are in line with the conclusions of the main trial which found non-inferior recovery between 
the combined and standard protocols (76.3% vs 73.5%, risk difference of .03 (95% CI -0.05 to 
0.10, p = 0.52)) [8]. 
Body composition outcomes were also similar at four months post-discharge and MAM 
children treated with RUTF did not have significantly different amounts or ratios of adiposity 
than those treated with RUSF. The mean subcutaneous fat levels remained close to the WHO 
global norm (mean tricep = -0.28 z-score; mean subscapular = 0.25 z-scores) suggesting no evi- 
dence of excessive fat gain at this stage post-treatment. Catch-up in in fat mass after SAM 
 
Table 6. Predictors of relapse at four months post-discharge. 
 
 All follow-ups Discharged as cured 
 Relapsed (GAM to 
GAM) 
N = 666 
Didn’t Relapse 
N = 117 
Odds ratio P value Relapsed (GAM to 
GAM) 
N = 534 
Didn’t Relapse 
N = 73 
Odds ratio P value 
Mean (SD) or % Mean (SD) or % (95% CI) Mean (SD) or % Mean (SD) or % (95% CI) 
Food security score 3.14 (3.1) 3.16 (3.1) 0.99 (0.9, 
1.1) 
0.97 2.94 (3.1) 3.04 (3.0) 0.99 (0.9, 1.1) 0.84 
Female Sex 70.0% 58.0% 1.69 (1.0, 
2.7) 
0.03� 73.6% 57.3% 2.07 (1.1, 3.9) 0.03� 
MUAC at admission 11.80 (0.5) 11.96 (0.4) 0.53 (0.4, 
0.8) 
0.001� 12.00 (0.3) 12.03 (0.4) 0.87 (0.5, 1.6) 0.66 
MUAC at discharge 12.54 (0.6) 12.99 (0.5) 0.14 (0.1, 
0.2) 
<0.001� 12.81 (0.4) 13.05 (0.4) 0.11 (0.04, 
0.3) 
<0.001� 
Age at admission 11.63 (9.0) 11.79 (6.4) 1.00 (0.8, 
1.0) 
0.81 12.37 (8.6) 12.21 (6.4) 1.00 (0.96, 
1.0) 
0.85 
Weight gain (g /kg/ 
day) 
1.58 (1.2) 2.02 (1.3) 0.74 (0.6, 
0.9) 
0.001� 1.79 (1.3) 2.12 (1.3) 0.81 (0.7, 1.0) 0.05 
 
MUAC = mid-upper arm circumference. Food security score was generated from the FAO Food Insecurity Experience Scale (FIES) questionnaire. GAM = global acute 
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recovery may be beneficial at mitigating high post-discharge mortality, and this may be at a 
cost of muscle mass gain, as seen in long-term SAM follow-up studies [21, 23, 24]. 
Relapse rates up until four months post-discharge were 3% for children admitted with SAM 
and 11% for children admitted with MAM, when restricting the analysis to those discharged as 
cured. If we include the whole sample (i.e. also those who defaulted treatment or who did not 
respond to treatment), relapse proportions were greater (8% for SAM and 13% for MAM), 
however it can be argued that this is not true relapse as children who defaulted or failed treat- 
ment may not have recovered to begin with. The reduced dosage in the combined protocol 
may have impacted relapse rates [25], however we found the odds of relapsing were similar 
between the two protocol arms. Another study with a reduced RUTF dosage regime also 
reported no impact on relapse rates compared to standard dosage in uncomplicated SAM 
cases in Burkina Faso (2.4% relapse vs 1.8%; p = 0.69) [26]. They did however find a small but 
significant negative effect on linear growth, which we did not find. Among those who recov- 
ered, being female and having a lower MUAC at discharge (mean MUAC 12.54 vs 12.99) were 
positively associated with odds of relapsing, suggesting that these children might benefit from 
more proactive follow-up at discharge. Comparing relapse rates with those in other studies is 
difficult due to varying follow-up periods and differing definitions for both the numerator and 
the denominator, as highlighted by a recent review [12]. Papers in that review with a follow-up 
period up to six months found SAM relapse rates between 1.9% and 17% [12, 27, 28]. Across 
the studies, the strongest, most consistent risk factor associated with relapse was having lower 
anthropometric measurements upon admission to and discharge from treatment, which is in 
line with one of our findings. 
It is important to note that this was a semi-passive follow-up process, hence relapse 
rates may not be accurate. Participants were asked to attend their follow-up appointments 
at the clinic and were called or visited to encourage attendance if they missed their 
appointment. Loss to follow-up would likely have been lower if study measurements took 
place at participant’s homes. Budget constraints, which prevented follow-up of the final 
children enrolled between February and May 2018, as well as the two general elections that 
took place in 2017, also contributed to loss to follow-up. This limitation affects both the 
study arms equally and those lost to follow-up had similar baseline characteristics as the 
sample retained, although a small element of survivor bias may be present. Since children 
in this study were recruited based on MUAC definitions of wasting, these findings may not 
be generalisable to children diagnosed with SAM based on WHZ. Another limitation of 
this study is the short follow-up period. In trying to move towards a more standard defini- 
tion of relapse, follow-up until 6 months post-discharge is recommended [12, 25]. Addi- 
tionally, longer-term follow-up is needed to further explore effects of treatment on body 




Acutely malnourished children treated with a simplified, combined protocol have similar sus- 
tained recovery and post-discharge morbidity risk as children treated with current standard 
care. SAM children treated with the combined protocol had similar anthropometry and 
relapse rates four months post-discharge to those treated with the standard protocol, despite 
reduced dosages of RUTF. MAM children treated with RUTF in the combined protocol had 
similar body composition to those treated with RUSF in the standard protocol and neither 
group exhibited excess adiposity at four months post-discharge. These results strengthen the 
conclusions of the main trial that a combined protocol is non-inferior in terms of recovery to 
standard care. Moving towards a simplified, combined approach could treat more children, 
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stretch existing resources further, and contribute to achieving Sustainable Development Goal 
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